timestamp,question,success,status_code,response_time,error,response_id,answer_length,answer_preview,qa_score,qa_combination,qa_badge,qa_directly_answers,qa_addresses_question,qa_grounded_in_context,qa_assessment,qa_assessment_length,source_count,source_unique_docs,source_avg_length,source_total_length,source_titles,source_uris,answer_llm,eval_llm,customer
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 9, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Do patients with high blood pressure have higher incidence of stroke during follow up, compared to patients with normal blood pressure', 'role': 'user'}]}",True,200.0,38.48073196411133,,897dde31-8b48-4dab-91b9-8fd7834d312f,979.0,"Limitation: Study definitions and populations vary (prehypertension vs hypertension; age groups), so...",3.0,T/T/T,3.0,True,True,True,"The context includes studies and meta-analyses that directly address the question: both prehypertension and higher blood pressure are associated with increased risk/incidence of stroke compared to optimal/normal blood pressure over follow-up. The AI's answer is fully grounded in this evidence, summarizes the studies correctly, notes differences in definitions and populations, and avoids extrapolating beyond the data (does not introduce unsupported claims). Therefore, all three criteria are met.",499,3,3,153.66666666666666,461,"Prehypertension and the risk of stroke: a meta-analysis; Presence of baseline prehypertension and risk of incident stroke: a meta-analysis; Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study",https://pubmed.ncbi.nlm.nih.gov/24623843/; https://pubmed.ncbi.nlm.nih.gov/21956722/; https://pubmed.ncbi.nlm.nih.gov/11343441/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 1, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'pediatric patients size in the United States diagnosed with cutaneous lupus erythematosus at initial diagnosis between 2015 and 2024', 'role': 'user'}]}",True,200.0,62.151883602142334,,3dc5a7a8-4d4c-4aaa-a466-18890537ae74,800.0,"No published, population-level count of pediatric patients in the United States specifically diagnos...",2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question regarding the number or size of pediatric patients in the US diagnosed with cutaneous lupus erythematosus (CLE) at initial diagnosis between 2015 and 2024. Instead, it notes that data on pediatric CLE are limited and only provides detailed epidemiologic statistics for systemic lupus erythematosus (SLE), not CLE specifically. The AI's answer accurately reflects this limitation and does not introduce information beyond the provided context. It is faithful to the context, acknowledges the lack of direct data, and discusses related but not identical data (SLE prevalence/incidence). Thus, the context is relevant to the question, but does not directly answer it, and the answer remains grounded in the context.",762,3,3,194.33333333333334,583,"Cutaneous Lupus Erythematosus in Children - PubMed; Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study: A Lupus Midwest Network (LUMEN) Study - PMC; Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population - PubMed",https://pubmed.ncbi.nlm.nih.gov/33655840/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9038612/; https://pubmed.ncbi.nlm.nih.gov/22847366/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 3, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'True Out of pocket in asthma biologics', 'role': 'user'}]}",True,200.0,68.41354012489319,,e8848ae3-8fc6-42b1-8148-903e97cf8a69,1514.0,"Limitations: the published literature does not report a single, universal “true” patient out-of-pock...",2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The context does not provide a single, explicit ""true out-of-pocket"" amount for patients using asthma biologics; instead, it discusses manufacturer prices, payer costs, and access disparities, and notes barriers due to high medication costs. 
2. context_addresses_question: True. The context is highly relevant as it discusses the cost of asthma biologics, insurance differences, and patient access, all of which relate directly to out-of-pocket exposure even though it lacks a direct patient OOP value.
3. answer_grounded_in_context: True. The AI's answer is careful to explain the limitations of the context, accurately summarizes what is present in the literature, and does not introduce unsupported claims. It references access disparities, insurer differences, and high costs exactly as reflected in the context. ",863,4,4,219.75,879,"The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council; A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective - PMC; Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals - PMC; Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals - PubMed",https://pmc.ncbi.nlm.nih.gov/articles/PMC10397880/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10776277/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8549114/; https://pubmed.ncbi.nlm.nih.gov/33556592/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 6, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the prevalence of dyslipidemia in patients aged 65 years and older in the US', 'role': 'user'}]}",True,200.0,71.06463193893433,,2392fa9a-40f7-41ef-b1f3-87b91fb24c20,1104.0,"Limitations: recent, nationally representative estimates specifically restricted to age ≥65 are limi...",3.0,T/T/T,3.0,True,True,True,"The context provides direct, specific prevalence data for dyslipidemia in U.S. adults aged 65 and older (60.3% in NHANES 1999–2004), as well as more recent, though broader, prevalence estimates (53% in NHANES 2011–2018 for adults overall, and 11.3% for high cholesterol in adults aged 60+). The AI answer accurately reports these statistics, clearly indicates which refer specifically to the ≥65 subgroup, addresses time periods and changes in definitions, and does not make unsupported claims. Therefore, the answer is directly supported by context, relevant, and fully grounded.",580,3,3,191.33333333333334,574,"Prevalence, Awareness, and Management of Hypertension, Dyslipidemia, and Diabetes Among United States Adults Aged 65 and Older; Awareness of having hypertension, diabetes and dyslipidaemia among US adults: The 2011–2018 NHANES data; Total and High-density Lipoprotein Cholesterol in Adults: United States, August 2021–August 2023 (NCHS Data Brief)",https://pmc.ncbi.nlm.nih.gov/articles/PMC2655011/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12048732/; https://www.ncbi.nlm.nih.gov/books/NBK610675/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 7, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population size of patients with Cutaneous lupus erythematosus who are pediatric at the time of index diagnosis and are diagnosed between 2015 to 2024 in US', 'role': 'user'}]}",True,200.0,73.67771553993225,,aaa3bf4b-b7af-46d7-a494-d0a5ca3a94b1,1148.0,Limitations: No published US national count of pediatric-onset cutaneous lupus erythematosus (CLE) d...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, as it does not provide a specific US population size for pediatric cutaneous lupus erythematosus (CLE) patients diagnosed from 2015-2024. Instead, it notes the absence of such data in the literature, the small scale and limited scope of the available pediatric CLE studies, and the distinction between CLE and better-characterized childhood-onset systemic lupus erythematosus (cSLE). However, the context is relevant because it addresses epidemiological data sources, methodologies, and the challenges in estimating this population, making it appropriate to say the context addresses the question. The AI's answer correctly summarizes this, remains grounded in the context, and does not introduce unsupported information.",772,4,4,210.0,840,Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study: A Lupus Midwest Network (LUMEN) Study; Cutaneous Lupus Erythematosus in Children: Experience from a Tertiary Care Pediatric Dermatology Clinic - PubMed; Cutaneous Lupus Erythematosus in Children - PubMed; Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC9038612/; https://pubmed.ncbi.nlm.nih.gov/27001318/; https://pubmed.ncbi.nlm.nih.gov/33655840/; https://pubmed.ncbi.nlm.nih.gov/33474834/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 12, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many patients has CKD stage 2 and hypertension, and CKD stage 3 and hypertension?', 'role': 'user'}]}",True,200.0,13.090259790420532,,dce8bc99-7062-47b0-ac24-2bd6849cf73c,339.0,I don’t have enough context to give counts. Do you mean (a) number of patients in a specific dataset...,1.0,F/F/T,1.0,False,False,True,"There is no context provided, so the answer cannot be directly supported by the context nor address the question using context. The AI's answer correctly acknowledges the lack of context and does not fabricate an answer, so it is grounded in the (lack of) context.",264,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 5, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What proportion of patients takins statins for primary prevention achieve LDL goal', 'role': 'user'}]}",True,200.0,83.44368243217468,,d1f5ce62-5a24-4f8f-95ec-f1190fb3597b,900.0,Published observational studies in primary-prevention settings report widely variable LDL-goal attai...,3.0,T/T/T,3.0,True,True,True,"The context provided contains direct data from studies reporting the proportion of patients achieving LDL goals with statin use for primary prevention. The AI's answer accurately summarizes and cites the reported proportions (65.4%, 41.5%, and less than one-third), and clarifies differences between studies and populations. The AI does not introduce unsupported claims or external knowledge outside of restating the approximate range from the provided results. Therefore, the answer is directly supported by the context, addresses the question fully, and is grounded solely in the evidence presented in the context.",616,3,3,168.33333333333334,505,Statin use and low-density lipoprotein cholesterol target achievement for primary prevention of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus: a multicenter cross-sectional study in Sri Lanka; Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia; Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care,https://pubmed.ncbi.nlm.nih.gov/39982907/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6916674/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8549660/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 4, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Exacerbations in ASthmatics on biologics', 'role': 'user'}]}",True,200.0,93.8933310508728,,4a09b181-73d0-4a63-94c2-9be846afb8c7,1871.0,Limitations: Available systematic reviews and trials quantify exacerbation-rate reductions and ident...,3.0,T/T/T,3.0,True,True,True,"The context provides direct evidence about the impact of biologics on asthma exacerbations, reporting quantitative reductions in exacerbation rates for various biologics, highlighting residual exacerbation burden, and noting predictors of better response. The AI's answer relies exclusively on these contextual findings, summarizing drug effects, population subgroups, real-world data, and predictors, as well as implications for ongoing management in clinical practice. No information is introduced that is not supported by the context, and the answer is both relevant and directly responsive to the question about exacerbations in asthmatics on biologics.",657,5,5,223.0,1115,"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma; Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials; Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis; Severe asthma exacerbations in the United States: Incidence, characteristics, predictors, and effects of biologic treatments; Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta-Analysis",https://pubmed.ncbi.nlm.nih.gov/32034960/; https://pubmed.ncbi.nlm.nih.gov/37015033/; https://pubmed.ncbi.nlm.nih.gov/35772597/; https://pubmed.ncbi.nlm.nih.gov/34273485/; https://pubmed.ncbi.nlm.nih.gov/40956008/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 0, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'pediatric patients in the United States diagnosed with cutaneous lupus erythematosus at initial diagnosis between 2015 and 2024', 'role': 'user'}]}",True,200.0,106.77489924430847,,b475f5d5-9b02-4cc6-bab9-94ad47aef86a,1142.0,"Limitation: No published, population-level count of pediatric patients in the United States newly di...",2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct, population-level count or incidence of pediatric patients in the US with cutaneous lupus erythematosus at initial diagnosis between 2015–2024. Instead, it discusses the absence of such data, describes the limitations of available studies, and notes the lack of pediatric-specific, national-scale epidemiology for this period and condition. The AI's answer accurately reflects these limitations and cites the studies and their shortfalls regarding the original question. All statements in the answer are grounded in the context; no unsupported claims are made. However, the context does not directly answer the original question, but it is clearly relevant.",695,4,4,176.0,704,Cutaneous Lupus Erythematosus in Children - PubMed; Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre - PubMed; Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-Based Study - PubMed; Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study - PubMed,https://pubmed.ncbi.nlm.nih.gov/33655840/; https://pubmed.ncbi.nlm.nih.gov/23601021/; https://pubmed.ncbi.nlm.nih.gov/37313079/; https://pubmed.ncbi.nlm.nih.gov/34825516/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 8, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the estimated number of pediatric patients in the United States who were diagnosed with Cutaneous Lupus Erythematosus (CLE) at the time of their initial diagnosis between 2015 and 2024?', 'role': 'user'}]}",True,200.0,123.87530493736267,,ac451316-afbf-4e17-bbd5-21edd2f80cc9,1505.0,"No published, population-level estimate specific to pediatric Cutaneous Lupus Erythematosus (CLE) in...",2.0,F/T/T,2.0,False,True,True,"The context shows that there is no published, population-level estimate specific to pediatric CLE in the US for 2015-2024, as noted in source [2]. The AI's answer correctly cites the lack of direct data and uses incidence estimates from related or proxy populations (general CLE and cSLE incidence), transparently explaining these are not direct figures for pediatric CLE but extrapolations. Calculations are based on context data, and all assumptions are clearly stated. However, since the question asks for the estimated number of pediatric patients diagnosed with CLE—and the context, as well as the answer, emphasizes that no such direct data exist—the context does not directly answer the question, but it is relevant and the answer remains grounded in the provided evidence.",780,4,4,161.75,647,"Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study; Cutaneous Lupus Erythematosus in Children; Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study (LUMEN); Children in the United States: Demographics, Health, and Wellbeing - NCBI Bookshelf",https://pubmed.ncbi.nlm.nih.gov/19289752/; https://pubmed.ncbi.nlm.nih.gov/33655840/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9038612/; https://www.ncbi.nlm.nih.gov/books/NBK610731/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 10, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with BMI 30 or higher, is there a difference in use of GLP1-RA in those with vs without a recorded obesity diagnosis?\u200b', 'role': 'user'}]}",True,200.0,88.47343850135803,,65acf522-c833-4e1b-b911-5018cbe81ce8,2019.0,Limitations: No published study was identified that directly reports GLP‑1 receptor agonist (GLP‑1 R...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context does not supply explicit data on GLP-1 RA use comparing those with BMI ≥30 who do and do not have a recorded obesity diagnosis. Instead, it discusses rates of obesity diagnosis, associations between diagnosis and obesity-related treatment in general, and prescribing/diagnosis overlap, but not the direct comparison requested by the question.

2. context_addresses_question: True. The context is highly relevant to the question, addressing trends of underdiagnosis, relationships between recorded diagnosis and likelihood of treatment, and reporting on GLP-1 RA prescribing in relation to diagnosis and BMI.

3. answer_grounded_in_context: True. The AI's answer relies exclusively on the details from the provided studies. It accurately summarizes and synthesizes the evidence, avoids external speculation, and clearly states that no study directly answers the question.",936,4,4,256.75,1027,Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system; Factors associated with receiving an obesity diagnosis and obesity-related treatment for patients with obesity class II and III within a single integrated health system; Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study; Persistently low initiation of GLP-1 receptor agonists for weight management in individuals without diabetes in Poland: a major unmet need,https://pubmed.ncbi.nlm.nih.gov/29150468/; https://pubmed.ncbi.nlm.nih.gov/39309697/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12003583/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12509864/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 2, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Character (role):\n You are a senior Real-World Data Analyst specializing in patient affordability.\n \n Objective (business question):\n Quantify and benchmark True Out-of-Pocket (T-OOP) costs (patient-paid deductible + co-pay + co-insurance) among asthma patients newly treated with FDA-approved biologic therapies, using IQVIA’s ELAAD → FIA (fill-level integrated adjudicated claims) dataset.\n \n Request (tasks):\n \n  Cohort definition\n \n  Identify patients with ≥ 2 encounters coded for asthma (ICD-10 J45.x) [LOOK-BACK WINDOW: 12 months] before index date.\n \n  Index = first fill of any biologic asthma therapy: omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab \n \n  Require continuous enrollment in FIA for [BASELINE = 6 mo] pre-index and [FOLLOW-UP = 12 mo] post-index.\n \n  Outcome construction\n \n  For each patient, sum patient-paid amounts (deductible + co-pay + co-insurance) on all claims for the index biologic during follow-up.\n \n  Report: mean, median, IQR, SD, and % patients with annual T-OOP ≥ $500, ≥ $1 000, ≥ $2 000.\n \n  Break out results by payer channel (Commercial, Medicare Advantage, Medicare Part D, Medicaid, Other) and by biologic agent.\n \n  Sensitivity / sub-analyses\n \n  Restrict to patients with high eosinophilic phenotype (ICD-10 D72.18 or blood eos ≥ 300/mm³ in lab feed) \n  Exclude patients with concomitant biologic use for non-asthma indications .\n \n  Repeat outcome using patient-year and claim-level units.\n \n  Output format\n \n  Return three tables (Overall, By Payer, By Biologic) plus a brief narrative (< 250 words) summarizing key cost drivers and any notable payer/agent disparities.\n \n  Include an appendix with SQL-style pseudocode for cohort and outcome logic.\n \n Examples (optional):\n \n  “Example of desired table layout attached below.” \n \n Adjustments / refinements:\n \n  Apply IQVIA standard inflation adjustment to 2025 USD.\n \n  Flag if > 10 % of fills lack patient-paid fields (possible data quality issue).\n \n  Use exact drug NDCs; i', 'role': 'user'}]}",True,200.0,127.05947422981262,,88412b6f-2a35-40fa-a709-f4c20ab6e343,7374.0,Limitations: direct computation of patient-level T‑OOP from IQVIA ELAAD→FIA is not possible here bec...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: TRUE. The provided context contains direct, relevant evidence for key components of the question: asthma cohort selection (≥2 ICD-10 J45 diagnoses in 12 months), blood eosinophil thresholds (≥300/≥150) for phenotype, as well as data quality/missingness recommendations (flag >10% missing patient-paid data). The AI's answer closely ties to these with explicit citations, and the SQL-style logic and output tables address all requested analyses, cohort logic, outcomes, and sensitivity checks.

2. context_addresses_question: TRUE. All referenced material directly concerns asthma cohort definition, phenotype biomarker thresholds, and claims data quality/missingness, which are the central elements of the question. The context is highly relevant to the question posed.

3. answer_grounded_in_context: TRUE. The AI's response relies heavily and explicitly on the provided context for clinical definitions, data handling, and analytic flags. There are no unsupported claims or hallucinated facts; all recommended strategies or cohort definitions are tied to publications included in the context with specific reference numbers.",1164,4,4,237.0,948,"Comparing Two Approaches to Identify Individuals with Severe Asthma in United States Claims Data; Biomarkers in asthma: state of the art; Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review; Completeness of prescription information in US commercial claims databases",https://pubmed.ncbi.nlm.nih.gov/40930965/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6302401/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10272272/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4012425/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 13, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic kidney disease and hypertension, Cohort_1: chronic kidney disease stage 2 and hypertension, Cohort_2: chronic kidney disease stage 3 and hypertension', 'role': 'user'}]}",True,200.0,58.574432373046875,,f9249612-03b3-4ca1-b8af-8af6b583dffb,1329.0,"Limitations: the request did not specify a particular outcome (e.g., BP control, cardiovascular even...",3.0,T/T/T,3.0,True,True,True,"The context directly addresses the question by providing comparative statistics between CKD stage 2 and stage 3 for hypertension prevalence and cardiovascular disease, which matches the cohort comparisons in the question. The AI's answer correctly synthesizes these points, accurately citing specific prevalence data and adjusted odds ratios. The context is directly relevant, as it focuses on the CKD stages and their relationship with hypertension and outcomes like CVD and eGFR decline, which are invoked in the synthesis. The answer is well-grounded in the provided context, making no unsupported or hallucinated claims.",624,3,3,225.33333333333334,676,Hypertension in Chronic Kidney Disease: Navigating the Evidence; Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE); Association Between Hypertension and Kidney Function Decline: The Atherosclerosis Risk in Communities (ARIC) Study,https://pmc.ncbi.nlm.nih.gov/articles/PMC3124254/; https://pubmed.ncbi.nlm.nih.gov/28088175/; https://pubmed.ncbi.nlm.nih.gov/31031087/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 11, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what proportion of patients with CKD stage 2 and hypertension, and CKD stage 3 and hypertension, treated with SLGT2 along, MRA along, SGLT2 and MRA together, or none?', 'role': 'user'}]}",True,200.0,76.83626914024353,,5d31520a-583d-44ff-a352-ffb0e44bdc1c,1444.0,No published study was identified that reports the exact cross‑tabulated proportions (CKD stage 2 + ...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the question, as it does not supply the requested exact proportions of CKD stage 2 and 3 patients with hypertension treated with SGLT2 alone, MRA alone, both, or neither. The context, however, is relevant to the question: it discusses general SGLT2 usage by CKD stage, describes low real-world MRA use, and explains that combination therapy has been studied only in small groups without prevalence reporting. The AI's answer accurately conveys these limitations, remains grounded in the information provided, and does not introduce unsupported claims.",597,4,4,208.5,834,Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study; A real-world study on SGLT2 inhibitors and diabetic kidney disease progression; Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease; Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials,https://pmc.ncbi.nlm.nih.gov/articles/PMC11794911/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9217649/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10227157/; https://pubmed.ncbi.nlm.nih.gov/39510041/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 14, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with Type 1 Diabetes with a clearly identifiable first diagnosis date and at least two c-peptide laboratory test records within one year before and one year after diagnosis, Outcomes: count and average number of c-peptide laboratory test records', 'role': 'user'}]}",True,200.0,102.04129123687744,,fc440b98-2321-47f3-8b19-021371088c31,1834.0,Limitation: Published cohort and trial reports do not present a published summary table giving the p...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include a direct answer to the question of the count and average number of c-peptide laboratory test records for the specified population. Rather, the context details how published studies either display serial measurements, participant counts at intervals, or report paired measurements (e.g., at diagnosis and one year), without directly tabulating or summarizing the per-patient mean or total in the defined window. The AI's answer accurately synthesizes and grounds itself in the supplied context, clearly noting these limitations and citing relevant studies. The context is relevant to the question but stops short of providing the requested direct numerical outcome.",702,3,3,284.3333333333333,853,C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet; Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1; Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents,https://pubmed.ncbi.nlm.nih.gov/32457058/; https://pmc.ncbi.nlm.nih.gov/articles/PMC2571043/; https://pubmed.ncbi.nlm.nih.gov/23529064/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 15, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with type 1 diabetes and have multiple (i.e., more than 2) c-peptide records within one year before the first T1D diagnosis and within one year after first T1D diagnosis. The multiple c-peptide records (in both pre- and post-diagnosis windows) can be any number of days apart (e.g., 1 day, 7 days, 30 days), but should not be on the same day, Outcomes: Number of patients in the cohort and how many c peptide records are present on average for this population cohort before index and after index', 'role': 'user'}]}",True,200.0,96.49900317192078,,6819412c-eaa8-4016-a86e-c69d64b66172,1386.0,No published article reports the exact cohort you define (subjects with >2 C‑peptide measurements bo...,2.0,F/T/T,2.0,False,True,True,"The AI's answer correctly states that the literature does not provide the specific outcome data requested (cohort count and per-window averages for patients with >2 c-peptide records in the 1-year pre- and post-diagnosis windows). It summarizes what is available in the cited sources, indicating that while related data (e.g., 80 TrialNet subjects with pre/post-diagnosis tests, semiannual testing schedules, mean visits over full follow-up, and high-frequency home sampling in small studies) exist, none exactly match the specified cohort definition or report the requested outcomes. Thus, the answer is relevant and fully grounded in the provided context, but the context does not directly answer the main quantitative question.",730,4,4,252.0,1008,C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet; Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial–Type 1 participants; Cell type–specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes; Frequent Monitoring of C‑Peptide Levels in Newly Diagnosed Type 1 Subjects Using Dried Blood Spots Collected at Home,https://pubmed.ncbi.nlm.nih.gov/32457058/; https://pubmed.ncbi.nlm.nih.gov/20032282/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6478408/; https://pubmed.ncbi.nlm.nih.gov/29860430/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 18, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with type 1 diabetes, Outcomes: type 2 diabetes', 'role': 'user'}]}",True,200.0,81.25810170173645,,a93063d0-5203-4348-9389-1cb4ea299d4f,1148.0,Limitations: longitudinal incidence data quantifying how often patients with established type 1 diab...,2.0,F/T/T,2.0,False,True,True,"The context does not provide direct evidence or quantification of patients with type 1 diabetes developing type 2 diabetes, but it does discuss the phenomenon of 'double diabetes' (T1D patients with insulin resistance characteristic of T2D) and its prevalence. Thus, the context doesn't answer the question of T2D outcomes directly, but strongly addresses the topic with relevant details about overlap and risk factors. The AI answer is strictly grounded in the given context, referencing prevalence data, clinical implications, and limitations as outlined in the sources, without introducing outside information.",613,5,5,127.4,637,"Double diabetes-when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition - PubMed; Prevalence of Insulin Resistance in Type 1 Diabetes Mellitus and Its Correlation with Metabolic Parameters: The Double Trouble - PubMed; Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: ""double diabetes"" in the Diabetes Control and Complications Trial - PubMed; Double Diabetes: A Converging Metabolic and Autoimmune Disorder Redefining the Classification and Management of Diabetes - PubMed; Double or hybrid diabetes associated with an increase in type 1 and type 2 diabetes in children and youths - PubMed",https://pubmed.ncbi.nlm.nih.gov/38341550/; https://pubmed.ncbi.nlm.nih.gov/35703516/; https://pubmed.ncbi.nlm.nih.gov/17327345/; https://pubmed.ncbi.nlm.nih.gov/40225541/; https://pubmed.ncbi.nlm.nih.gov/17991137/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 17, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: ATTR patients identified by the above confirmed cohort definitions, Cohort_1: ATTR-PN (confirmed with nerve conduction studies and specific peripheral neuropathy diagnosis codes) and exclude stem cell transplant, chemotherapy , Cohort_2: ATTR-CM (confirmed with cardiac imaging evidence and additional cardiomyopathy diagnosis codes), and exclude stem cell transplant, chemotherapy , Cohort_3: ATTR - Mixed (confirmed with nerve conduction studies, specific peripheral neuropathy, or cardiomyopathy diagnosis) and exclude stem cell transplant and chemotherapy , Outcomes: first recorded ATTR diagnosis based on diagnosis and procedure records in 2024 and 2025 separately', 'role': 'user'}]}",True,200.0,98.79385590553284,,88f1673a-426e-40dd-bd94-1a8dafafc872,2414.0,Limitation: No published study was found that reports first-recorded counts for 2024 and 2025 using ...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context does not include specific evidence about first-recorded ATTR diagnosis counts for 2024 and 2025 using the requested cohort definitions; it only describes related methodologies and general data limitations up to 2023. 
2. context_addresses_question: True. The context is relevant, describing identification methods for ATTR-CM and ATTR-PN, the importance of nerve conduction studies, coding criteria, and data limitations in recent literature, which aligns with the question's requirements for cohort construction and exclusions.
3. answer_grounded_in_context: True. The answer closely follows the evidence from the context, including details about phenotyping approaches, exclusion rules, and the lack of direct incidence data for the requested years and cohort definitions. No unsupported or hallucinated claims are made.",888,4,4,206.0,824,Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review; Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records; Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in‑ and out‑patient databases; Diagnosis of peripheral neuropathy,https://pmc.ncbi.nlm.nih.gov/articles/PMC11740649/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10682883/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10626733/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7650053/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 23, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension , Intervention: uncontrolled hypertension (SBP>130mmHg and on at least 2 antihypertensive medications), Control: controlled hypertension (SBP<130mmHg and on at least 2 antihypertensive medications), Outcomes: ischemic stroke and myocardial infarction', 'role': 'user'}]}",True,200.0,58.02807569503784,,acb4af15-f8a0-41b1-b064-a30c329929ac,1501.0,No published study was found that directly compares patients taking ≥2 antihypertensive medications ...,3.0,T/T/T,3.0,True,True,True,"The provided context contains evidence directly comparing uncontrolled versus controlled hypertension (on multiple antihypertensives) and their risks of ischemic stroke and myocardial infarction. Specifically, reference [3] notes higher event rates of these outcomes among uncontrolled hypertensives on multiple medications versus controlled. The AI's answer accurately summarizes this, also noting the lack of an exact direct trial at a specific SBP threshold (which the context supports), and correctly draws attention to higher risks of events in the uncontrolled group, grounded in the supplied context. The context is highly relevant and supports the main points made in the AI's answer.",692,4,4,252.75,1011,Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study; Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES); Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment‐Resistant Hypertension; Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis,https://pubmed.ncbi.nlm.nih.gov/29925884/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6485047/; https://pmc.ncbi.nlm.nih.gov/articles/PMC5837039/; https://pubmed.ncbi.nlm.nih.gov/21364140/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 16, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD, Intervention: Breztri, Control: Trelegy, Outcomes: % with COPD-Related Hospitalization', 'role': 'user'}]}",True,200.0,115.09911775588989,,c357f408-2f94-4a57-80c7-423a857c7fac,2190.0,No randomized trial directly reports the percent of patients with COPD-related hospitalization compa...,2.0,F/T/T,2.0,False,True,True,"The context does not directly report the percent of patients with COPD-related hospitalization comparing Breztri to Trelegy—there is only indirect data (about exacerbation rates and comparisons to other therapies). The provided context is relevant as it discusses both interventions and related outcomes, and the AI's answer correctly states that direct comparative data are unavailable while accurately describing what the context contains. The answer does not introduce hallucinations or external information beyond the context.",530,4,4,281.25,1125,"Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis; Impact of the IMPACT Trial - PMC; Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study; Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study",https://pubmed.ncbi.nlm.nih.gov/35849317/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6296790/; https://pubmed.ncbi.nlm.nih.gov/33252985/; https://pubmed.ncbi.nlm.nih.gov/29370819/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 20, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'average c peptide levels of patients before and after first diagnosis of T1D', 'role': 'user'}]}",True,200.0,78.02902865409851,,f930600d-bbcd-4792-9010-b0d36db01ad1,1688.0,"Limitations: reported “average” C‑peptide at diagnosis and early postdiagnosis varies by age, assay ...",3.0,T/T/T,3.0,True,True,True,"The AI's answer summarizes the range of C-peptide levels reported in the context for patients before and after the first diagnosis of T1D, including median values at onset, at 3 months, and at 12 months after diagnosis, as cited from the pediatric cohort study (reference [1]). It also discusses changes in C-peptide measured around diagnosis from the DPT-1 perionset study (reference [2]) and mentions the rate of decline from the TrialNet data (reference [3]). The data provide specific numeric values (e.g., 0.17 pmol/mL at onset, 0.27 pmol/mL at 3 months, and 0.13 pmol/mL at 12 months), which directly answer the question. The answer is fully grounded in and limited by the context and does not introduce unsupported information.",734,4,4,198.75,795,Prediction of clinical remission using the C-peptide level in type 1 diabetes in children; Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1; Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data; The Predictive Ability of C-Peptide in Distinguishing Type 1 Diabetes From Type 2 Diabetes: A Systematic Review and Meta-Analysis,https://pubmed.ncbi.nlm.nih.gov/17880810/; https://pubmed.ncbi.nlm.nih.gov/18650369/; https://pubmed.ncbi.nlm.nih.gov/22688329/; https://pubmed.ncbi.nlm.nih.gov/36641115/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 22, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension, Intervention: patients with uncontrolled blood pressure (SBP>130mmHg and on 2 antihypertensive medications), Control: patients with controlled blood pressure (SBP<130mmHg and on 2 antihypertensive medications), Outcomes: ischemic stroke, myocardial infarction', 'role': 'user'}]}",True,200.0,82.28487181663513,,53c1f44e-c089-4643-b466-b6164346f74c,2116.0,Limitations: No published study was identified that directly compares ischemic stroke and myocardial...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the precise question, as none of the studies present a direct comparison of ischemic stroke and myocardial infarction incidence for patients on exactly two antihypertensive medications with SBP >130 mmHg vs <130 mmHg. Instead, the context provides partially relevant evidence—either using different BP thresholds, more drugs, or focusing on regimen composition. Therefore, while the context is relevant and addresses the general question, it does not directly answer it. The AI’s answer appropriately notes this limitation, synthesizes the available related evidence, and does not introduce unsupported claims or hallucinated facts. It stays grounded in the context provided.",712,5,5,274.0,1370,Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus; Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients; Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study; Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study; Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy - NIHR HTA (NCBI Bookshelf),https://pubmed.ncbi.nlm.nih.gov/37461262/; https://pubmed.ncbi.nlm.nih.gov/10657416/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6010458/; https://pmc.ncbi.nlm.nih.gov/articles/PMC2811239/; https://www.ncbi.nlm.nih.gov/books/NBK62259/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 25, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do patients with uncontrolled hypertension have higher rates of cardiovascular outcomes compared to patients with controlled hypertension?', 'role': 'user'}]}",True,200.0,53.0546338558197,,adbc6733-1918-4f8e-9dbf-12c937c64417,1185.0,Yes. Observational cohort analyses report higher cardiovascular event and mortality rates for patien...,3.0,T/T/T,3.0,True,True,True,"The answer is directly supported by the provided context. The AI correctly cites multiple studies that compare cardiovascular outcomes in patients with uncontrolled versus controlled hypertension, including exact hazard ratios and reference numbers that match the context. The context explicitly states that uncontrolled hypertension is associated with higher cardiovascular and all-cause mortality, higher incident heart failure, and a graded increase in cardiovascular events with higher systolic blood pressure. The answer remains grounded in the provided evidence, does not introduce unsupported claims, and summarizes the findings accurately. Therefore, all three evaluation criteria are met.",697,5,5,182.8,914,The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control; Impact of Intensive Blood Pressure Control Versus Standard Control on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials; Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study; Uncontrolled hypertension increases risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study; Low on-treatment blood pressure and cardiovascular events in patients without elevated risk: a nationwide cohort study,https://pubmed.ncbi.nlm.nih.gov/26967236/; https://pubmed.ncbi.nlm.nih.gov/40772210/; https://pubmed.ncbi.nlm.nih.gov/29925884/; https://pubmed.ncbi.nlm.nih.gov/20374948/; https://pubmed.ncbi.nlm.nih.gov/38355817/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 19, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with BMI 30 or higher, is there a difference in use of GLP1-RA in those with vs without a recorded obesity diagnosis?\u200b\n \n \u200b\n \n \u200b\n \n \u200b\n \u200b', 'role': 'user'}]}",True,200.0,111.93952226638794,,00bea690-504c-492f-b81b-cf9b8623fe98,2478.0,Limitations: No published study was identified that directly compares GLP‑1 receptor agonist (GLP‑1 ...,2.0,F/T/T,2.0,False,True,True,"The context provided is highly relevant to the question, addressing the issue of GLP-1 RA use in relation to documented obesity diagnosis and the undercoding of obesity among those with BMI ≥30. However, none of the cited studies make a direct comparison of GLP-1 RA use between patients with BMI ≥30 who do and do not have a recorded obesity diagnosis. The AI answer accurately reflects this limitation, synthesizing evidence to explain what is and is not directly answered by the literature. The answer closely adheres to the supplied context and does not introduce unsupported claims.",587,4,4,239.0,956,Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system; Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study; Trends in glucagon-like peptide 1 receptor agonist prescribing patterns; Development and Validation of a Measure Identifying Patients with Obesity by BMI Without an Official Diagnosis,https://pmc.ncbi.nlm.nih.gov/articles/PMC5702021/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12003583/; https://pubmed.ncbi.nlm.nih.gov/40829097/; https://pubmed.ncbi.nlm.nih.gov/40826492/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 21, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Pulmonologists caring for adult patients who are maintenance therapy–naive and newly diagnosed with either chronic obstructive pulmonary disease (COPD) or asthma., Intervention: Prescribing triple inhaled therapy (fluticasone+umeclidinium+vilanterol or budesonide+glycopyrolate+formoterol)) to maintenance-naive COPD patients., Control: Prescribing triple inhaled therapy (fluticasone+umeclidinium+vilanterol or budesonide+glycopyrolate+formoterol) to maintenance-naive asthma patients., Outcomes: Likelihood (rate or proportion) of fluticasone+umeclidinium+vilanterol or budesonide+glycopyrolate+formoterol initiation among maintenance-naive asthma patients compared to maintenance-naive COPD patients by pulmonologists who already prescribe triple therapy to maintenance-naive COPD patients.', 'role': 'user'}]}",True,200.0,110.23782062530518,,ee1628be-7861-48fe-b5b7-b864028d243f,2352.0,"No published study was identified that directly compares, among pulmonologists who already prescribe...",2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question of the comparative likelihood of triple therapy initiation in maintenance-naive asthma versus maintenance-naive COPD patients by pulmonologists who already prescribe to maintenance-naive COPD. There is no head-to-head comparative study or explicit likelihood ratio between the two groups in the provided context. However, the context is clearly relevant: it contains real-world data on prescribing patterns of triple therapy in maintenance-naive COPD and separately in asthma, as well as pulmonologists' prescribing behavior. The AI's answer is properly grounded in these sources, synthesizing the findings to provide an indirect inference, acknowledging the absence of direct comparative evidence, and refraining from introducing unsupported claims or numbers not in the context. This approach is methodologically appropriate for the evidence available.",904,4,4,232.0,928,Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD; Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey; Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: A Real-World Population Study; Real-world users of triple therapy for asthma in the US,https://pmc.ncbi.nlm.nih.gov/articles/PMC9166325/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8995154/; https://pubmed.ncbi.nlm.nih.gov/35946353/; https://pubmed.ncbi.nlm.nih.gov/38381542/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 26, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension, Intervention: controlled hypertension (SBP<130mmHg and on 2 antihypertensive medications), Outcomes: ischemic stroke', 'role': 'user'}]}",True,200.0,50.09668302536011,,5ad14153-9e17-4b57-9d31-85085a6cdd80,1575.0,Limitations: No randomized trial or pooled analysis specifically tested the strategy “achieve SBP <1...,2.0,F/T/T,2.0,False,True,True,"The context discusses the impact of achieving systolic BP <130 mmHg compared with higher targets on stroke and cardiovascular outcomes. It mentions that lower SBP is associated with lower risk of major cardiovascular disease, including stroke, and that in patients with prior stroke, intensive control reduced recurrent stroke but did not show statistically significant reduction in ischemic stroke. However, none of the sources directly address the outcome of ischemic stroke specifically in the context of patients with hypertension who have controlled SBP <130 mmHg and are on exactly two antihypertensive medications. The AI's answer correctly notes these contextual limitations, relies solely on the provided context, and appropriately summarizes the evidence and its gaps, without introducing external claims.",815,3,3,224.66666666666666,674,Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis; Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis; Optimal blood pressure target for patients with prior stroke: A systematic review and meta-analysis,https://pubmed.ncbi.nlm.nih.gov/28564682/; https://pubmed.ncbi.nlm.nih.gov/39263736/; https://pubmed.ncbi.nlm.nih.gov/40097615/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 24, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Do patients taking spironolactone have higher rates of hyperkalemia than patients taking eplerenone?', 'role': 'user'}]}",True,200.0,69.49037671089172,,2c64b3f4-1c12-4691-82e8-fb1e3a1d0e90,1265.0,"Limitations: Direct, high‑quality head‑to‑head data on hyperkalemia incidence are limited and the av...",3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The provided context includes direct references to head-to-head randomized trials and systematic reviews/meta-analyses that evaluate hyperkalemia rates between spironolactone and eplerenone. Specifically, the studies found no definitive or consistent difference in hyperkalemia incidence between the two drugs.
2. context_addresses_question: True. All included studies pertain directly to the question of hyperkalemia rates with spironolactone versus eplerenone, whether in heart failure or hyperaldosteronism.
3. answer_grounded_in_context: True. The AI's answer consistently cites the findings and limitations reported in the context, emphasizes the reported lack of a clear difference in hyperkalemia, and accurately reflects the low certainty and limited power of available data. No unsupported claims or facts are introduced.",874,3,3,231.0,693,Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis; Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis; Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism,https://pubmed.ncbi.nlm.nih.gov/39271992/; https://pubmed.ncbi.nlm.nih.gov/38511069/; https://pubmed.ncbi.nlm.nih.gov/18312153/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 28, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD patients with Mucus plug, Intervention: fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Outcomes: % with COPD related Hospitalization', 'role': 'user'}]}",True,200.0,56.87448811531067,,23eedec7-0aca-471b-a180-2a129ef68aa0,1703.0,No published study was identified that reports the effect of fluticasone furoate/umeclidinium/vilant...,2.0,F/T/T,2.0,False,True,True,"The context discusses the relationship between mucus plugs and clinical outcomes in COPD, as well as the effects of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy on hospitalization rates in general COPD populations. However, there is no data in the context that directly answers the question regarding the percentage of COPD patients with mucus plugs who experienced hospitalization when treated with FF/UMEC/VI. The AI's answer correctly notes the absence of direct data for this specific subgroup, summarizes relevant findings, and does not introduce information unsupported by the context. The context is relevant but indirect regarding the precise population and outcome asked.",707,4,4,224.75,899,Mucus Plugs as Precursors to Exacerbation and Lung Function Decline in COPD Patients; Silent Airway Mucus Plugs in COPD and Clinical Implications; Impact of the IMPACT Trial - PMC; Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes,https://pubmed.ncbi.nlm.nih.gov/39122616/; https://pubmed.ncbi.nlm.nih.gov/38013161/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6296790/; https://pubmed.ncbi.nlm.nih.gov/39453592/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 33, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the prevalence of heart failure across different age brackets?', 'role': 'user'}]}",True,200.0,43.54799509048462,,9885670f-15dd-41a3-8494-bfdc58814322,789.0,"Available population-based studies show a steep, age-related rise in heart‑failure (HF) prevalence, ...",3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question by reporting specific prevalence percentages for heart failure across different age brackets, drawn from the provided context (notably source [1]). It also accurately mentions the variability in estimates across studies and the trend for increasing prevalence with age, summarizing relevant points from sources [2] and [3]. There are no unsupported claims; all data points and generalizations are grounded in the provided context. Therefore, all three criteria are fully met.",523,3,3,183.33333333333334,550,"Heart failure in primary care: prevalence related to age and comorbidity; Prevalence, incidence and survival of heart failure: a systematic review; Epidemiology of heart failure",https://pmc.ncbi.nlm.nih.gov/articles/PMC6683237/; https://pubmed.ncbi.nlm.nih.gov/35042750/; https://pubmed.ncbi.nlm.nih.gov/2000773/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 29, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: prescribers identified through retrospective EHR or claims data, Cohort_1: prescribers of maintenance naive chronic obstructive pulmonary disease inhaled ics/lama/laba, Cohort_2: prescribers of maintenance naive asthma inhaled ics/laba/lama', 'role': 'user'}]}",True,200.0,90.79524993896484,,06ce540e-7098-4806-8dee-52e9dd4ac274,3261.0,"Limitation: the published, claims/EHR–based literature identified in this search is focused on COPD;...",3.0,T/T/T,3.0,True,True,True,"The provided context specifically describes how maintenance-naive cohorts are defined in claims/EHR-based studies for COPD, including methods for identifying prescribers and operational definitions for cohort selection. The AI answer mirrors this information, noting the operational definition for COPD, reference to a 12-month baseline, prescriber identifiers, and prescriber attribution, all supported by citations from the context (references 1, 2, and 4). It also correctly identifies the absence of published studies in maintenance-naive asthma triple-therapy prescriber-level cohorts in the context, aligning with what is mentioned in the original sources. Further, the answer discusses nuances and limitations mentioned in the source material, such as claims reflecting fill behavior and the need for sensitivity analyses. Thus, the answer is directly grounded in, and does not exceed, the context provided.",914,4,4,249.0,996,Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count 6le;300 Cells/bcl; Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD; Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study; Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015	62019),https://pmc.ncbi.nlm.nih.gov/articles/PMC12478208/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9166325/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10372961/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12169042/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 35, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with heart failure, Intervention: NT-proBNP measured post-diagnosis, Outcomes: NT-proBNP level >4000 pg/mL', 'role': 'user'}]}",True,200.0,63.77410936355591,,91f239c1-4785-4390-8e20-8487a6ff2cd5,2313.0,Limitations: No identified study analyzed prognosis in a heart-failure–only cohort using a pre-speci...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct answer to the question of outcomes specifically for patients with heart failure and an NT-proBNP level >4000 pg/mL; rather, it describes a range of NT-proBNP values, their prognostic significance, and cutoffs used in related but not identical cohorts. Nonetheless, the context is clearly relevant to the question, as it discusses NT-proBNP thresholds and associated risk stratification in heart failure populations. The AI's response accurately represents the context and does not introduce outside knowledge or unsupported claims; it remains grounded in the referenced studies.",616,4,4,252.5,1010,NT-proBNP as an Independent Predictor of Long-Term All-Cause Mortality in Heart Failure Across the Spectrum of Glomerular Filtration Rate - PubMed; Prognostic value of extreme NT-proBNP levels in patients hospitalized for heart failure - PubMed; Natriuretic Peptides to Predict Short-Term Mortality in Patients With Sepsis: A Systematic Review and Meta-analysis - PubMed; NT-proBNP cut-off value for ruling out heart failure in atrial fibrillation patients - A prospective clinical study - PubMed,https://pubmed.ncbi.nlm.nih.gov/40507648/; https://pubmed.ncbi.nlm.nih.gov/40409228/; https://pubmed.ncbi.nlm.nih.gov/32055771/; https://pubmed.ncbi.nlm.nih.gov/37320999/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 27, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Are primary care physicians who prescribe triple therapy to maintenance naive asthma patients more likely to prescribe triple therapy to maintenance naive copd patients?', 'role': 'user'}]}",True,200.0,109.61484503746033,,960f3ee7-e6cc-4146-ba4c-e396e6f23383,1712.0,Limitations: No published study was identified that directly measures whether the same primary care ...,2.0,F/T/T,2.0,False,True,True,"The provided context discusses the prescribing patterns of triple therapy separately in asthma and COPD, including provider type influence and the rarity of maintenance-naïve triple therapy initiation in asthma. It also notes between-physician variation in COPD triple therapy prescribing. However, there is no direct data or study provided in the context that answers whether primary care physicians who prescribe triple therapy to maintenance-naïve asthma patients are more likely to do so for maintenance-naïve COPD patients. The AI correctly identifies this limitation and grounds its answer in the available context, appropriately stating that direct evidence is lacking and summarizing the relevant findings.",714,4,4,294.0,1176,Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD - PMC; Real‑world users of triple therapy for asthma in the US - PubMed; Treatment Patterns and Disease Burden Associated with Multiple‑Inhaler Triple‑Therapy Use in Asthma - PubMed; An Exploratory Study of Physician Decision‑Making When Treating Uncontrolled COPD - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC9166325/; https://pubmed.ncbi.nlm.nih.gov/38381542/; https://pubmed.ncbi.nlm.nih.gov/34626859/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11193463/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 32, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do GLP1s improve outcomes for Asthma patients?', 'role': 'user'}]}",True,200.0,73.98965406417847,,dcdbd319-d478-4f5f-8d9e-5e935d6a23e1,1481.0,Limitations: Most randomized trials of GLP‑1 receptor agonists were conducted in people with diabete...,3.0,T/T/T,3.0,True,True,True,"The provided context contains direct evidence addressing the impact of GLP-1 receptor agonists (GLP-1RAs) on asthma outcomes, including findings from meta-analyses, cohort studies, and reviews. The AI's answer accurately summarizes these findings and appropriately acknowledges the limitations of current data, such as the lack of asthma-specific randomized clinical trials. The answer is fully grounded in the context, citing specific results (e.g., reduced risk in meta-analyses, real-world evidence of improved asthma control and lower exacerbations, and preclinical/retrospective data). It avoids introducing unsupported claims and is well-aligned with the provided evidence, meeting all three evaluation criteria.",718,5,5,184.8,924,The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis - PubMed; The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials - PubMed; Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists - PubMed; The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity - PubMed; Evaluating the glucagon-like peptide-1 receptor in managing asthma - PubMed,https://pubmed.ncbi.nlm.nih.gov/38988111/; https://pubmed.ncbi.nlm.nih.gov/37491292/; https://pubmed.ncbi.nlm.nih.gov/33052715/; https://pubmed.ncbi.nlm.nih.gov/40198520/; https://pubmed.ncbi.nlm.nih.gov/34772827/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 36, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Among heart failure patients, what proportion have NT-proBNP levels exceeding 4000 pg/mL at any point after diagnosis?', 'role': 'user'}]}",True,200.0,67.25654363632202,,2d19959e-799c-462b-aa54-842b9a8fee18,894.0,"Limitations: available, full-text data describe NT‑proBNP distributions mainly in patients with HFrE...",3.0,T/T/T,3.0,True,True,True,"The provided context includes precise statistics, stating that 25.5% of HFrEF patients who had NT-proBNP tested exceeded 4000 pg/mL, which directly addresses the question. Additionally, the AI clearly mentions the proportion (25.5%) and clarifies testing limitations in the interpretation, mirroring details from the context. The AI's answer is firmly grounded in the supplied data, with no extrapolated or unsupported claims. Therefore, all three criteria are met.",465,2,2,236.5,473,N‑terminal pro‑B‑type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction; Impact of NT‑proBNP on prognosis of acute decompensated chronic heart failure versus de novo heart failure,https://pmc.ncbi.nlm.nih.gov/articles/PMC8787988/; https://pubmed.ncbi.nlm.nih.gov/35753618/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 31, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'STUDY DESIGN\n  Title: Difference in all-cause hospitalization rates between Breztri Aerosphere and Trelegy Ellipta users in US commercial + Medicare claims\n  Data Source: ATROPOS-claims (open adjudicated + Pharmetrics, 2019-2024)\n  Study Period: 01-Jan-2020 to 31-Dec-2023\n  Follow-up Window: index date → earliest of 12 months, death, plan disenrollment, or end of data\n  \n COHORT 1 (Breztri)\n  Index Event:\n  first dispensing or administration of Breztri Aerosphere (NDC or J-code list)\n  Continuous Enrollment:\n  ≥6 months pre-index medical + pharmacy\n  ≥1 day post-index enrollment\n  Exclusions:\n  any Trelegy (NDC/J-code) dispensing in the 6 months pre-index\n  \n COHORT 2 (Trelegy)\n  Index Event:\n  first dispensing or administration of Trelegy Ellipta\n  Continuous Enrollment:\n  ≥6 months pre-index medical + pharmacy\n  ≥1 day post-index enrollment\n  Exclusions:\n  any Breztri dispensing in the 6 months pre-index\n  \n BASELINE COVARIATES (look-back = 6 months pre-index)\n  Age, Sex, Region, Insurance Type\n  Quan-Charlson Comorbidity Index\n  COPD severity proxy: # COPD exacerbations, OCS bursts, prior hospitalizations\n  Respiratory comedications: LABA, LAMA, ICS, SABA, OCS\n  Health-care utilization: total inpatient stays, ER visits, office visits, total cost\n  \n OUTCOME\n  All-cause inpatient hospitalization (IP stay with admission date within follow-up)\n  \n ANALYSES\n  1. Crude incidence rate\n  numerator: patients with ≥1 hospitalization\n  denominator: person-years of follow-up\n  output: incidence rate/100 PY, 95 % CI\n  2. Time-to-first hospitalization\n  Kaplan–Meier curve, log-rank p-value\n  3. Adjusted hazard ratio\n  Cox PH model: treatment (Breztri vs Trelegy) + baseline covariates\n  4. Propensity score IPTW sensitivity\n  PS estimated via logistic regression on baseline covariates\n  apply stabilized weights; run weighted Cox model\n  \n OUTPUTS\n  • Table 1: baseline characteristics by cohort (unweighted and weighted) \n  • Incidence rate table \n  • KM plot', 'role': 'user'}]}",True,200.0,108.98238635063171,,b23e69af-86e2-4c81-b2c6-d3abf33bde1a,2903.0,"Recommended, citation-grounded analysis plan (concise):

1) Crude incidence rates (per 100 person‑ye...",3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The answer provides step-by-step recommendations for incidence rate calculation (with the correct formula and reference to proper CI estimation), time-to-event analysis using Kaplan-Meier and log-rank test, Cox proportional hazards modeling for adjusted HR with PH assessment, and IPTW (including use of stabilized weights and correct citation for variance estimation and balance diagnostics), all of which are specifically evidenced by the provided context. 2. context_addresses_question: True. Every step in the AI's answer matches topics directly discussed in the context (incidence rate calculation and CIs, KM/Greenwood/Cox PH, IPTW with stabilized weights and balance diagnostics). 3. answer_grounded_in_context: True. All methods and statements in the answer are explicitly justified by the context references (including limitations and expected reporting practices); there are no unsupported claims or reliance on external knowledge.",985,5,5,262.0,1310,Methods of analysis - Field Trials of Health Interventions - NCBI Bookshelf; Appendix A: Models for Time-to-Event Outcomes - Artificial Intelligence and Machine Learning in Health Care and Medical Sciences - NCBI Bookshelf; Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals - PubMed; Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies - PubMed; Assessing Covariate Balance With Small Sample Sizes - PubMed,https://www.ncbi.nlm.nih.gov/books/NBK305516/; https://www.ncbi.nlm.nih.gov/books/NBK610554/; https://pubmed.ncbi.nlm.nih.gov/19912596/; https://pubmed.ncbi.nlm.nih.gov/26238958/; https://pubmed.ncbi.nlm.nih.gov/40772805/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 37, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: outpatients with transthyretin (ATTR) amyloidosis, Intervention: silencer therapy, Outcomes: duration of silencer therapy', 'role': 'user'}]}",True,200.0,88.47135496139526,,7b2822e5-dde4-4839-b81f-d7a10133b5eb,996.0,Randomized trials and regulatory/clinical reports show TTR “silencer” therapies are given as continu...,3.0,T/T/T,3.0,True,True,True,"The context provides direct, specific evidence regarding the duration of silencer therapies (inotersen: 15 months, patisiran: 18 months, vutrisiran: up to 36 months) in randomized trials involving outpatients with transthyretin amyloidosis. The AI's answer accurately cites these durations and dosing schedules as described in the context documents, and does not introduce information beyond what is provided. All statements are grounded in the cited clinical trial data from the supplied context. Therefore, all criteria are satisfied.",536,4,4,197.75,791,"Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy - PMC; Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis - PubMed; Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy - PubMed; Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis - PubMed",https://pmc.ncbi.nlm.nih.gov/articles/PMC10339464/; https://pubmed.ncbi.nlm.nih.gov/31322739/; https://pubmed.ncbi.nlm.nih.gov/39213194/; https://pubmed.ncbi.nlm.nih.gov/29972757/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 34, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with BMI 30 or higher, is there a difference in use of GLP1-RA in those with vs without a recorded obesity diagnosis?', 'role': 'user'}]}",True,200.0,114.13500332832336,,301338f8-cdf2-422f-ad65-18ad32b3b984,1953.0,Limitations: no published study was identified that directly compares GLP‑1 RA prescribing rates amo...,2.0,F/T/T,2.0,False,True,True,"The AI's answer accurately reflects the provided context, stating that there is no published study directly comparing GLP-1 RA use among BMI ≥30 patients with versus without a recorded obesity diagnosis. This matches the context, which notes that while some studies report the proportion of GLP-1 users who have an obesity diagnosis code, none directly compare use rates by diagnosis status. The AI further synthesizes related findings regarding code sensitivity/specificity and general prescription patterns, all supported by the cited references. Thus, the answer is strongly grounded in the context, addresses the question's subject, but does not provide a direct answer because the context lacks such evidence.",714,4,4,241.25,965,Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills; Validation of obesity-related diagnosis codes in claims data; Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital regiona register-based cross-sectional study; Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data,https://pubmed.ncbi.nlm.nih.gov/38287140/; https://pubmed.ncbi.nlm.nih.gov/34338404/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12003583/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10702395/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 30, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD, Intervention: budesonide-glycopyrrolate-formoterol, Control: fluticasone-umeclidinium-vilanterol, Outcomes: % Hospitalization', 'role': 'user'}]}",True,200.0,158.89847469329834,,613a611f-3388-4d33-b128-bc4d28446fb8,1444.0,"Limitations: no randomized, head‑to‑head trial compares hospitalization % for budesonide–glycopyrrol...",3.0,T/T/T,3.0,True,True,True,"The AI's answer closely reflects the contents of the provided context. The question asks for hospitalization outcomes comparing two triple therapies (BGF vs FF/UMEC/VI) in COPD. The assistant identifies and summarizes a key propensity-score matched observational study which directly compares these two therapies and specifies there was no difference in pneumonia admissions but a higher hazard of severe exacerbation (hospitalization-level) with BGF. It correctly notes the absence of direct RCT percentage comparison and contextualizes relevant secondary evidence. All claims regarding outcomes and study design are based on the references in the context, without introducing external or unsupported information. Therefore, all criteria are fulfilled.",753,3,3,229.33333333333334,688,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Once‑Daily Single‑Inhaler Triple versus Dual Therapy in Patients with COPD (IMPACT); Reduced All‑Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/29668352/; https://pubmed.ncbi.nlm.nih.gov/33252985/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 42, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Lupus , Cohort_1: Hydroxychloroquine, Cohort_2: Steroid, Outcomes: ED visit', 'role': 'user'}]}",True,200.0,61.53428101539612,,1ac1d855-2093-49bc-b4b6-2e35947892ab,870.0,Limitation: the reviewed literature did not report a head‑to‑head study comparing hydroxychloroquine...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include a direct, head-to-head comparison of ED visits between lupus patients treated with hydroxychloroquine and those treated with steroids, which was the specific question asked. Instead, the context supplies evidence that hydroxychloroquine is associated with fewer acute care visits (not exclusively ED visits) and that high-dose steroid users have higher ED visit rates compared to low-dose users. The AI answer accurately reflects this limitation and summarizes the findings from the context without introducing external information. Therefore, the context does not directly answer the question, but it does address it (by providing some indirectly relevant data), and the AI's answer remains well-grounded in the context.",759,3,3,207.66666666666666,623,Therapeutic Hydroxychloroquine Blood Levels Are Associated With Fewer Hospitalizations and Possible Reduction of Health Disparities in Lupus; Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus; Health care utilization and costs of systemic lupus erythematosus in the United States: A systematic review,https://pubmed.ncbi.nlm.nih.gov/39187461/; https://pubmed.ncbi.nlm.nih.gov/30068254/; https://pubmed.ncbi.nlm.nih.gov/35467448/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 39, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the prevalence of heart failure', 'role': 'user'}]}",True,200.0,77.91651844978333,,a1bce2d6-72d7-4514-bc32-6bcaf125526d,802.0,"Limitations: reported prevalence varies substantially by case definition, age group, and study metho...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is comprehensive and quotes exact prevalence numbers from the context for both US and global populations, referencing varied prevalence figures, methodological differences, and projections. Each numerical estimate and limitation mentioned is directly supported by a referenced source from the context. The answer also addresses the effect of age, diagnostic criteria, and setting as indicated in the context. No external information or hallucinated data is introduced, and all statements are firmly grounded in the context provided. Thus, all evaluation criteria are met.",587,4,4,98.5,394,"Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America - PMC; Prevalence, incidence and survival of heart failure: a systematic review - PMC; Global Public Health Burden of Heart Failure: An Updated Review - PubMed; Global, regional, and national burden of heart failure and its underlying causes, 1990-2021: results from the global burden of disease study 2021 - PubMed",https://pmc.ncbi.nlm.nih.gov/articles/PMC10864030/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9380485/; https://pubmed.ncbi.nlm.nih.gov/37547123/; https://pubmed.ncbi.nlm.nih.gov/39849627/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 38, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the prevalence of HF', 'role': 'user'}]}",True,200.0,90.82621693611145,,de26a587-2040-43ab-916e-09b25c46da66,908.0,"Estimates depend on population, age structure, and case definition: a systematic review found study ...",3.0,T/T/T,3.0,True,True,True,"The context provides multiple specific estimates on the prevalence of heart failure (HF) both in the U.S. and globally, including percentages, number of cases, and the variation due to case definition and study methods. The AI assistant's answer accurately summarizes all these data points: the estimated U.S. prevalence (1.9–2.6%, ≈6.7 million), projected increases, lifetime risk, and global prevalence (tens of millions, 64 million), and the wide range of prevalence found in systematic reviews (0.2–17.7%). The answer stays grounded in the provided context and does not introduce any external or unsupported claims. Thus, all evaluation criteria are fully met.",664,5,5,162.0,810,"Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America; Global Public Health Burden of Heart Failure: An Updated Review; Global, regional, and national burden of heart failure and its underlying causes, 1990-2021: results from the global burden of disease study 2021; Prevalence, incidence and survival of heart failure: a systematic review; Epidemiology and aetiology of heart failure",https://pmc.ncbi.nlm.nih.gov/articles/PMC10864030/; https://pubmed.ncbi.nlm.nih.gov/37547123/; https://pubmed.ncbi.nlm.nih.gov/39849627/; https://pubmed.ncbi.nlm.nih.gov/35042750/; https://pubmed.ncbi.nlm.nih.gov/26935038/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 44, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: female patients with systemic lupus erythematosus, Intervention: diagnosis code for hormone replacement therapy, Control: non-hormone replacement therapy management of menopausal symptoms, Outcomes: SLE Flaire', 'role': 'user'}]}",True,200.0,59.310394287109375,,9f81ef48-2ea9-49f7-8cde-9a8c374582b0,1386.0,"Limitations: Available studies evaluated actual HRT exposure (randomized or observational), not a cl...",3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The provided context directly addresses the comparison between HRT (as an intervention) and non-HRT management in female SLE patients, specifically regarding SLE flares. The context explicitly includes randomized controlled trial data and systematic reviews that report the impact of HRT on SLE flare rates, which matches the specified outcomes of the original question. 

2. context_addresses_question: True. The context includes studies that assess the effects of hormone replacement therapy versus alternative management of menopausal symptoms in women with SLE, thus being highly relevant to the PICOS elements outlined in the question.

3. answer_grounded_in_context: True. The AI answer closely summarizes and references the specific trial and systematic review findings from the context, accurately describing both quantitative and qualitative results (e.g., risk ratios, nature/severity of flares, and caveats regarding population risk and recommendations). The answer does not introduce information not supported by the context and appropriately notes the limitations (such as study exposure definitions vs diagnosis code exposure).",1185,4,4,253.75,1015,The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial; Effect of menopause hormone therapy on disease progression in systemic lupus erythematosus: A systematic review; Hormone therapy effect on menopausal systemic lupus erythematosus patients: a systematic review; Systemic lupus erythematosus and hormone replacement therapy,https://pubmed.ncbi.nlm.nih.gov/15968009/; https://pubmed.ncbi.nlm.nih.gov/25882762/; https://pubmed.ncbi.nlm.nih.gov/35438053/; https://pubmed.ncbi.nlm.nih.gov/17540136/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 43, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD, Intervention: budesonide-glycopyrrolate-formoterol, Control: fluticasone-umeclidinium-vilanterol, Outcomes: % with COPD-related hospitalization', 'role': 'user'}]}",True,200.0,81.98685622215271,,c4b164c7-0421-4352-be55-5a8e8c676466,1862.0,Limitations: No published head-to-head randomized trial reports a single pooled percentage of patien...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the question regarding the percentage of patients with COPD-related hospitalizations for the specified interventions; it states that outcomes are given as hazard ratios, annualized rates, or summarized efficacy measures rather than explicit percentages hospitalized. The context is clearly relevant to the question, as it details the comparative studies involving the specified drug regimens and discusses outcome reporting. The AI's answer accurately summarizes and remains grounded in the provided context, stating the lack of a direct percent comparison, describing the nature of reported outcomes, and providing relevant findings from the studies without introducing unsupported information.",741,3,3,337.3333333333333,1012,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease; Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/39731707/; https://pubmed.ncbi.nlm.nih.gov/33929661/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 45, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the incidence of cdiff in immunocompromised patients?', 'role': 'user'}]}",True,200.0,53.07160949707031,,f5eabcac-dc2b-4870-bfef-a96d846a05e6,1221.0,Published data report subgroup-specific incidence rather than a single overall incidence for all “im...,3.0,T/T/T,3.0,True,True,True,"The context provides subgroup-specific incidence rates of C. difficile infection (CDI) in various immunocompromised populations (hematology-oncology, solid organ transplant, HSCT, HIV). The AI answer accurately reflects these nuances and rates, specifying the ranges and citing subgroups with figures directly traceable to the context. It refrains from extrapolating beyond the provided data or synthesizing unsupported claims and mentions recurrence rates as addressed by the context. All elements of the answer align with the evidence presented, directly and explicitly answering the original question.",604,4,4,248.0,992,"Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention; Prevalence of Clostridium difficile Infection in the Hematopoietic Transplantation Setting: Update of Systematic Review and Meta-Analysis; Incidence and Outcomes Associated With Clostridioides difficile Infection in Solid Organ Transplant Recipients - PubMed; Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice",https://pubmed.ncbi.nlm.nih.gov/30281082/; https://pubmed.ncbi.nlm.nih.gov/35265530/; https://pubmed.ncbi.nlm.nih.gov/34964852/; https://pubmed.ncbi.nlm.nih.gov/31002420/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 41, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Intervention: Dupixent, Control: Fasenra, Outcomes: % of asthma related ED visit', 'role': 'user'}]}",True,200.0,93.80574154853821,,c136a267-428f-4da6-951d-b3ac18308420,1979.0,Limitation: No randomized head‑to‑head trial reporting asthma‑related emergency‑department (ED) visi...,2.0,F/T/T,2.0,False,True,True,"
- context_answers_question_directly: False. The provided context does not include specific, quantitative, head-to-head comparative data on the percentage of asthma-related ED visits between Dupixent and Fasenra. The AI notes this absence and synthesizes indirect and separate evidence from studies on each drug, but no direct comparative answer is available.
- context_addresses_question: True. The context is relevant as it discusses studies involving Dupixent and Fasenra (benralizumab) and their impacts on asthma-related ED visits, both in RCT and real-world settings, addressing the question's subject matter.
- answer_grounded_in_context: True. The AI's answer relies exclusively on the information presented in the context, accurately reflecting limitations, findings from pooled RCTs, and real-world evidence without introducing outside or unsupported claims.",868,3,3,228.33333333333334,685,"Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study; Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)",https://pubmed.ncbi.nlm.nih.gov/40261563/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9990964/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8684207/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 46, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the distribution of IV gluccocorticoid use in SLE patients?', 'role': 'user'}]}",True,200.0,57.066903591156006,,806261ea-0a14-4036-b666-bbcfe82947d6,1095.0,Available observational cohorts and reviews show that intravenous (IV) glucocorticoids (usually IV m...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately captures the evidence from the provided context, citing specific statistics for parenteral/IV glucocorticoid use in SLE patients (26.3% in the SLICC cohort and 38.7% in a separate cohort). The answer notes between-center and definitional variability, in line with how the context discusses these issues. Explanatory remarks regarding the variability, definitions, and clinical context of IV glucocorticoid use are supported by the cited review and study data. The response does not make unsupported claims and is grounded in the provided context throughout. Thus, all three criteria are satisfied.",624,3,3,232.66666666666666,698,Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort; Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study; Use of Glucocorticoids in SLE: A Clinical Approach,https://pmc.ncbi.nlm.nih.gov/articles/PMC5888922/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9330647/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345604/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 47, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do GLP1 affect COPD exacerbation rates?', 'role': 'user'}]}",True,200.0,50.893147468566895,,7cd57ed0-0b90-40db-9af7-0b191e4140b0,1479.0,Available evidence—primarily observational studies synthesized in recent systematic reviews and a Me...,3.0,T/T/T,3.0,True,True,True,"The provided context directly addresses the question by reporting data from multiple systematic reviews and analyses showing that GLP-1 receptor agonists are associated with lower COPD exacerbation rates compared to sulfonylureas and DPP-4 inhibitors. It also mentions supporting evidence from Mendelian randomization studies. The AI's answer accurately summarizes the key findings, references the strength and limitations of the evidence, and does not introduce unsupported claims. The context and the answer both focus on the relationship between GLP-1 therapy and COPD exacerbation rates, making the answer fully grounded in the supplied material.",650,4,4,197.0,788,"Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis; Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes - PubMed; Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization - PubMed",https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/41011208/; https://pubmed.ncbi.nlm.nih.gov/37647574/; https://pubmed.ncbi.nlm.nih.gov/40722198/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 50, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients diagnosed with severe acute kidney injury, Intervention: Encounter for care involving renal dialysis, Control: patients diagnosed with severe acute kidney injury not receiving renal replacement therapy, Outcomes: death', 'role': 'user'}]}",True,200.0,69.63926219940186,,3e81f61f-1694-4b29-8083-eb73d0cc72a6,1041.0,Limitations: randomized trials compare strategies that change how often patients receive renal repla...,2.0,F/T/T,2.0,False,True,True,"The context provided focuses on studies that compared early (accelerated) versus late (standard/deferred) initiation strategies for renal replacement therapy (RRT) in patients with acute kidney injury, rather than directly comparing outcomes between patients receiving RRT versus those not receiving it at all. Thus, the context does not directly answer whether RRT, compared to no RRT, affects mortality, but it is relevant in that it addresses timing and related mortality outcomes within groups where not all patients in the control arm received RRT. The AI answer accurately represents the limitations and findings described in the context, stating there is no clear evidence of a mortality benefit and outlining the methodological issue (i.e., studies do not randomize to 'RRT vs no RRT'). However, because neither the studies in context nor the summary answer directly address the precise PICO question (RRT vs no RRT), the first criterion is not met, although the other two are.",985,3,3,201.66666666666666,605,Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury; The impact of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury on mortality and clinical outcomes: a meta-analysis; Early strategy vs. late initiation of renal replacement therapy in adult patients with acute kidney injury: an updated systematic review and meta-analysis of randomized controlled trials,https://pubmed.ncbi.nlm.nih.gov/32668114/; https://pubmed.ncbi.nlm.nih.gov/36158157/; https://pubmed.ncbi.nlm.nih.gov/37458646/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 52, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do GLP1 reduce COPD exacerbation rates?', 'role': 'user'}]}",True,200.0,54.49000692367554,,9cb6e5d5-bc7b-408c-a0c6-0bcf7fd4f95f,1319.0,The available clinical evidence—consisting mainly of observational cohort studies and systematic rev...,3.0,T/T/T,3.0,True,True,True,"The context directly addresses whether GLP-1 receptor agonists reduce COPD exacerbation rates by providing specific results from systematic reviews, meta-analyses, and retrospective cohort studies. The AI's answer accurately summarizes these findings, highlighting significant reductions in COPD exacerbation rates with GLP-1RAs compared to sulfonylureas and DPP-4 inhibitors, but not versus SGLT2 inhibitors. It also correctly notes the lack of randomized controlled trials. The answer is entirely based on the provided context, without introducing external information or unsupported claims.",593,3,3,294.0,882,"Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis; Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes",https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/41011208/; https://pubmed.ncbi.nlm.nih.gov/37647574/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 40, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Intervention: Airsupra, Control: Albuterol, Outcomes: % with asthma related ED visit', 'role': 'user'}]}",True,200.0,148.3563747406006,,8dc1d599-7a44-4fe7-9de2-65048ca04e4f,1202.0,Limitation: The pivotal trials and label use “severe asthma exacerbation” as the endpoint (which by ...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question regarding the percentage of asthma-related ED visits for Airsupra versus albuterol. Instead, it reports outcomes for the composite endpoint of 'severe exacerbation' (which includes ED/urgent care visits requiring corticosteroids) but does not disaggregate ED-only data. The AI's answer accurately reflects this limitation, clearly stating that ED-only percentages are not provided, thus grounding its answer in the context. The context is still relevant since it addresses the related clinical outcomes and the relevant populations and interventions.",600,3,3,287.0,861,"AIRSUPRA- albuterol sulfate and budesonide aerosol, metered; Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma; Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e60aa9f9-5139-44df-b886-ebddc3c7eb13; https://pubmed.ncbi.nlm.nih.gov/35569035/; https://pubmed.ncbi.nlm.nih.gov/37003355/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 56, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'does uncontrolled hypertension increase the risk of stroke', 'role': 'user'}]}",True,200.0,45.05820035934448,,d0d86c13-ea9c-41a2-9daf-c3ce40ea9fc0,788.0,Yes. Multiple observational and trial-based syntheses show higher (uncontrolled or elevated) blood p...,3.0,T/T/T,3.0,True,True,True,"The context directly addresses the question, providing quantitative evidence that uncontrolled blood pressure is associated with increased risk of both ischemic and hemorrhagic stroke. The AI assistant's answer correctly summarizes this information and adds specific risk ratios and references, all of which are supported by the context. While the assistant also mentions the benefits of blood pressure lowering and the risk elevation in prehypertension, these points are grounded in the documented studies included within the context. Thus, all evaluation criteria are met.",574,4,4,157.25,629,Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients - PubMed; Prehypertension and the risk of stroke: a meta-analysis - PubMed; Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review - PubMed; Impact of Intensive Blood Pressure Control Versus Standard Control on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed,https://pubmed.ncbi.nlm.nih.gov/10657416/; https://pubmed.ncbi.nlm.nih.gov/24623843/; https://pubmed.ncbi.nlm.nih.gov/14576382/; https://pubmed.ncbi.nlm.nih.gov/40772210/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 48, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'suggest some novel indications for existing AstraZeneca drugs', 'role': 'user'}]}",True,200.0,103.8079161643982,,103ceb4b-ddd9-4d15-9d56-26a124643602,2461.0,Limitations: several of the proposals below rest on preclinical or class-level evidence rather than ...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly suggests novel indications for multiple AstraZeneca drugs, matching the specific evidence from the provided context. For example, dapagliflozin for NAFLD/NASH cites clinical trial and meta-analysis data; acalabrutinib for bone loss is supported by preclinical findings; BTK inhibition in MS is attributed to class-level evidence; olaparib plus anti-PD1 for gastric cancer relies on preclinical synergy; and ticagrelor for pneumonia uses data from a randomized mechanistic human study. Each claim is grounded in the referenced context and the answer accurately describes the level of evidence, making no claims unsupported by the context. The answer is thus directly responsive, relevant, and contextually grounded.",739,5,5,240.4,1202,"Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis - PubMed; A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption - PubMed; A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis - PubMed; Olaparib Combined with Anti-PD1 Enhances Immunotherapy of Gastric Cancer Via NF-κB/c-Myc/PD-L1 Signaling - PMC (preclinical) - PubMed; Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia - PMC - PubMed",https://pubmed.ncbi.nlm.nih.gov/35202771/; https://pubmed.ncbi.nlm.nih.gov/30387495/; https://pubmed.ncbi.nlm.nih.gov/38638671/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12185624/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6115703/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 54, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with type 2 diabetes and chronic obstructive pulmonary disease, Intervention: glucagon-like peptide-1 agonists, Control: dipeptidyl peptidase-4 inhibitors, Outcomes: hospitalisation for chronic obstructive pulmonary disease exacerbations', 'role': 'user'}]}",True,200.0,79.44507765769958,,726a11a4-4c15-4bbd-a7e1-6a484953f5a3,1102.0,Limitations: available evidence is observational (retrospective cohort / EHR studies); randomized tr...,3.0,T/T/T,3.0,True,True,True,"The context provided directly answers the question: all three cited studies are focused on patients with type 2 diabetes (T2DM) and chronic lower respiratory diseases (including COPD), comparing GLP-1 receptor agonists (GLP-1RAs) to DPP-4 inhibitors (DPP-4is), and measuring outcomes related to COPD/CLRD exacerbations requiring hospitalization. The AI answer accurately reports the studies' findings, citing specific hazard ratios and incidence rate ratios, and correctly states that the evidence is based on observational studies rather than randomized controlled trials. The summary and interpretation given in the AI answer are rooted in the provided context without introducing unsupported claims.",702,3,3,191.66666666666666,575,Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes; Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes,https://pubmed.ncbi.nlm.nih.gov/33875487/; https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/37647574/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 53, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'do GLP1s reduce the risk of COPD exacerbations', 'role': 'user'}]}",True,200.0,82.81838297843933,,ecd5a5f4-8606-42df-b864-92975df77763,1625.0,Available human-data from observational cohorts and syntheses show GLP‑1 receptor agonist (GLP‑1RA) ...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The context includes multiple systematic reviews, meta-analyses, and cohort studies directly evaluating whether GLP-1 receptor agonists reduce COPD exacerbations, with specific quantitative results reported (e.g., IRR 0.52, RR ~0.66, lower unadjusted exacerbation counts). 2. context_addresses_question: True. All cited studies, including observational, genetic, and preclinical data, are directly relevant to GLP-1s' effect on COPD exacerbations. 3. answer_grounded_in_context: True. The AI's answer is well-grounded in the context—it accurately summarizes the study findings, limitations (nonrandomized data), and even mentions the mixed evidence from preclinical studies, reflecting the content provided.",751,5,5,226.0,1130,"Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis; Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes - PubMed; Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization - PubMed; Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases - PubMed",https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/41011208/; https://pubmed.ncbi.nlm.nih.gov/37647574/; https://pubmed.ncbi.nlm.nih.gov/40722198/; https://pubmed.ncbi.nlm.nih.gov/31996306/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 51, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with body mass index 30 or higher, Intervention: obesity diagnosis, Control: no obesity diagnosis, Outcomes: semaglutide or tirzepatide', 'role': 'user'}]}",True,200.0,98.59326910972595,,e3d45231-bfcd-41ed-8422-6bba44551d02,1467.0,Limitations: No published randomized trial or observational study was identified that directly compa...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the question of whether there are differences in semaglutide or tirzepatide outcomes between patients with a BMI ≥30 who receive an obesity diagnosis versus those who do not; it mainly reports on trial results by BMI categories regardless of diagnosis, and also highlights the frequent underdiagnosis of obesity. Therefore, the AI correctly states the absence of direct comparative studies and appropriately cites that efficacy trials enroll by BMI, not diagnosis status. The context broadly addresses the question by discussing the issue of obesity diagnosis and BMI-based enrollment in studies, making it relevant. The AI answer remains grounded in the context and does not introduce unsupported information.",756,4,4,248.75,995,"Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety; Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis; The Incomplete Medicalization of Obesity: Physician Office Visits, Diagnoses, and Treatments, 1996-2014; Semaglutide for the treatment of obesity",https://pubmed.ncbi.nlm.nih.gov/38463003/; https://pubmed.ncbi.nlm.nih.gov/37253796/; https://pubmed.ncbi.nlm.nih.gov/30794761/; https://pubmed.ncbi.nlm.nih.gov/34942372/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 60, 'customer': 'Astrazeneca BBU', 'messages': [{'content': '1) How many patients are treated with at least one dose of each of the following biologics in 2024? Report the number of patients for each of the three disease areas 1) patients with asthma (without CRSwNP), 2) patients with asthma and CRSwNP, 3) Patients with CRSwNP (without asthma)\n • Patients on Dupixent\n • Patients on Nucala\n • Patients on Xolair\n • Patients on Fasenra \n • Patients on Tezspire \n  \n 2) among patients from 1), report the number of patients with a valid eosinophilic lab test value by each disease cohorts\n \n 3) among three, split the patient counts by eosinophilic lab value of a) <=150/μL, b) 150-<300/μL, c) >=300/μL', 'role': 'user'}]}",True,200.0,23.25748038291931,,a5a567fe-76d7-4c8d-81e4-6c5485560751,68.0,The published literature does not contain an answer to this question,1.0,F/F/T,1.0,False,False,True,"There is no context provided, so the specific questions regarding the number of patients treated with each biologic by disease area, those with valid eosinophilic lab results, and the stratification by eosinophil count cannot be addressed at all from the context. The AI's answer indicates the literature does not contain the answer, which avoids introducing unsupported claims and remains grounded in the (lack of) context, but the response does not answer or address any part of the question directly.",503,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 49, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with BMI 30 or higher, is there a difference in use of GLP1-RA in those with vs without a recorded obesity diagnosis?', 'role': 'user'}]}",True,200.0,119.89820289611816,,cda46d8e-2ee1-4bf4-8a96-b343579cc5e9,1787.0,Limitations: No published study was identified that directly compares GLP‑1 receptor agonist (GLP‑1 ...,2.0,F/T/T,2.0,False,True,True,"The context does not supply a direct comparison of GLP1-RA use among patients with BMI ≥30 by presence or absence of a recorded obesity diagnosis; the AI answer correctly notes the lack of such a specific analysis. However, the context does address related facets including the prevalence of recorded obesity diagnoses, the association of diagnosis with treatment more broadly, and patterns of GLP1-RA prescribing with and without an obesity diagnosis. The AI's answer is grounded in the context, cites sources accurately, and avoids unsupported statements, but ultimately the definitive, directly requested data is acknowledged as missing in both the evidence and the summary.",677,3,3,282.6666666666667,848,Factors associated with receiving an obesity diagnosis and obesity-related treatment for patients with obesity class II and III within a single integrated health system; Weight Loss Treatment and Longitudinal Weight Change Among Primary Care Patients With Obesity; Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study,https://pubmed.ncbi.nlm.nih.gov/39309697/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10870179/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12003583/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 55, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Do GLP1 reduce risk of COPD exacerbation in non T1 or T2 diabetes patients?', 'role': 'user'}]}",True,200.0,83.45542883872986,,67a42a34-bb71-45cd-902a-5bdafd2ab69b,1634.0,Limitations: No published randomized trial or large observational study directly tests whether GLP‑1...,3.0,T/T/T,3.0,True,True,True,"The AI answer accurately reflects the information provided in the context. It makes clear that there is no direct clinical evidence that GLP-1 receptor agonists reduce COPD exacerbations in non-diabetic patients, summarizing the findings from the cited studies: the one randomized controlled trial in non-diabetic obese COPD patients showed improvements in lung function but did not examine exacerbations as an endpoint; all observational and meta-analysis evidence specifically assessed populations with diabetes; and Mendelian randomization suggests an association with reduced overall COPD risk but not specifically exacerbations in non-diabetic patients. The AI answer does not go beyond the context or introduce unsupported claims. Therefore, all three evaluation criteria are satisfied.",792,4,4,251.75,1007,Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease; Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review; Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes - PubMed; Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization,https://pmc.ncbi.nlm.nih.gov/articles/PMC8882670/; https://pubmed.ncbi.nlm.nih.gov/40480531/; https://pubmed.ncbi.nlm.nih.gov/37647574/; https://pubmed.ncbi.nlm.nih.gov/40722198/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 57, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the incidence rate of bacterial meningitis in patients with rheumatoid arthritis compared to patients without rheumatoid arthritis with similar baseline characteristics?', 'role': 'user'}]}",True,200.0,63.78680896759033,,c8863a04-96e1-465d-8fb9-02b4c99b6d91,1242.0,No published population-based or cohort study was identified that reports the incidence rate of cult...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False — The provided context does not include a direct, numeric comparison of the incidence rate of bacterial meningitis in RA vs. non-RA patients; it either discusses overall serious infections or provides only general comments about meningitis in RA. 
2. context_addresses_question: True — The context addresses the question's domain by discussing serious infection rates in RA patients, overall infection rates, and the rarity of meningitis reports in RA, but not specifically bacterial meningitis incidence.
3. answer_grounded_in_context: True — The AI's answer accurately reflects the limitations and content of the provided context, explicitly stating the lack of direct incidence data and matching the information drawn from the referenced studies, without introducing unsupported assertions.",837,3,3,220.33333333333334,661,Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study; Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance; Rheumatoid meningitis: A systematic review and meta-analysis,https://pubmed.ncbi.nlm.nih.gov/31245055/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10391097/; https://pubmed.ncbi.nlm.nih.gov/33966315/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 59, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'how many patients diagnosed with MYASTHENIA.GRAVIS', 'role': 'user'}]}",True,200.0,76.697505235672,,e5a956f3-59db-4b41-87db-d8c06197e268,815.0,Limitations: the question gives no region or year; reported MG frequency varies widely across studie...,3.0,T/T/T,3.0,True,True,True,"The AI’s answer is directly supported by and accurately summarizes data from the provided context, citing prevalence estimates globally and in the US, including actual patient number estimates where available. The context includes systematic reviews and epidemiological studies giving relevant prevalence figures and patient counts for different regions and time frames, exactly as summarized in the AI’s response. The answer notes limitations due to geographic and temporal variation, which the context also supports. No external data or unsubstantiated claims are introduced. Thus, the response meets all evaluation criteria.",627,5,5,179.8,899,"Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review; Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis; The epidemiology of myasthenia gravis; Incidence and prevalence of myasthenia gravis in the United States: A claims-based analysis; Epidemiology of myasthenia gravis in the United States",https://pubmed.ncbi.nlm.nih.gov/39380477; https://pmc.ncbi.nlm.nih.gov/articles/PMC8686543/; https://pubmed.ncbi.nlm.nih.gov/14592908/; https://pubmed.ncbi.nlm.nih.gov/38040629/; https://pubmed.ncbi.nlm.nih.gov/38434198/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 64, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with essential hypertension , Cohort_1: systolic blood pressure > 140, Cohort_2: systolic blood pressure < 140, Outcomes: BMI', 'role': 'user'}]}",True,200.0,53.80919146537781,,6c5fe5d7-b966-48d5-ab6a-d1556243719f,1457.0,Limitations: No primary cohort study explicitly reporting mean BMI for essential-hypertensive patien...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The context does not provide direct comparison of mean BMI between patients with systolic blood pressure >140 mmHg and those with <140 mmHg. It presents the relationship between BMI and continuous BP, as well as BP control rates by BMI category, but not the exact cohort split as per the question.
2. context_addresses_question: True. The context is highly relevant as it discusses the association between BMI and systolic blood pressure, including details about BP control by BMI category and the quantitative BMI-SBP relationship.
3. answer_grounded_in_context: True. The AI's answer accurately summarizes and synthesizes only what is presented in the provided context, including the referenced statistics and study findings; it does not introduce extraneous or hallucinated information.",834,3,3,228.66666666666666,686,BMI and blood pressure control among United States adults with hypertension; Association of Body Mass Index With Blood Pressure Among 1.7 Million Chinese Adults; Changes in the body mass index and blood pressure association across time: Evidence from multiple cross-sectional and cohort studies,https://pubmed.ncbi.nlm.nih.gov/35001034/; https://pubmed.ncbi.nlm.nih.gov/30646115/; https://pubmed.ncbi.nlm.nih.gov/34599929/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 58, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients identified in retrospective electronic health record or claims data with a minimum 12 months of continuous enrollment prior to the index diagnosis, Intervention: patients with a diagnosis of rheumatoid arthritis, Control: patients with Myasthenia gravis matched on baseline characteristics, Outcomes: bacterial meningitis', 'role': 'user'}]}",True,200.0,84.278883934021,,37e48f51-04e5-4f20-8b27-642eb81813c1,1578.0,Limitations: No published retrospective EHR or claims study was identified that directly compares th...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context does not include any study that directly compares the incidence of bacterial meningitis between RA and MG patients under the specified study design. It also does not provide numerical or qualitative findings for such a comparison; it primarily describes related findings or limitations (e.g., reports on rheumatoid meningitis in RA, overall infection risk in MG, effects of eculizumab, and notes about lack of comparative studies).
2. context_addresses_question: True. The context is relevant to the question: it addresses studies concerning serious infections in RA and MG, the nature of meningitis in RA, MG therapies' infection risk, and explicitly comments on the lack of direct comparative EHR or claims data studies for the outcome in question.
3. answer_grounded_in_context: True. The AI answer accurately reflects the context and its limitations, does not introduce new data or unsupported claims, and properly summarizes the lack of direct comparative studies as well as relevant indirect information.",1076,4,4,249.5,998,Rheumatoid meningitis: A systematic review and meta-analysis; Radiological insights into rheumatoid meningitis - a rare central nervous system manifestation of rheumatoid arthritis: a retrospective review of six cases; Serious infections in patients with myasthenia gravis: population-based cohort study - PubMed; Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study,https://pubmed.ncbi.nlm.nih.gov/33966315/; https://pubmed.ncbi.nlm.nih.gov/38748074/; https://pubmed.ncbi.nlm.nih.gov/31997519/; https://pubmed.ncbi.nlm.nih.gov/37690847/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 67, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'length of hospital stay with renal failure', 'role': 'user'}]}",True,200.0,48.24046087265015,,c323729a-6f19-4a23-b1d8-ebe392ec8cae,917.0,"Limitations: Available, high-quality inpatient data largely address acute kidney injury (AKI) rather...",3.0,T/T/T,3.0,True,True,True,"The context provides specific information on the association between renal failure (specifically acute kidney injury/AKI) and length of hospital stay, including a quantitative figure (median 21 days for AKI requiring dialysis) and qualitative associations (increased LOS with AKI, stage-dependent increases, prolonged stays in ICU). The AI answer summarizes this evidence accurately and makes it clear that the main data pertain to AKI rather than chronic/end-stage renal failure, matching the limits of the provided context. The answer is directly grounded in the context and does not introduce unsupported information.",620,4,4,193.75,775,"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients; The Incidence of Acute Kidney Injury and Associated Hospital Mortality; Incidence and Outcomes of Acute Kidney Injury Requiring Renal Replacement Therapy: A Retrospective Cohort Study; Acute kidney injury, length of stay, and costs in patients hospitalized in the intensive care unit",https://pubmed.ncbi.nlm.nih.gov/16177006/; https://pubmed.ncbi.nlm.nih.gov/31366430/; https://pubmed.ncbi.nlm.nih.gov/27380264/; https://pubmed.ncbi.nlm.nih.gov/18283996/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 61, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Among hospital in-patients, does vitamin D deficiency predict fecal incontinence?', 'role': 'user'}]}",True,200.0,77.8307089805603,,185fb545-eab8-4e81-a008-b920421edb42,1526.0,Limitations: No study was identified that specifically evaluated vitamin D deficiency as a predictor...,2.0,F/T/T,2.0,False,True,True,"The context does not include direct evidence answering whether vitamin D deficiency predicts fecal incontinence specifically among hospital in-patients. Instead, it provides data from a large EHR cohort (not limited to in-patients) demonstrating an association between vitamin D deficiency and fecal incontinence, and general information about the prevalence and risk factors for fecal incontinence among acute in-patients. The AI answer accurately summarizes these limitations, indicating no study directly addresses the in-patient predictive relationship. The answer is grounded in the provided context, is cautious not to overstate findings, and appropriately restricts its conclusions to what is supported by the context.",725,3,3,299.6666666666667,899,The association between vitamin-D deficiency and fecal incontinence; Prevalence of incontinence and associated skin injury in the acute care inpatient; Association of intestinal permeability with admission vitamin D deficiency in patients who are critically ill,https://pubmed.ncbi.nlm.nih.gov/38316640/; https://pubmed.ncbi.nlm.nih.gov/17505245/; https://pubmed.ncbi.nlm.nih.gov/31672717/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 63, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with essential hypertension , Cohort_1: systolic blood pressure of 140 and above , Cohort_2: systolic blood pressure of less than 140, Outcomes: number of hospitalizations', 'role': 'user'}]}",True,200.0,73.40121102333069,,f4d759d0-0211-475c-9791-ae60b6a24f71,1486.0,No published study was identified that directly reports the number of hospitalizations comparing out...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include direct evidence or explicit numeric hospitalization rates specifically comparing essential hypertension patients with SBP ≥140 mm Hg to those with SBP <140 mm Hg. Instead, the context provides indirect information, such as the SPRINT trial comparing <120 mm Hg and <140 mm Hg goals, and studies of hospitalization risks related to BP control in COVID-19 cohorts and the effect of medication adherence. The AI's answer accurately reflects this by stating that there is no direct evidence and accurately summarizing the main points from the context. The answer does not introduce external information and is grounded solely in the provided context. Thus, while the context does not directly answer the question, it is relevant, and the answer properly reflects this limitation.",813,4,4,211.75,847,Effects of Intensive Systolic Blood Pressure Control on All-Cause Hospitalizations - PubMed; Risk of hospitalization and mortality associated with uncontrolled blood pressure in patients with hypertension and COVID-19 - PubMed; Association Between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45 418 Symptomatic Patients With Hypertension: An Observational Cohort Study - PubMed; Medication Adherence and Incident Preventable Hospitalizations for Hypertension - PubMed,https://pubmed.ncbi.nlm.nih.gov/33100049/; https://pubmed.ncbi.nlm.nih.gov/34778888/; https://pubmed.ncbi.nlm.nih.gov/33325240/; https://pubmed.ncbi.nlm.nih.gov/26526163/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 66, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients aged 40 and older with chronic obstructive pulmonary disease, Intervention: budesonide/glycopyrrolate/formoterol fumarate, Control: fluticasone furoate/umeclidinium/vilanterol, Outcomes: % with 1 or more hospitalization', 'role': 'user'}]}",True,200.0,68.40418314933777,,0972ed61-f2d6-49e7-bc62-c65305f85c4b,1654.0,Limitations: PubMed-indexed comparative studies and reviews identify hazard ratios and rates for exa...,2.0,F/T/T,2.0,False,True,True,"The context cites three studies comparing budesonide/glycopyrrolate/formoterol and fluticasone furoate/umeclidinium/vilanterol in COPD patients aged 40 and older. None of these studies report the exact percentage of patients with one or more hospitalizations, though they do provide related outcomes such as hazard ratios for exacerbations, pneumonia admissions, and mortality. The AI's answer correctly states that the specific data requested ('% with ≥1 hospitalization') is not directly available in the provided summaries, and that consultation of full texts would be required for that precise metric. The answer is therefore not directly answered by the context, but it is relevant to the question and does not introduce information not grounded in the context.",766,3,3,285.0,855,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease; Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/39731707/; https://pubmed.ncbi.nlm.nih.gov/33929661/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 70, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with at least 2 Asthma encounters, Intervention: Symbicort or Dulera, Outcomes: % with >4 Albuterol fills', 'role': 'user'}]}",True,200.0,25.08953833580017,,f970e86b-1fba-4dbf-84ca-6eaf99ce3d61,414.0,I attempted to run the required literature search but encountered an internal error accessing the NL...,1.0,F/F/T,1.0,False,False,True,"The context provided is empty, so there is no information available that specifically answers or addresses the question regarding the population, intervention, and outcomes described. The AI's answer truthfully indicates it was unable to retrieve relevant sources due to an internal error and therefore does not introduce unsupported claims. However, because there is no content in the context, the answer cannot be grounded in or supported by the context. The AI's response is grounded in the available context by not making unsupported statements, but the context itself is not relevant or sufficient for the question.",620,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 65, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension , Cohort_1: BMI > 30, Cohort_2: BMI < 30, Outcomes: systolic blood pressure', 'role': 'user'}]}",True,200.0,114.92467403411865,,06861932-f61a-41f9-9e03-557ffbfb12a1,1857.0,Limitations: No single paper in the retrieved set directly reports the mean systolic blood-pressure ...,2.0,F/T/T,2.0,False,True,True,"The provided context contains relevant data about the association between BMI and systolic blood pressure in large populations, including per-unit BMI increases in SBP and BP control rates by BMI category, but does not directly report mean SBP differences between hypertensive patients with BMI >30 versus those with BMI <30. The AI's answer correctly acknowledges this limitation, accurately summarizes the available evidence, and confines its reasoning to numerical inferences based on the provided data without introducing external information.",547,4,4,219.0,876,"Association of Body Mass Index With Blood Pressure Among 1.7 Million Chinese Adults; Changes in the body mass index and blood pressure association across time: Evidence from multiple cross-sectional and cohort studies; Body mass index and blood pressure control among United States adults with hypertension (NHANES 2015–2018); Does body mass index impact on the relationship between systolic blood pressure and cardiovascular disease?: meta-analysis of 419,488 individuals from the Asia Pacific Cohort Studies Collaboration",https://pubmed.ncbi.nlm.nih.gov/30646115/; https://pubmed.ncbi.nlm.nih.gov/34599929/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8897212/; https://pubmed.ncbi.nlm.nih.gov/22426316/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 68, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the length of inpatient hospital stay for patients admitted to hospital with renal failure DRG code 682-684', 'role': 'user'}]}",True,200.0,94.81857228279114,,167cd33c-7f39-4c63-832d-9c1e70903ded,812.0,Limitations: NLM/NCBI sources located do not report a single published mean or median inpatient leng...,2.0,F/T/T,2.0,False,True,True,"The AI's answer accurately summarizes the content and limitations of the provided context. The context does not include a specific value for the length of inpatient hospital stay for patients with renal failure DRG code 682-684 but does address the relevant DRGs and data sources, noting the absence of a direct LOS figure. The answer is well-grounded in the context and does not introduce outside information; however, because no LOS figure is present, it does not directly answer the specific numeric aspect of the question.",526,3,3,232.0,696,"Table 2, Top 10 conditions and procedures with discharges to PAC, 2013 - Healthcare Cost and Utilization Project (HCUP) Statistical Briefs - NCBI Bookshelf; Table 5, MS-DRG conditions and procedures with the highest proportion of ICU utilization - Healthcare Cost and Utilization Project (HCUP) Statistical Briefs - NCBI Bookshelf; Understanding Readmissions in Medicare Beneficiaries During the 90‐Day Follow‐Up Period of an Acute Myocardial Infarction Admission - PMC",https://www.ncbi.nlm.nih.gov/books/NBK373736/table/sb205.t2/?report=objectonly; https://www.ncbi.nlm.nih.gov/books/NBK343514/table/sb198.t5/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6898831/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 62, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with diagnosis of essential hypertension , Cohort_1: systolic blood pressure of 140 and above , Cohort_2: systolic blood pressure of less than 140, Outcomes: % of patients with at least 3 or more classes of antihypertensives', 'role': 'user'}]}",True,200.0,125.95671081542969,,3e06a0ce-7977-49b2-b357-41325a26e0b6,1550.0,Limitations: Available large studies report medication counts stratified by blood-pressure control u...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The context provides data on the prevalence of use of ≥3 antihypertensive classes among patients with hypertension, particularly those with 'uncontrolled' hypertension defined as office BP ≥140/90 mmHg. However, the original question specifically separates cohorts by systolic BP ≥140 vs <140 mmHg regardless of diastolic values, and this level of detail is not directly available in the context or reported in the studies cited. So the context does not directly answer the question as phrased.

2. context_addresses_question: True. The context is highly relevant to the question, discussing how many patients with hypertension or uncontrolled hypertension are on ≥3 antihypertensive classes. The overlap in topic and general approach to resistant hypertension is clear, even if stratification is not exactly as requested by the question.

3. answer_grounded_in_context: True. The AI's answer faithfully relies on the provided context, accurately reflecting the definitions and statistics available in the cited studies. It explicitly acknowledges the limitations of the available data and refrains from extrapolating or introducing facts not present in the context.",1211,3,3,193.66666666666666,581,"Prevalence of resistant hypertension in the United States, 2003-2008; Apparent and true resistant hypertension: definition, prevalence and outcomes; Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association",https://pubmed.ncbi.nlm.nih.gov/21502568/; https://pubmed.ncbi.nlm.nih.gov/24430707/; https://pubmed.ncbi.nlm.nih.gov/30354828/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 71, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Intervention: Symbicort or Dulera, Outcomes: % with >4 Albuterol fills', 'role': 'user'}]}",True,200.0,77.43502759933472,,b8367a55-4184-4e8c-bc99-413c94467f8e,1943.0,No published study was identified that reports the percentage of asthma patients treated with Symbic...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the question regarding the percentage of asthma patients on Symbicort or Dulera with more than four albuterol fills, as no studies reported this specific outcome. However, the context is relevant because it discusses related endpoints such as SABA overuse, definitions of overuse (3–4 canisters/year), and trial results of Symbicort and Dulera, albeit without the exact percentage requested. The AI's answer is grounded in the context, accurately reflecting the absence of the specific data and summarizing the closest related findings without introducing unsupported claims.",621,4,4,209.5,838,Adverse Outcomes Associated With Short‐Acting Beta‐Agonist Overuse in Asthma: A Systematic Review and Meta‐Analysis; Albuterol Overuse: A Marker of Psychological Distress?; Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma; Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function,https://pmc.ncbi.nlm.nih.gov/articles/PMC12186600/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4641773/; https://pubmed.ncbi.nlm.nih.gov/31112386/; https://pubmed.ncbi.nlm.nih.gov/21828036/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 69, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the length of inpatient hospital stay for patients admitted to hospital with DRG codes 682 683 or 684', 'role': 'user'}]}",True,200.0,94.4393093585968,,b24385d0-9237-4ae0-b7b3-3991a73606e4,921.0,Limitations: No NLM/NCBI source located that reports an explicit mean or median inpatient length‑of‑...,2.0,F/T/T,2.0,False,True,True,"The context identifies DRG codes 682–684 as related to renal failure and notes the lack of specific mean or median length-of-stay values for these DRGs. The context includes similar data on AKI stays (median 9 days), and notes a specific table with discharge information for these DRGs but without LOS data. The AI directly points out that no DRG-specific LOS is reported in the provided materials, cites what's closest and where to look for more, and refers appropriately to the context. However, there is no specific, direct answer to the exact LOS for DRG 682, 683, or 684 in the given context; the answer is otherwise well-grounded in context.",647,3,3,165.66666666666666,497,"Understanding Readmissions in Medicare Beneficiaries During the 90‑Day Follow‑Up Period of an Acute Myocardial Infarction Admission; Table 2, Top 10 conditions and procedures with discharges to PAC, 2013 rom HCUP Statistical Brief #205 (NCBI Bookshelf); Economic burden of in‑hospital AKI: a one‑year analysis of the nationwide French hospital discharge database",https://pmc.ncbi.nlm.nih.gov/articles/PMC6898831/; https://www.ncbi.nlm.nih.gov/books/NBK373736/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10664266/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 75, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Atherosclerotic cardiovascular disease, Cohort_1: age <18, Cohort_2: age >18, Outcomes: % patients with LDL > 70 mg/dL', 'role': 'user'}]}",True,200.0,70.7995617389679,,f7ca876a-11fa-4157-9722-23c15940126c,881.0,No published studies were identified that report the percent of patients with established atheroscle...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is accurate and fully grounded in the provided context. The context directly provides the proportion of US adults with ASCVD who have LDL-C ≥70 mg/dL, specifically citing that 11.6 million out of 14.7 million adults (approx. 79%) had LDL-C ≥70 mg/dL according to NHANES data. Additionally, a separate figure is provided for older adults with prior MI or stroke (80.4% with LDL-C ≥70 mg/dL), both of which pertain directly to the adult population in the question. For the population aged <18 years with ASCVD, the context notes that pediatric literature focuses on familial hypercholesterolemia and early detection, not on cohorts of children with manifest ASCVD and their LDL distributions. Thus, the AI is correct in stating that no published percentage for this cohort was found in the provided context. The answer does not introduce information outside the context, nor does it make unsupported claims. All statements are directly traceable to the supplied references.",987,3,3,184.33333333333334,553,The Projected Impact of Population‑Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD; Familial hypercholesterolemia in children and the importance of early treatment; Trend of Controlled Low‑Density Lipoprotein Cholesterol in Older Adults With a History of Myocardial Infarction or Stroke,https://pubmed.ncbi.nlm.nih.gov/34599698/; https://pubmed.ncbi.nlm.nih.gov/38363694/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11294686/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 74, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Hypertension population with > 18 years of age and having at least 2 dx', 'role': 'user'}]}",True,200.0,76.52168321609497,,9b2d2172-10fe-4a20-ad8f-0fe022ce95bc,1555.0,Limitations: the available literature evaluates administrative- or EHR-based case definitions (algor...,3.0,T/T/T,3.0,True,True,True,"The provided context directly discusses the use of administrative and EHR-based algorithms to identify a hypertension population with at least two diagnostic codes and validates these definitions in adults over 18 years old. The AI's answer accurately summarizes the evidence from the context, correctly specifies the validated definitions (≥2 diagnoses within certain time frames), and offers practical recommendations in line with the studies cited. No external or unsupported claims are introduced. Therefore, all evaluation criteria are met.",545,3,3,266.0,798,Validity of Health Administrative Database Definitions for Hypertension: A Systematic Review; Accuracy of administrative databases in identifying patients with hypertension - PMC; Identification of Hypertension in Electronic Health Records Through Computable Phenotype Development and Validation for Use in Public Health Surveillance: Retrospective Study - PMC,https://pubmed.ncbi.nlm.nih.gov/28754391/; https://pmc.ncbi.nlm.nih.gov/articles/PMC2801913/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10782284/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 78, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with type 2 diabetes, Intervention: Statin, Outcomes: number of patients on statins and number of patients not on statins', 'role': 'user'}]}",True,200.0,48.322221517562866,,51a58531-0866-4d58-8472-dd43caf8be9a,546.0,Published studies report counts of statin users and non-users among patients relevant to type 2 diab...,3.0,T/T/T,3.0,True,True,True,"The context contains explicit data on the number of type 2 diabetes patients who are statin users and non-users from multiple studies. The AI answer directly extracts these numbers, references the studies, and does not introduce unsupported details. All information provided by the AI is grounded in the given context and directly addresses each element of the original question.",379,3,3,118.0,354,Statin use for primary prevention in patients with type 2 diabetes: Can it benefit all ages? - A nationwide propensity-matched cohort study - PubMed; Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice - PMC; Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults - PubMed,https://pubmed.ncbi.nlm.nih.gov/34508736/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6421885/; https://pubmed.ncbi.nlm.nih.gov/25917657/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 77, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please define a number of hypertension patients in the USA who are uncontrolled despite being treated with major anti-hypertensive medicines', 'role': 'user'}]}",True,200.0,59.797130823135376,,37a26693-7a91-4994-a430-704550e664f0,735.0,Estimates vary by data source and year; the figures below use published US NHANES/CDC analyses from ...,3.0,T/T/T,3.0,True,True,True,"The context directly provides numerical estimates for the number of US hypertension patients who are uncontrolled despite being treated with antihypertensive medications, specifically noting 16.0 million who are aware, treated, but uncontrolled. The AI answer accurately cites this figure and supplements with prevalence estimates for resistant and refractory hypertension, all clearly referenced to the provided context. There are no hallucinated facts or unsupported claims. The context is clearly relevant and the answer is grounded in it.",542,3,3,195.33333333333334,586,"Vital signs: awareness and treatment of uncontrolled hypertension among adults--United States, 2003-2010; Prevalence of resistant hypertension in the United States, 2003-2008; Prevalence of refractory hypertension in the United States from 1999 to 2014",https://pubmed.ncbi.nlm.nih.gov/22951452/; https://pubmed.ncbi.nlm.nih.gov/21502568/; https://pubmed.ncbi.nlm.nih.gov/31058798/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 80, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: systemic lupus erythematosus, Outcomes: Saphnelo', 'role': 'user'}]}",True,200.0,48.486098527908325,,e3ef15d9-424a-4a50-a7c0-999277bd5a75,1215.0,Meta-analysis of randomized trials (three RCTs) found anifrolumab 300 mg increased BICLA response (O...,3.0,T/T/T,3.0,True,True,True,"The provided context includes direct evidence regarding the outcomes of Saphnelo (anifrolumab) in the treatment of systemic lupus erythematosus (SLE), reporting improvements in BICLA response rates, steroid reduction, and skin outcomes, which are all specifically mentioned in the AI's answer. The context details findings from multiple RCTs and clinical trials, consistent with the AI's summary. The answer is both relevant to the question and grounded fully in the referenced materials, without introducing outside information or unsupported claims. Thus, all three criteria are satisfied.",591,4,4,236.5,946,"Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials - PubMed; Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials - PubMed; Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial - PubMed; Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus - PubMed",https://pubmed.ncbi.nlm.nih.gov/33216191/; https://pubmed.ncbi.nlm.nih.gov/32814461/; https://pubmed.ncbi.nlm.nih.gov/38229377/; https://pubmed.ncbi.nlm.nih.gov/28130918/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 79, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what proportion of trelegy prescribing for asthma is by allergists, primary care, and pulmonology', 'role': 'user'}]}",True,200.0,69.6531970500946,,43a2a0d4-1e7b-4608-82d1-351f63ba1b0f,522.0,Available US real-world data from a Medicare Advantage cohort report that frequent prescribers of FF...,3.0,T/T/T,3.0,True,True,True,"The context directly provides the proportions of Trelegy (FF/UMEC/VI) prescribing for asthma by primary care (44.2%), pulmonologists (31.8%), and allergists (11.1%). The AI answer quotes these figures and properly attributes them to the Medicare Advantage cohort, correctly cautioning about the limited generalizability outside that population. The additional context from the second document is also represented accurately: the AI notes that it does not provide a specialty breakdown. The answer does not introduce unsupported claims and is fully grounded in the provided context.",581,2,2,162.0,324,Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI); Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US,https://pmc.ncbi.nlm.nih.gov/articles/PMC11787182/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10697089/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 73, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Among COPD age > 40 years what % of patients have hospitalization on Budesonide/ Glycopyrrolate/ Formoterol Fumarate vs Fluticasone Furoate/ Umeclidinium Bromide/ Vilanterol Trifenatate', 'role': 'user'}]}",True,200.0,123.60037684440613,,a4e6989e-5f9d-466c-9f66-c3faaf9542bb,838.0,No randomized head‑to‑head trial reports the percentage of COPD patients (age ≥40) hospitalized on b...,2.0,F/T/T,2.0,False,True,True,"The context does not provide the percentage of COPD patients (age >40) hospitalized on the specified regimens, aligning with the AI's statement that no direct percent-hospitalized data from head-to-head trials is available. However, the context does provide annual rates of severe exacerbations (a proxy for hospitalizations) per patient-year for both drug combinations, and the AI accurately cites these rates. The answer is grounded in and accurately reflects the limitations of the context, but the context does not directly answer the question with the percentage requested.",578,3,3,249.33333333333334,748,"Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD; Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study; Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD (IMPACT)",https://pmc.ncbi.nlm.nih.gov/articles/PMC7935340/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7924571/; https://pubmed.ncbi.nlm.nih.gov/29668352/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 72, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Intervention: Symbicort or Dulera, Outcomes: % with >10 Albuterol fills', 'role': 'user'}]}",True,200.0,131.71942257881165,,4c24f85d-1d70-44f9-91b9-97bba00b6f5a,936.0,Limitations: The literature search did not identify any published head‑to‑head study reporting the p...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include published, product-specific percentages of asthma patients with >10 albuterol fills for Symbicort or Dulera. However, it does address the topic in a relevant manner, noting the general high rates of SABA overuse and the lack of direct comparison data. The AI answer accurately reflects this by acknowledging the lack of head-to-head, product-specific data and reporting on the population-level SABA overuse statistics that do exist. The answer is grounded in the provided context and does not introduce unsupported claims or outside information.",583,4,4,267.0,1068,"Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study; Mometasone furoate/formoterol in the treatment of persistent asthma - PubMed; Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma - PubMed; Patterns of Rescue and Maintenance Medication Claims Surrounding an Asthma Exacerbation in Patients Treated as Intermittent or Mild Persistent Asthma",https://pmc.ncbi.nlm.nih.gov/articles/PMC9068976/; https://pubmed.ncbi.nlm.nih.gov/22082160/; https://pubmed.ncbi.nlm.nih.gov/38346474/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11409924/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 76, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic obstructive pulmonary disease, Intervention: fluticasone furoate/umeclidinium/vilanterol, Control: Budesonide/glycopyrrolate/formoterol fumarate, Outcomes: % with 1 or more hospitalization', 'role': 'user'}]}",True,200.0,115.38243198394775,,04555141-64d4-4293-9fe8-90e2521b45d3,1291.0,No randomized head‑to‑head trial reporting the percentage of patients with ≥1 hospitalization compar...,2.0,F/T/T,2.0,False,True,True,"The context does not provide direct evidence for the percentage of patients with one or more hospitalizations when comparing the two triple therapies, which is the specific outcome asked in the question. However, the context is relevant as it discusses similar outcomes (exacerbations, mortality, and pneumonia admissions) in head-to-head and comparative effectiveness studies of the same interventions. The AI's answer is grounded in the provided context and accurately acknowledges that the specific outcome of interest was not reported, while summarizing the available data. Therefore, while the context does not directly answer the question, it does address it, and the answer does not introduce any unsupported claims.",723,3,3,273.0,819,Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease; Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching‑adjusted indirect comparison based on ETHOS and IMPACT,https://pubmed.ncbi.nlm.nih.gov/39731707/; https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/37583267/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 81, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: systemic lupus erythematosus, Outcomes: Saphnelo or Benlysta', 'role': 'user'}]}",True,200.0,66.43237805366516,,64550784-154e-4f24-951d-912fced3374b,1778.0,Limitations: No randomized head‑to‑head trial comparing anifrolumab (Saphnelo) with belimumab (Benly...,3.0,T/T/T,3.0,True,True,True,"The context provides specific comparative evidence from clinical trials regarding the use of anifrolumab (Saphnelo) and belimumab (Benlysta) in systemic lupus erythematosus, including details on trial outcomes (BICLA and SRI-4), flare rates, and quality-of-life improvements. The AI's answer accurately summarizes this data, highlights the absence of direct head-to-head trials, and uses cited indirect comparisons to discuss comparative efficacy, referencing the uncertainties in indirect data. The answer is closely grounded in the provided context, does not introduce external information, and synthesizes the relevant points directly answering the question for comparative efficacy of Saphnelo vs. Benlysta in SLE. Therefore, it satisfies all three evaluation criteria.",773,5,5,204.0,1020,Anifrolumab (Saphnelo) - NCBI Bookshelf; Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus - PubMed; Improvements in health‑related quality of life with belimumab ... from the randomised controlled BLISS trials - PubMed; Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks - PubMed; Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus - PubMed,https://www.ncbi.nlm.nih.gov/books/n/tr8269671151140717/; https://pubmed.ncbi.nlm.nih.gov/33977796/; https://pubmed.ncbi.nlm.nih.gov/23524886/; https://pubmed.ncbi.nlm.nih.gov/37147022/; https://pubmed.ncbi.nlm.nih.gov/35546484/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 91, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: asthma patients on advair, airduo, breo ellipta, dulera, and symbicort, Cohort_1: patients receiving Symbicort, Cohort_2: asthma patients on advair, airduo, breo ellipta, dulera,', 'role': 'user'}]}",True,200.0,17.860086679458618,,9967bf38-f691-4c87-a91b-fef97e6f5b24,745.0,I don’t have a clear question to answer yet. Do you want (pick one or more): 1) a literature summary...,1.0,F/F/T,1.0,False,False,True,"There is no provided context, so the assistant cannot answer the question directly or even address it based on relevant information. The answer consists of clarification questions and options, not clinical or scientific information tied to the context. However, the assistant does not introduce unsupported information, speculation, or hallucinations; it simply requests clarification. Thus, the answer is still grounded in context (or rather, does not exceed it), but fails the first two criteria.",498,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 83, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with atherosclerotic cardiovascular disease, Cohort_1: Coronary artery bypass graft, Cohort_2: Coronary artery bypass graft, Cohort_3: Coronary artery bypass graft, Outcomes: patients with LDL > 70 mg/dL', 'role': 'user'}]}",True,200.0,86.58876538276672,,47c19ea1-a233-4035-8a43-0da2ee3857c1,1893.0,Limitations: Direct randomized evidence comparing clinical outcomes in CABG patients stratified by L...,2.0,F/T/T,2.0,False,True,True,"The provided context contains relevant studies on the relationship between LDL levels and outcomes in CABG patients, but does not include direct, randomized evidence comparing outcomes in patients with LDL >70 mg/dL as the original question asks. The AI's answer correctly summarizes the evidence, acknowledges the limitations, and remains grounded in the context. However, the context does not directly answer the specific comparison for CABG patients with LDL >70 mg/dL—most evidence is about LDL thresholds at <70 mg/dL or <100 mg/dL, or in broader ASCVD populations—so the directness criterion is not fulfilled. The context is highly relevant and the answer is strictly based on the context provided.",704,5,5,229.8,1149,"The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial; Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial - PubMed; The prognostic role of the low and very low baseline LDL-C level in outcomes of patients with cardiac revascularization; comparative registry-based cohort design - PubMed; Sustained low-density lipoprotein-cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting - PubMed; Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention - PubMed",https://pubmed.ncbi.nlm.nih.gov/10532693/; https://pubmed.ncbi.nlm.nih.gov/21958773/; https://pubmed.ncbi.nlm.nih.gov/37507734/; https://pubmed.ncbi.nlm.nih.gov/34908162/; https://pubmed.ncbi.nlm.nih.gov/32943162/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 89, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage patients with at least three different classes of anti-hypertension treatment after a diagnosis of hypertension?', 'role': 'user'}]}",True,200.0,44.50994658470154,,a97802bc-713b-49bc-bbe7-12c7d3b08c46,436.0,"Estimates vary by cohort and setting. In a large U.S. incident-hypertension cohort, 20.6% (42,474/20...",3.0,T/T/T,3.0,True,True,True,"The provided context includes specific data points directly answering the question: percentages of patients with at least three different classes of anti-hypertensive medication are given (20.6%, 24%, less than 16% at baseline and about 20% at follow-up from three different studies). The AI's answer accurately reflects these percentages, citing them appropriately to their corresponding studies, and does not introduce any information not present in the context. The answer is grounded in the context and does not rely on external knowledge.",543,3,3,150.33333333333334,451,Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients - PMC; Prevalence and Correlates of Low Medication Adherence in Apparent Treatment‐Resistant Hypertension - PMC; Antihypertensive drug treatment changes in the general population: the colaus study - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3464920/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4021828/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 82, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with any prescription record for glucagon-like peptide-1 agonists in calendar year 2024, Outcomes: total number of glucagon-like peptide-1 agonist prescriptions by drug name, dose, day supply, total cost, and patient co-pay', 'role': 'user'}]}",True,200.0,91.13941669464111,,a5bf9a32-5c8a-4539-965e-289be4d9a707,2003.0,"No published study was identified that provides a complete, national-level dataset for calendar year...",2.0,F/T/T,2.0,False,True,True,"The context does not provide a complete, national-level dataset for calendar year 2024 that reports GLP-1 agonist prescriptions broken down by drug name, dose, day supply, total cost, and patient co-pay. It includes only elements such as monthly prescription numbers for some drugs as of early 2024, per-person annual costs, and sample-based analysis from prior years or shorter periods. Therefore, the context does not directly answer the detailed requirements of the question, but it is relevant as it discusses partial data and costs related to GLP-1 agonist prescriptions. The AI's answer accurately reflects these limitations, is consistent with the context, and does not introduce unsupported information.",711,4,4,235.0,940,"Longitudinal Analysis of Obesity Drug Use and Public Awareness - PubMed; Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes - PMC; Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication - PubMed; Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024 - PMC",https://pubmed.ncbi.nlm.nih.gov/39878977/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12467763/; https://pubmed.ncbi.nlm.nih.gov/41071563/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10725810/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 90, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage patients with at least one different classes of anti-hypertension treatment after a diagnosis of hypertension?', 'role': 'user'}]}",True,200.0,57.91354179382324,,571c0d1e-0955-4ee7-8600-75b3b121302c,770.0,Reported proportions of patients who receive at least one antihypertensive drug class after a new di...,2.0,F/T/T,2.0,False,True,True,"The original question specifically asks for the percentage of patients who receive at least one different class of anti-hypertension treatment after a diagnosis of hypertension. This suggests an interest in patients treated with at least one class—i.e., treatment initiation—rather than patients treated with multiple different classes (polytherapy or class switching), unless interpreted otherwise. The provided context presents data on the percentage of patients who started any antihypertensive treatment after diagnosis (e.g., 74.9% within 1 year, 80.6% ever), but does not clearly specify the percentage who received at least one different class or more than one class. Therefore, the context addresses being treated after diagnosis (i.e., initiation), relevant to the question, but does not answer directly regarding exposure to different classes specifically. The AI's answer accurately summarizes the available context, reporting initiation rates and grounded estimates based on follow-up duration, but does not make unsupported claims. However, it does not and cannot provide a direct answer to the more specific question if interpreted as about multiple classes. If the question is interpreted as 'at least one class,' the answer is direct; if as 'at least one different class (polytherapy),' it is not. The context is relevant and the answer is grounded.",1365,3,3,164.66666666666666,494,Antihypertensive medications and cancer risk: Evidence from 0.27 million patients with newly diagnosed hypertension - PMC; Treatment in the First Month After Hypertension Diagnosis Improves Blood Pressure Control - PMC; Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney Disease - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC12259635/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12071505/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7380443/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 88, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what proportion of asthma patients on ics/laba are on symbicort', 'role': 'user'}]}",True,200.0,65.12275648117065,,a921a90c-7117-4990-a514-b0fb64717f98,491.0,Estimates vary by dataset and definition (all ICS/LABA users vs. only FP/SAL vs. BUD/FOR users) and ...,3.0,T/T/T,3.0,True,True,True,"The context provides a direct answer to the question regarding the proportion of asthma patients on ICS/LABA who are on Symbicort, specifying that in the SPRINT study, 298 out of 1,101 (about 27.1%) were on Symbicort. The AI's answer correctly references this data. The answer also discusses additional data (FP/SAL vs. BUD/FOR users) from another study, noting cohort limitations, which is accurately reflected and does not introduce unsupported claims. All information in the AI answer is grounded in the provided context.",524,3,3,181.33333333333334,544,Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study); Comparative effectiveness of inhaled fluticasone propionate/salmeterol and budesonide/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis; Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting β2-agonists,https://pmc.ncbi.nlm.nih.gov/articles/PMC6946676/; https://pubmed.ncbi.nlm.nih.gov/40446865/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11865622/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 84, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'who are the prescribers for GLP1 in the latest 12 month period?', 'role': 'user'}]}",True,200.0,94.4938497543335,,fb71bc4f-c398-427e-9871-924188952004,1091.0,Limitations: available peer‑reviewed analyses report prescriber specialty data through 2019–2023 (no...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include data specifically referring to prescribers for GLP-1 in the 'latest 12 month period,' nor does it give a detailed or granular breakdown for a strictly defined recent window. Instead, the sources reference trends from 2018-2023, and do not specifically isolate only the most recent 12 months. However, the context is relevant to the question, addressing the types of prescribers generally and recent prescribing trends. The AI's answer accurately reflects this limitation, draws conclusions solely from the context, and does not introduce information beyond what is contained in the supplied references.",640,3,3,195.66666666666666,587,"Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits; Trends in glucagon-like peptide 1 receptor agonist prescribing patterns; Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study",https://pubmed.ncbi.nlm.nih.gov/40057872/; https://pubmed.ncbi.nlm.nih.gov/40829097/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10577502/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 86, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what percent of patients on ics/laba are treated with symbicort', 'role': 'user'}]}",True,200.0,84.79913711547852,,060c5961-2d4f-446d-9284-851db9dc003e,1576.0,Published studies do not report a single global percentage of ICS/LABA patients treated with Symbico...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a single, direct percentage for the global or general proportion of ICS/LABA patients treated with Symbicort. However, it does include relevant data on the numbers or shares of patients using budesonide/formoterol (the drug combination in Symbicort) in different settings and countries, which addresses the question indirectly. The AI's answer grounds its reasoning in the provided cohort numbers and percentages from different studies and clarifies the limitations, without introducing facts not found in the context.",547,4,4,175.25,701,"Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting ; Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population; Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety; Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865622/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532544/; https://pubmed.ncbi.nlm.nih.gov/34757243/; https://pubmed.ncbi.nlm.nih.gov/32361850/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 95, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with atherosclerotic cardiovascular disease, Intervention: age > 18, Outcomes: LDL result', 'role': 'user'}]}",True,200.0,51.96318531036377,,db5ee873-8fa6-4c00-a5e9-4b95dee75ed4,968.0,Limitations: No single pooled estimate for 'LDL result' across all adults with established ASCVD was...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately synthesizes findings from the provided context: it correctly cites the mean LDL-C value for a large MI cohort, references the mortality benefit of LDL-C under 1.4 mmol/L, notes the proportion of ASCVD patients who meet LDL-C targets, and discusses the lack of a lower safety threshold for LDL-C based on the review, all of which are found in the context. While there is no single pooled LDL outcome summarized, the answer is faithful to the actual data and limitations seen in the context and does not introduce any unsupported claims. Therefore, all three criteria are satisfied.",607,4,4,195.75,783,"Post-treatment level of LDL cholesterol and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting - PubMed; Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction - PubMed; LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals - PubMed; The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better - PubMed",https://pubmed.ncbi.nlm.nih.gov/37966728/; https://pubmed.ncbi.nlm.nih.gov/37052867/; https://pubmed.ncbi.nlm.nih.gov/36004573/; https://pubmed.ncbi.nlm.nih.gov/38576462/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 85, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Overall patients with atherosclerotic cardiovascular disease and LDL > 70 mg/dL, Intervention: Statin', 'role': 'user'}]}",True,200.0,115.99222421646118,,4afdb548-3f38-46c8-b02b-3bf5ee4eb6b6,1608.0,Limitation: the question gives population and intervention but no comparator or specified outcomes; ...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context and accurately reflects the data from the cited studies. It summarizes key results from a meta-analysis (CTT) and major randomized trials (PROVE-IT TIMI 22, IMPROVE-IT) which are directly relevant to the population (atherosclerotic cardiovascular disease, LDL>70 mg/dL) and the intervention (statins). The answer details clinical outcomes (major vascular events, mortality), echoing the outcomes reported in context, and references the intensification of therapy as covered in the articles. The AI notes the absence of a comparator and explicitly interprets the findings within the context given by the studies (statin intensity, LDL levels, incremental benefit), closely following the evidence without introducing information not present in the context. Therefore, all three evaluation criteria are fully met.",867,3,3,179.33333333333334,538,"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials; Improved outcome after acute coronary syndromes with an intensive versus standard lipid‑lowering regimen: results from the PROVE IT‑TIMI 22 trial; Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes",https://pubmed.ncbi.nlm.nih.gov/21067804/; https://pubmed.ncbi.nlm.nih.gov/16356805/; https://pubmed.ncbi.nlm.nih.gov/26039521/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 87, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what proportion of GLP1 users have T2D, CKD, HF, and without any comorbidites?', 'role': 'user'}]}",True,200.0,122.52113676071167,,364ff50d-8cce-4cd0-bab0-c4b532fb3378,2047.0,"Limitations: No single, general-population study in the retrieved literature reports a complete, rep...",2.0,F/T/T,2.0,False,True,True,"The context provides partial information relevant to the question—such as the proportion of GLP-1 users with T2D and heart disease/heart failure from a large cohort, and comorbidity data for T2D populations—but does not directly answer what proportion of GLP-1 users specifically have T2D, CKD, HF, and no comorbidities. The AI's answer correctly reflects these limitations, synthesizing findings and stating where direct data are unavailable, so the answer is well grounded in the context. However, because no source gives a complete, direct breakdown for all groups (T2D, CKD, HF, without comorbidities) among GLP-1 users, the response does not fulfill 'context_answers_question_directly' but does meet the other criteria.",724,4,4,140.25,561,"Use of GLP‐1 receptor agonists and subsequent risk of alcohol‐related events. A nationwide register‐based cohort and self‐controlled case series study; Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence; Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study; Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804689/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225085/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547934/; https://pubmed.ncbi.nlm.nih.gov/34154020/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 98, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma patients with at least two Symbicort or Dulera prescriptions, Intervention: Fasenra, Control: Dupixent, Outcomes: asthma-related emergency department visits or hospitalizations', 'role': 'user'}]}",True,200.0,62.77941846847534,,75287b02-988f-4b45-87b0-dbe1cea262f4,1881.0,Limitations: No direct head-to-head randomized trials comparing benralizumab (Fasenra) versus dupilu...,3.0,T/T/T,3.0,True,True,True,"The context directly addresses the comparison between Fasenra (benralizumab) and Dupixent (dupilumab) regarding asthma-related exacerbations, and provides data relevant to asthma-related emergency department visits or hospitalizations. The AI's answer accurately summarizes the evidence and limitations presented in the context, noting the lack of direct head-to-head trials and indicating the mixed results from indirect and observational studies regarding ED visits and hospitalizations. All of the AI's claims are grounded in the context, with references provided for each point. Therefore, all three criteria are met.",621,5,5,200.0,1000,"Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review; Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta‑analysis; Real‑world effectiveness of dupilumab versus benralizumab and mepolizumab; Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma‑Related Hospitalizations Compared With Overall Exacerbations; Impact of benralizumab on asthma exacerbation‑related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study",https://pubmed.ncbi.nlm.nih.gov/32019141/; https://pubmed.ncbi.nlm.nih.gov/35772597/; https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/38431251/; https://pubmed.ncbi.nlm.nih.gov/37441729/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 97, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma and >=2 Symbicort or Dulera prescriptions, Intervention: Fasenra, Control: Dupixent, Outcomes: Count of Steroid prescriptions', 'role': 'user'}]}",True,200.0,69.7556586265564,,c9ff3641-2193-4766-ad39-6d18196c26e9,1490.0,Limitations: No published head‑to‑head randomized trial or observational study was identified that c...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the precise question about the count of steroid prescriptions in a population defined by asthma and ≥2 Symbicort or Dulera prescriptions. Instead, it gives evidence from studies of OCS-dependent severe asthma examining reduction in corticosteroid dose (not prescription count) with Fasenra (benralizumab) and Dupixent (dupilumab), and a network meta-analysis indicating no clear superiority between the two. The context is relevant and supports the AI's discussion of the lack of direct evidence for the specified outcome, and the AI's answer is grounded in and confined to what the context provides.",646,4,4,198.25,793,Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma; Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma; Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis; Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma,https://pubmed.ncbi.nlm.nih.gov/28530840/; https://pubmed.ncbi.nlm.nih.gov/36572184/; https://pubmed.ncbi.nlm.nih.gov/37972921/; https://pubmed.ncbi.nlm.nih.gov/31859541/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 93, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage of patients with LDC > 70 by age for patients with diagnosis of ASCVD?', 'role': 'user'}]}",True,200.0,104.61781239509583,,9fed824a-f096-4258-89ff-734a748c08e6,1109.0,Limitations: Reviewed NLM/PubMed sources did not report LDL-C >70 mg/dL specifically stratified by a...,2.0,F/T/T,2.0,False,True,True,"The context does not provide percentage of patients with LDL-C >70 by age groups for patients with ASCVD; it gives only overall percentages across entire adult ASCVD cohorts and mean ages for some cohorts. The AI assistant correctly notes this limitation, accurately summarizes the overall statistics provided in the context, and does not introduce information not present in the context. The answer is relevant to the question and responsibly points out the absence of age-stratified data in the referenced studies.",516,3,3,163.66666666666666,491,The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD; Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease; Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists,https://pubmed.ncbi.nlm.nih.gov/34599698/; https://pubmed.ncbi.nlm.nih.gov/28768335/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8707804/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 96, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with atherosclerotic cardiovascular disease, Intervention: age > 18, Outcomes: LDL result (DO NOT calculate change in LDL. Just provide LDL value)', 'role': 'user'}]}",True,200.0,92.35212850570679,,2b9e6455-34d1-47f2-b691-483603783cfc,562.0,Limitations: the following LDL values are baseline/entry LDL levels reported in large randomized tri...,3.0,T/T/T,3.0,True,True,True,"The AI's answer summarizes baseline LDL values from large randomized trials involving adult patients with established atherosclerotic cardiovascular disease, which directly matches the context provided. The specific values cited (e.g., 92 mg/dL in FOURIER, 2.20–2.28 mmol/L in ODYSSEY OUTCOMES, and 93.8 mg/dL in IMPROVE-IT) are explicitly stated in the provided materials. The answer cautions that these are baseline/entry values (as do the contexts) and does not introduce unsupported statements. The context is directly relevant and sufficient to answer the question as stated.",580,3,3,134.33333333333334,403,Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial - PubMed; Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome - PubMed (ODYSSEY OUTCOMES); The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial - PubMed,https://pubmed.ncbi.nlm.nih.gov/31116355/; https://pubmed.ncbi.nlm.nih.gov/30403574/; https://pubmed.ncbi.nlm.nih.gov/27569841/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 94, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage of patients with LDL > 70 by age for patients with diagnosis of ASCVD?', 'role': 'user'}]}",True,200.0,108.4189682006836,,e5f5996f-cdfb-4f47-9f35-475602b5cb77,692.0,Limitations: the age-stratified values below are computed from patient counts reported in an EHR-bas...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly provides the requested percentages of patients with LDL ≥70 mg/dL by age group, using values computed from Table 3 as referenced in the context. It also cites the secondary source with the overall national estimate (NHANES) as presented in the context. There is no introduction of external knowledge or unsupported facts; all numbers and limitations are clearly attributed to the context. Both the EHR cohort and NHANES findings are relevant and properly referenced. Therefore, the answer meets all three evaluation criteria.",550,2,2,195.0,390,Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study; Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline,https://pmc.ncbi.nlm.nih.gov/articles/PMC10397866/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10168648/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 99, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma with >=2 Symbicort prescription, Cohort_1: Fasenra, Cohort_2: Dupixent, Outcomes: asthma-related emergency department visits', 'role': 'user'}]}",True,200.0,83.11335730552673,,064f74f5-e03d-4099-88f1-067f6bf3e987,1694.0,No published study was identified that directly compares benralizumab (Fasenra) versus dupilumab (Du...,2.0,F/T/T,2.0,False,True,True,"The provided context includes studies evaluating the effects of Fasenra (benralizumab) and Dupixent (dupilumab) on asthma outcomes, including exacerbation rates and some mention of reductions in emergency department (ED) visits. However, none of the cited studies directly compare the two drugs specifically in the population defined by ≥2 Symbicort prescriptions, nor do they report head-to-head results for asthma-related ED visits in such a strictly defined cohort. The AI's answer accurately states this and describes the indirect evidence available, staying within the provided context and not introducing unsupported information. The context is relevant to the question but does not directly answer it. Therefore: 1) The context does not answer the question directly; 2) The context is relevant and addresses the question; 3) The AI's answer is grounded in the context.",875,4,4,231.5,926,"Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study; Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study - PubMed; Real‑world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE study - PubMed; Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma - PubMed",https://pubmed.ncbi.nlm.nih.gov/40250559/; https://pubmed.ncbi.nlm.nih.gov/37441729/; https://pubmed.ncbi.nlm.nih.gov/37967668/; https://pubmed.ncbi.nlm.nih.gov/40261563/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 101, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Cohort_1: Fasenra, Cohort_2: Dupixent', 'role': 'user'}]}",True,200.0,60.18560266494751,,100f022d-f823-4d7c-8366-9df42b762afc,1688.0,Limitations: No randomized head-to-head trials comparing benralizumab (Fasenra) with dupilumab (Dupi...,3.0,T/T/T,3.0,True,True,True,"The AI's answer provides a thorough summary based closely on the provided context. It accurately states that there are no head-to-head trials and relies on details from indirect and real-world studies, which matches the context. The key findings about efficacy, exacerbation rates, benefits in subpopulations with high eosinophils, and the methodological limitations are clearly drawn from the articles provided. No unsupported claims are introduced. Thus, the answer is directly supported by and grounded in the context, and all points in the context are addressed.",566,4,4,216.0,864,"Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review - PubMed; Real-world effectiveness of dupilumab versus benralizumab and mepolizumab - PubMed; Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study - PubMed; Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis - PubMed",https://pubmed.ncbi.nlm.nih.gov/32019141/; https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/40250559/; https://pubmed.ncbi.nlm.nih.gov/35772597/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 100, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma, Cohort_1: Fasenra, Cohort_2: Dupixent, Outcomes: Steroid prescription', 'role': 'user'}]}",True,200.0,95.72944259643555,,aa5d6e53-5020-449e-ac48-4743d1d3beab,1117.0,Limitations: the trials were separate randomized studies with dissimilar enrolment criteria and popu...,3.0,T/T/T,3.0,True,True,True,"The provided context includes specific evidence for steroid (oral corticosteroid) prescription reductions with both Fasenra (benralizumab) and Dupixent (dupilumab) from separate clinical trials as well as a matching-adjusted indirect comparison (MAIC) of both drugs. The AI's answer correctly summarizes the key findings for each drug as presented in the context and appropriately cites the limitations of indirect comparisons as described. The response relies solely on the provided context and makes no unsupported claims. All parts of the question regarding population, intervention, comparator, and outcome are addressed using the data from the context.",657,3,3,218.66666666666666,656,Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma; Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma; Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics,https://pubmed.ncbi.nlm.nih.gov/28530840/; https://pubmed.ncbi.nlm.nih.gov/29782224/; https://pubmed.ncbi.nlm.nih.gov/31943429/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 108, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hypertension, Outcomes: receipt of at least two different classes of anti-hypertensive treatments', 'role': 'user'}]}",True,200.0,53.59226369857788,,c101e373-499e-4de7-8e80-59d43309be7e,918.0,U.S. population-level surveys indicate that a majority of treated adults with hypertension receive t...,3.0,T/T/T,3.0,True,True,True,"The context provides direct evidence regarding the proportion of hypertensive patients receiving at least two different classes of antihypertensive medications from several large US surveys and studies. The AI's answer correctly synthesizes these statistics (e.g., NHANES dual/triple/quadruple therapy, combination therapy rates from outpatient data, and combination therapy in the ASPREE cohort) without introducing unsupported information. The answer is well-grounded in the context and directly addresses the outcome stated in the original question for the defined population (patients with hypertension). Therefore, all three evaluation criteria are met.",658,3,3,232.0,696,"Trends in antihypertensive medication monotherapy and combination use among US adults, NHANES 2005–2016; Screening, Treatment and Control of Hypertension in U.S. Private Physician Offices, 2003–2004; Antihypertensive medication use and blood pressure control among treated older adults",https://pmc.ncbi.nlm.nih.gov/articles/PMC7398637/; https://pmc.ncbi.nlm.nih.gov/articles/PMC2671992/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7901812/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 92, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with atherosclerotic cardiovascular disease, Cohort_1: age > 18 and age < 65, Cohort_2: age > 64, Outcomes: Percentage of patients with LDL > 70', 'role': 'user'}]}",False,,,"HTTPSConnectionPool(host='dbc-7a32c3d1-0aa9.cloud.databricks.com', port=443): Read timed out. (read timeout=180)",,,,0.0,,,,,,,0,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 103, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with asthma, Cohort_1: Fasenra, Cohort_2: Dupixent, Outcomes: Hospitalizations or ED visits', 'role': 'user'}]}",True,200.0,83.58231830596924,,4006d907-f2e8-4d08-966b-488c0ded4d4b,1433.0,Limitations: No randomized head‑to‑head trials directly comparing dupilumab (Dupixent) versus benral...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately synthesizes and references the provided context. It acknowledges the lack of direct head-to-head RCT data comparing Dupixent and Fasenra for the specific outcome of hospitalizations or ED visits, which matches the information in Reference 1. The answer notes that general pooled evidence for biologics supports substantial reduction in these outcomes versus placebo (Reference 2), and notes specifically that both real-world comparative studies (References 3 and 4) and pre/post analyses (Reference 5) support reduced exacerbations and healthcare utilization, favoring dupilumab in indirect comparisons. Each statement is traceable to the supplied context, with no unsupported claims or external knowledge introduced. The context is directly relevant and contains substantial evidence addressing the outcome of interest, justifying each part of the answer.",883,5,5,224.0,1120,"Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review; Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Real‑world effectiveness of dupilumab versus benralizumab and mepolizumab; Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study; Impact of benralizumab on asthma exacerbation‑related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study",https://pubmed.ncbi.nlm.nih.gov/32019141/; https://pubmed.ncbi.nlm.nih.gov/40261563/; https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/40250559/; https://pubmed.ncbi.nlm.nih.gov/37441729/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 109, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is percentage patients with at least three or more different classes of anti-hypertensive treatment after a diagnosis of hypertension?', 'role': 'user'}]}",True,200.0,65.23412561416626,,4afc8456-15dc-4685-96c6-3ec105adafdc,784.0,"Reported proportions vary by setting. In a US cohort of 205,750 incident hypertensive patients, 42,4...",3.0,T/T/T,3.0,True,True,True,"The context provides several studies directly reporting the percentage of patients on at least three classes of antihypertensive therapy, ranging from about 12% to 27%, and up to 24%. The AI answer summarizes these findings accurately, citing appropriate numbers and referencing the sources. The answer is grounded solely in the context, uses no external or hallucinated information, and clearly addresses the original question by giving percentages from different studies and settings.",486,4,4,162.75,651,Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients - PMC; Hypertension Treatment and Control Among 28 Physician Practices Across the United States: Results of the Hypertension: Assessment of Treatment to Target (HATT) Study - PMC; Association between the size of healthcare facilities and the intensity of hypertension therapy: a cross-sectional comparison of prescription data from insurance claims data - PMC; Polypharmacy among patients with hypertension attending primary healthcare centres - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8816464/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7872892/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10289761/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 105, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype, as identified via ICD codes., Cohort_1: Dupilumab, Cohort_2: fluticasone furoate/umeclidinium/vilanterol , Outcomes: hospitalizations or ED visits', 'role': 'user'}]}",True,200.0,86.92353701591492,,ece1a2a9-83d2-4c19-8ad3-4b3ba439fecc,2166.0,Limitations: No published head-to-head trial comparing add-on dupilumab versus single‑inhaler flutic...,2.0,F/T/T,2.0,False,True,True,"The context provides evidence that both dupilumab (in patients with eosinophilic COPD) and FF/UMEC/VI reduce exacerbations and hospital utilization (such as hospital readmissions or ED visits) compared to comparators like placebo or delayed therapy. However, the context does not provide direct, head-to-head data comparing dupilumab versus FF/UMEC/VI for hospitalizations or ED visits in the specified patient population. It does address the question by being relevant and summarizing the existing findings for each therapy in appropriate populations and outcomes. The AI's answer mirrors this context, stating that there are no direct comparative studies and summarizing cohort or trial results for each therapy separately. The answer is fully grounded in the provided context, not introducing external facts. However, because no direct comparison is available, the context does not answer the question directly.",914,4,4,268.0,1072,"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts; Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double‑blind, placebo‑controlled trials; Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes; Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7‑year population‑based cohort study",https://pubmed.ncbi.nlm.nih.gov/37272521/; https://pubmed.ncbi.nlm.nih.gov/39900091/; https://pubmed.ncbi.nlm.nih.gov/39453592/; https://pubmed.ncbi.nlm.nih.gov/39368553/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 102, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with asthma, Intervention: Fasenra, Control: Dupixent, Outcomes: Hospitalizations or ED visits', 'role': 'user'}]}",True,200.0,117.88948321342468,,752b9c9d-abba-4086-a184-9e184c6456b4,831.0,No randomized head‑to‑head trials comparing benralizumab (Fasenra) versus dupilumab (Dupixent) for h...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include direct evidence specifically on the comparative effect of Fasenra (benralizumab) versus Dupixent (dupilumab) regarding hospitalizations or ED visits, as no head-to-head RCT is reported. The context describes many indirect and observational real-world studies suggesting Dupixent may be associated with better outcomes and that both reduce these events relative to placebo. The answer correctly reflects the limitations of the evidence, is well referenced, and does not introduce claims not found in the context. However, the lack of direct comparative data between the two drugs on hospitalization or ED visits means the context does not directly answer the clinical question. The context is definitely relevant and fully supports the answer's cautious take.",796,5,5,240.2,1201,"Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis; Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis; Real‑world effectiveness of dupilumab versus benralizumab and mepolizumab; Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review",https://pubmed.ncbi.nlm.nih.gov/38241013/; https://pubmed.ncbi.nlm.nih.gov/38423294/; https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12085395/; https://pubmed.ncbi.nlm.nih.gov/32019141/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 107, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with validated asthma diagnoses based on ICD codes, combined with evidence of clinically significant asthma such as corticosteroid prescriptions or asthma-related hospitalizations/ED visits, Outcomes: Airsupra or Albuterol', 'role': 'user'}]}",True,200.0,101.34792947769165,,61293a27-a26a-43b7-8d17-e17e251b0c81,1013.0,"Randomized, controlled trials of as‑needed fixed‑dose albuterol–budesonide versus albuterol alone sh...",3.0,T/T/T,3.0,True,True,True,"The context contains specific evidence from randomized controlled trials comparing as-needed albuterol–budesonide (Airsupra) versus albuterol alone, demonstrating reduction in risk of severe asthma exacerbation and commenting on comparable adverse event profiles. The AI’s answer summarizes trial results from the context, including hazard ratios and trial designs, and accurately reflects the findings. It does not introduce unsupported claims or outside information. It directly answers the question about outcomes of Airsupra versus Albuterol in the described population (patients with clinically significant asthma).",620,4,4,195.5,782,Airsupra: An inhaled albuterol/budesonide combination for asthma; Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma; As-Needed Albuterol-Budesonide in Mild Asthma; Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial,https://pubmed.ncbi.nlm.nih.gov/38466211/; https://pubmed.ncbi.nlm.nih.gov/35569035/; https://pubmed.ncbi.nlm.nih.gov/40388330/; https://pubmed.ncbi.nlm.nih.gov/37003355/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 104, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype, as identified via ICD codes., Cohort_1: Dupixent (dupilumab), Cohort_2: Breztri or Trelegy, Outcomes: Hospitalizations or ED visits', 'role': 'user'}]}",True,200.0,119.63590693473816,,b7d30ad5-7d60-4bc4-9d30-2b15a67ffcd9,2275.0,Limitations: No randomized head-to-head trials comparing dupilumab versus single‑inhaler triple ther...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context does not include any randomized controlled trial evidence comparing Dupixent (dupilumab) head-to-head with Breztri or Trelegy for hospitalizations/ED visits in eosinophilic COPD. The context only supplies results for each treatment versus placebo or a non-triple therapy comparator, not each other, nor specifically for the ICD-coded eosinophilic phenotype population defined in the question. Therefore, it does not substantially answer the direct comparative question.

2. context_addresses_question: True. The context is relevant since it presents evidence on the outcomes of interest (moderate/severe exacerbations, which include hospitalizations/ED visits) for the named interventions in patients with eosinophilic COPD (as defined by blood eosinophils or type 2 inflammation).

3. answer_grounded_in_context: True. The AI's answer correctly reflects the limitations of the context (lack of head-to-head trials) and only presents findings that are directly supported by the provided context, without introducing unsupported claims or external knowledge.",1123,4,4,258.5,1034,"Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation; Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double‑blind, placebo‑controlled trials; Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate‑to‑Very‑Severe COPD (ETHOS); Impact of the IMPACT Trial - PMC review",https://pubmed.ncbi.nlm.nih.gov/38767614/; https://pubmed.ncbi.nlm.nih.gov/39900091/; https://pubmed.ncbi.nlm.nih.gov/32579807/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6296790/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 106, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients diagnosed with severe asthma (ICD-10: J45.5)\u200b with documented eosinophil count ≥300 cells/μL\u200b, Intervention: Fasenra, Control: Trelegy, Outcomes: Oral corticosteroid prescription count over 12 months\u200b', 'role': 'user'}]}",True,200.0,110.94535112380981,,7c5908af-859e-4fd2-852d-05749626806e,1676.0,No randomized head‑to‑head evidence was identified that compares benralizumab (Fasenra) versus singl...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The context does not contain direct, head-to-head comparative data for Fasenra (benralizumab) versus Trelegy (FF/UMEC/VI) for oral corticosteroid prescription counts over 12 months. It presents separate results for each intervention, but not a direct comparison meeting the PICO requirements.

2. context_addresses_question: True. The context is relevant, discussing the OCS-sparing effect and prescription patterns for both benralizumab and Trelegy in severe asthma, using various study types.

3. answer_grounded_in_context: True. The AI answer is firmly grounded in the provided context; it accurately reflects the limitations of the evidence (noting lack of direct comparative data) and summarizes the results cited in the context with proper attribution.

Overall, the answer provides a clear synthesis of what is and is not available in the context but does not contain direct comparative data.",945,4,4,206.5,826,"Oral Glucocorticoid‑Sparing Effect of Benralizumab in Severe Asthma; Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open‑label, single‑arm study; Efficacy and Safety of Biologics for Oral Corticosteroid‑Dependent Asthma: A Systematic Review and Network Meta‑Analysis; Real‑World Study of Single‑Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US",https://pubmed.ncbi.nlm.nih.gov/28530840/; https://pubmed.ncbi.nlm.nih.gov/34619104/; https://pubmed.ncbi.nlm.nih.gov/37972921/; https://pubmed.ncbi.nlm.nih.gov/38058516/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 110, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'For patients with a diagnosis of primary hypertension treated with at least 1 or more different classes of anti-hypertension medications, what is the systolic blood pressure within 1 year of index anti-hypertension therapy?', 'role': 'user'}]}",True,200.0,73.8709728717804,,457036c1-9206-4ca1-a7e8-9e5a600c0618,763.0,"Direct, representative estimates for mean systolic blood pressure (SBP) within 1 year after index an...",3.0,T/T/T,3.0,True,True,True,"The provided context includes a direct answer regarding mean systolic blood pressure at 1 year in patients treated for hypertension (127.5 mm Hg in the intensive group, 135.3 mm Hg in the standard group from the referenced trial). The AI accurately conveys this data, clearly tying it to the relevant population (older patients in a trial) and specifies the treatment groups. It also references additional data on BP control rates from a second context about patients with proteinuric kidney disease, which while not directly answering the mean SBP, is relevant as supportive information. The AI answer is grounded solely in the supplied context, with no evidence of external or hallucinated information.",704,2,2,127.5,255,Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension; Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney Disease - PMC,https://pubmed.ncbi.nlm.nih.gov/34491661/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7380443/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 111, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'For patients with a diagnosis of primary hypertension treated with at least 4 or more different classes of anti-hypertension medications, what is the systolic blood pressure?', 'role': 'user'}]}",True,200.0,59.777233839035034,,61da2e6b-c8cb-465c-9000-c97ec59d0af6,868.0,"Limitations: Guidelines differ on BP targets, so there is no single systolic BP value that applies u...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is fully supported by the provided context. The context establishes that guidelines differ in defining blood pressure targets for resistant hypertension, referencing BP goals of <140/90 mmHg in older guidelines and <130/80 mmHg in more recent AHA/ACC guidelines. The AI correctly incorporates this information to explain that there is no single systolic BP, but patients controlled on ≥4 drugs would have systolic BP below the relevant target (<130 mmHg by newest, <140 mmHg by older). All components of the answer are grounded in the references, particularly the AHA/ACC guidelines and commentary on changing definitions. The context directly answers the question (expected BP for patients on ≥4 antihypertensive classes) and the answer does not introduce anything unsupported.",794,3,3,179.33333333333334,538,"Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association - PubMed; Resistant hypertension-defining the scope of the problem - PubMed; Management of Resistant Hypertension Based on Recommendations from Different Guidelines and the Systolic Blood Pressure Intervention Trial - PMC",https://pubmed.ncbi.nlm.nih.gov/30354828/; https://pubmed.ncbi.nlm.nih.gov/31863785/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6784919/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 112, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the average numbers of day from diagnosis of hypertension to the first anti-hypertension treatment?', 'role': 'user'}]}",True,200.0,85.7810628414154,,01babfa6-c4bd-4f0e-b63f-2a0f57a8f32f,1300.0,Limitations: Available studies report cohort-specific median or mean intervals (and sometimes propor...,3.0,T/T/T,3.0,True,True,True,"The context provides cohort-specific data about the time from hypertension diagnosis to first antihypertensive treatment, such as median and mean intervals (e.g., 3.3 months median, 6.9 months mean in one cohort), and details about proportions treated within 30 days. The AI's answer accurately summarizes these findings, discusses limitations in inferring a universal average, and directly cites statistics from the context. The answer remains faithful to the context and does not introduce any unsupported claims. Therefore, all three criteria are met.",554,3,3,246.0,738,Diagnosis and Treatment of Incident Hypertension Among Patients with Diabetes: a U.S. Multi-Disciplinary Group Practice Observational Study; Delayed Hypertension Diagnosis and Its Association With Cardiovascular Treatment and Outcomes; Treatment in the First Month After Hypertension Diagnosis Improves Blood Pressure Control,https://pmc.ncbi.nlm.nih.gov/articles/PMC4441679/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12261005/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12071505/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 118, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: cirrhosis patients , Cohort_1: portal hypertension and decompensate cirrhosis, Cohort_2: portal hypertension and compensated cirrhosis , Outcomes: mortality', 'role': 'user'}]}",True,200.0,58.74734687805176,,b5a75ec9-f510-4602-9af5-dde36de53778,1583.0,"In cirrhosis patients with portal hypertension, mortality is substantially higher once patients are ...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context. It directly and correctly summarizes mortality differences between compensated and decompensated cirrhosis patients with portal hypertension, citing the specific data points (1-year mortality of 5.4% for compensated versus 20.2% for decompensated—reference [1]). It accurately describes the role of HVPG as a predictor of decompensation and mortality, referencing several provided studies ([2], [3], [4]). The answer also includes correct information about the rising mortality with additional decompensation events ([5]). All claims made in the answer are directly supported by the context, accurately reflect the outcomes for the specified cohorts, and do not introduce outside knowledge or unsupported claims. The context is directly relevant and specifically answers the primary question about mortality in the defined patient groups.",896,5,5,213.0,1065,Prognostic indicators of survival in patients with compensated and decompensated cirrhosis; Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient 60 mm Hg; Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis; Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD - multicentre study; Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient 8  mm Hg,https://pubmed.ncbi.nlm.nih.gov/22679906/; https://pubmed.ncbi.nlm.nih.gov/32453061/; https://pubmed.ncbi.nlm.nih.gov/17681169/; https://pubmed.ncbi.nlm.nih.gov/38823501/; https://pubmed.ncbi.nlm.nih.gov/35113276/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 119, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients diagnosed with severe asthma (ICD-10: J45.5), Intervention: Allergist or Pulminologist visit within 60 days post asthma related Hospitalization, ED visit, or urgent care visit, Outcomes: Rate of subsequent asthma-related ED visits within 6 months', 'role': 'user'}]}",True,200.0,52.91859149932861,,c76c8ca8-fbb7-4613-9f89-3e6c2f791078,2030.0,"Limitations: No published study was identified that specifically evaluates patients defined as ""seve...",2.0,F/T/T,2.0,False,True,True,"The context provides several relevant studies on follow-up care after asthma-related ED or hospital visits and subsequent outcomes; however, none directly address the precise population (severe asthma, ICD-10: J45.5) receiving an allergist or pulmonologist visit within 60 days with subsequent 6-month ED visits as an outcome. The studies instead discuss outcomes for broader or different asthma populations, various follow-up timings, and sometimes different provider types. The AI's answer accurately summarizes this gap in the literature and correctly interprets and relays the available evidence, grounding its answer solely in the context provided. However, because the context does not directly answer the exact question posed, the first criterion is not met, though the context is highly relevant and the answer faithful to it.",834,4,4,145.75,583,Follow-Up After Asthma Emergency Department Visits and Its Relationship With Subsequent Asthma-Related Utilization - PubMed; Follow-up care after an emergency department visit for asthma and subsequent healthcare utilization in a universal-access healthcare system - PubMed; Predictors of outpatient follow-up care after adult emergency department asthma visits and association with 30-day outcomes - PubMed; A randomized controlled trial of follow-up of patients discharged from the hospital following acute asthma: best performed by specialist nurse or doctor? - PubMed,https://pubmed.ncbi.nlm.nih.gov/35339239/; https://pubmed.ncbi.nlm.nih.gov/22484353/; https://pubmed.ncbi.nlm.nih.gov/35938828/; https://pubmed.ncbi.nlm.nih.gov/16840382/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 116, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the prevalence of aldosterone dysregulation in patients with hypertension?', 'role': 'user'}]}",True,200.0,96.42874193191528,,93bdf418-d076-43c7-913d-8f8b48a54d8e,1481.0,"Estimates vary widely because prevalence depends strongly on diagnostic thresholds, testing methods,...",3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question by providing specific prevalence estimates for aldosterone dysregulation in various hypertensive populations, mirroring the data and ranges from the provided context. The answer also correctly notes the impact of diagnostic definitions, thresholds, and population (primary care vs. tertiary center) on prevalence rates, which is well-supported by multiple context documents. The nuances about severity and resistant hypertension with increasing prevalences are accurately summarized with values (e.g., 10% general, up to 29% in tertiary, up to 50% in resistant HTN), all of which are present in the context. No unsupported claims or hallucinations are introduced, and the answer is consistently grounded in the provided evidence.",777,4,4,214.5,858,Primary Aldosteronism: State-of-the-Art Review - PMC; The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study - PMC; Primary aldosteronism - PMC; Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC9729786/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7082264/; https://pubmed.ncbi.nlm.nih.gov/25538205/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 122, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with asthma, Cohort_1: Blood eosinophil levels ≥300 cells/µL, Cohort_2: Blood eosinophil levels <300 cells/µL, Outcomes: Asthma related Hospitalizations', 'role': 'user'}]}",True,200.0,54.59467649459839,,4acb0796-9880-4166-b25d-94db69c5a98a,1618.0,"Limitations: Studies differ in patient populations (EMR/claims cohorts, severe uncontrolled asthma c...",3.0,T/T/T,3.0,True,True,True,"The provided context includes direct data relevant to the question: specifically, it gives mean hospitalization numbers for patients with blood eosinophils ≥300 cells/µL versus lower counts (reference 1) and discusses hospitalization risk and patterns at various eosinophil cutoffs in multiple studies. The AI answer summarizes these findings and highlights the mixed nature of results, referencing each study according to the details in the context. The answer is therefore directly grounded in the contextual evidence and does not introduce unsupported claims, accurately addressing the question about asthma hospitalizations in relation to blood eosinophil levels.",667,4,4,224.25,897,"Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma - PubMed; Peripheral eosinophil count as a biomarker for asthma exacerbation severity in acute care settings - PubMed; Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study - PubMed; Asthma Exacerbations in a Tertiary Hospital: Clinical Features, Triggers, and Risk Factors for Hospitalization - PubMed",https://pubmed.ncbi.nlm.nih.gov/32371242/; https://pubmed.ncbi.nlm.nih.gov/40254093/; https://pubmed.ncbi.nlm.nih.gov/27665383/; https://pubmed.ncbi.nlm.nih.gov/27973326/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 113, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What percentage of patients with a diagnosis of primary hypertension and treated with at least 2 different classes of anti-hypertension therapies have elevated systolic blood pressure of 130 and above within 1 year from index anti-hypertension therapies?', 'role': 'user'}]}",True,200.0,151.70373702049255,,410b2872-c873-4b09-acf9-04a2ad12aeae,1392.0,"No published study was identified that reports exactly “patients with primary hypertension, started ...",2.0,F/T/T,2.0,False,True,True,"The provided context does not include a specific statistic for the percentage of patients with primary hypertension, started on at least 2 antihypertensive classes, who have systolic BP ≥130 mm Hg within 1 year of starting therapy. It addresses related concepts and populations, reporting figures for similar cohorts (e.g., patients on ≥3 drugs, definitions using ≥140/90 mm Hg, or longer follow-up periods), but does not contain the precise answer to the question as formulated. The AI's answer accurately reflects the limitations of the context, presents the closest available evidence, and is firmly grounded in the supplied documents without introducing unsupported claims. Therefore: context does not answer the question directly, but does address it; the AI's answer is grounded in the context.",800,3,3,166.33333333333334,499,"Evaluation of Blood Pressure Control, Medication Adherence, and Therapeutic Inertia in US Patients With Hypertension Prescribed Multiple Antihypertensives; Uncontrolled and Apparent Treatment Resistant Hypertension in the U.S. 1988–2008; Resistant Hypertension: Incidence, Prevalence and Prognosis",https://pmc.ncbi.nlm.nih.gov/articles/PMC12229206/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3210066/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3350774/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 115, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Obesity , Intervention: Wegovy, Control: Zepbound, Outcomes: Weight loss', 'role': 'user'}]}",True,200.0,133.41879272460938,,94f7add5-b980-40fc-8417-55c50979090d,1181.0,No randomized head‑to‑head trial comparing Wegovy (semaglutide 2.4 mg) with Zepbound (tirzepatide) f...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-supported by the provided context. It directly compares the weight loss outcomes from both Wegovy (semaglutide) and Zepbound (tirzepatide) as reported in pivotal clinical trials (STEP and SURMOUNT-1, respectively) and references a network meta-analysis for indirect comparison. The AI clearly explains that no head-to-head trial exists while summarizing mean weight loss percentages for each intervention, precisely as provided in the context. Interpretive statements regarding tirzepatide showing greater mean weight loss are consistent with the contextual data. Therefore, all three criteria are satisfied: the answer is direct, relevant, and fully grounded in the context.",699,4,4,183.5,734,"Semaglutide for the treatment of overweight and obesity: A review; Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis; Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1); Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial",https://pubmed.ncbi.nlm.nih.gov/36254579/; https://pubmed.ncbi.nlm.nih.gov/38413012/; https://pubmed.ncbi.nlm.nih.gov/35658024/; https://pubmed.ncbi.nlm.nih.gov/36216945/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 114, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'For patients with a diagnosis of primary hypertension treated with at least 3 or more different classes of anti-hypertension medications, what is the systolic blood pressure within 1 year of index anti-hypertension therapy?', 'role': 'user'}]}",True,200.0,145.4735724925995,,ff828671-18c6-4026-8f1a-66b1093fc451,1448.0,No published report was identified that directly gives the mean systolic blood pressure (SBP) at 1 y...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a direct, specific value for systolic blood pressure (SBP) within 1 year for patients with primary hypertension on 3 or more antihypertensive medications. Instead, it discusses definitions, proportions of patients on multiple medications, and average BP reductions from a meta-analysis, none of which directly answer the precise question asked. The context is, however, relevant as it addresses resistant hypertension and related SBP data. The AI’s answer is appropriately grounded in the context, does not introduce unsupported facts, accurately communicates the absence of a direct answer, and attempts to provide relevant supplementary information.",680,4,4,222.5,890,"Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association; Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients; Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials; The Contributions of Unhealthy Lifestyle Factors to Apparent Resistant Hypertension: Findings from the REGARDS Study",https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9340038/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3838894/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 117, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What percentage of patients with a diagnosis of primary hypertension have elevated systolic blood pressure of 130 and above within 1 year from diagnosis?', 'role': 'user'}]}",True,200.0,130.38302063941956,,09ac6136-3e4c-476a-9163-64ae06eacb9e,1610.0,No published study was found that directly reports the percentage of patients with a new (incident) ...,2.0,F/T/T,2.0,False,True,True,"The AI's answer does not directly provide the exact percentage of patients with a diagnosis of primary hypertension who have a systolic blood pressure of 130 and above within 1 year from diagnosis, as no such data are present in the context. However, the answer is highly relevant, discussing available related data points (NHANES cross-sectional data for BP control at <130/80, and 1-year EHR data using a <140/90 threshold) and correctly noting the absence of a direct answer in the literature. The answer is firmly grounded in the provided context and does not introduce unsupported claims or external information.",617,3,3,282.0,846,Factors Associated With Hypertension Control in US Adults Using 2017 ACC/AHA Guidelines: National Health and Nutrition Examination Survey 1999–2016; Economics of Team-based Care for Blood Pressure Control: Updated Community Guide Systematic Review; Treatment and control of blood pressure in Welsh patients with and without depression: A study of whole-population electronic health records,https://pmc.ncbi.nlm.nih.gov/articles/PMC9720886/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10527860/; https://pubmed.ncbi.nlm.nih.gov/40560925/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 121, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients diagnosed with severe asthma (ICD-10: J45.5), Intervention: dupilumab, Control: benralizumab, Outcomes: Asthma-related hospitalizations or Asthma-related ER visits or Asthma-related urgent care visit', 'role': 'user'}]}",True,200.0,118.25411796569824,,0d69ceff-df35-49c9-900c-7b543b1801c2,1719.0,"Limitations: No randomized head‑to‑head trials report asthma‑related hospitalizations, ED visits, or...",2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context does not include direct comparative data specifically on asthma-related hospitalizations, ER visits, or urgent care visits between dupilumab and benralizumab. It provides indirect evidence (exacerbation rate reductions, some subgroups, real-world data) but lacks explicit head-to-head outcome data for the population and outcomes described in the question.
2. context_addresses_question: True. The context is highly relevant to the question, addressing comparative effectiveness of dupilumab and benralizumab in severe asthma and providing data related to exacerbations (somewhat proxy outcomes for hospital/ER/urgent care events), including in relevant subgroups.
3. answer_grounded_in_context: True. The AI answer accurately reflects the limitations and nuances of the provided evidence, avoids overstating conclusions, and cites the context appropriately without introducing unsupported claims.",963,4,4,235.5,942,"Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis; Real-world effectiveness of dupilumab versus benralizumab and mepolizumab; Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review",https://pubmed.ncbi.nlm.nih.gov/40261563/; https://pubmed.ncbi.nlm.nih.gov/35772597/; https://pubmed.ncbi.nlm.nih.gov/38760161/; https://pubmed.ncbi.nlm.nih.gov/32019141/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 120, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients diagnosed with severe asthma (ICD-10: J45.5)\u200b, Cohort_1: Continuous Fasenra for ≥12 months\u200b, Cohort_2: Continuous Dulera or Trelegy for ≥12 months\u200b, Outcomes: Asthma-related hospitalization; Asthma-related ED visits; Asthma-related urgent care visits', 'role': 'user'}]}",True,200.0,123.94076466560364,,db507de1-5c39-456e-bd00-2ec65d1dc0f6,2075.0,Limitations: No published head-to-head studies were identified that directly compare continuous benr...,2.0,F/T/T,2.0,False,True,True,"The provided context thoroughly addresses the question by summarizing available evidence regarding benralizumab (Fasenra) and its effect on asthma-related hospitalizations and ED visits in real-world settings, including specific statistics from the ZEPHYR 1 and 2 and CHRONICLE studies. It also notes the lack of long-term hospitalization/ED/urgent care outcome data for Trelegy or Dulera, and explicitly states that there are no head-to-head trials directly comparing Fasenra with Dulera or Trelegy on the specified outcomes. Therefore, the context is highly relevant and the answer is accurately grounded in the context. However, because no direct comparative data are available, the context does not specifically or directly answer the comparative question between the two cohorts.",784,5,5,226.6,1133,"Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study - PubMed; Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE - PubMed; Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study - PubMed; Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: trelegy ellipta for real asthma control study - PMC",https://pubmed.ncbi.nlm.nih.gov/40261563/; https://pubmed.ncbi.nlm.nih.gov/35247595/; https://pubmed.ncbi.nlm.nih.gov/37290579/; https://pubmed.ncbi.nlm.nih.gov/37441729/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11955660/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 125, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: asthma patients with blood eosinophil levels ≥300 cells/µL, Intervention: Asthma related hospitalizations', 'role': 'user'}]}",True,200.0,61.19156002998352,,43189d7c-8e7d-41f5-9429-8cb4a1231875,1901.0,Limitations: Available studies are mostly observational cohorts and cross-sectional analyses with he...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The provided context includes specific data indicating that asthma patients with blood eosinophils ≥300 cells/µL experience increased rates of hospital admission compared to those with lower eosinophil counts (13% greater rate). It also documents the prevalence of eosinophilia (≥300 cells/μL) among hospitalized patients and the increased frequency of hospitalizations with even higher eosinophil levels, all of which directly address the question regarding the relationship between eosinophil levels and asthma-related hospitalizations.

2. context_addresses_question: True. All contextual sources are clearly relevant to the population (asthma patients with elevated eosinophils) and outcome (hospitalization), providing data on hospital admission rates, prevalence of eosinophilia among inpatients, and treatment implications.

3. answer_grounded_in_context: True. The AI's answer summarizes findings, limitations, and practical implications entirely based on evidence and details from the provided context, without introducing unsupported claims. References to texts about variability of eosinophil measurements and treatment implications are also supported by the provided context.",1231,5,5,229.8,1149,Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland; Prevalence of eosinophilia in hospitalized patients with asthma exacerbation; Burden of asthma with elevated blood eosinophil levels; Measurement of Blood Eosinophils in Asthma and Chronic Obstructive Pulmonary Disease; Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma,https://pmc.ncbi.nlm.nih.gov/articles/PMC5912706/; https://pubmed.ncbi.nlm.nih.gov/26198894/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4944449/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9876705/; https://pubmed.ncbi.nlm.nih.gov/33130147/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 123, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: asthma patients with blood eosinophil levels ≥300 cells/µL, Cohort_1: Dupixent, Cohort_2: Trelegy, Outcomes: Asthma related hospitalizations', 'role': 'user'}]}",True,200.0,106.65796542167664,,9c50af76-bdb5-4de8-967a-6690194f4c58,2218.0,Limitations: No randomized head‑to‑head trials or comparative real‑world studies were identified tha...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, as there is no head-to-head or indirect comparative data on asthma-related hospitalizations between Dupixent and Trelegy in patients with eosinophils ≥300 cells/µL. However, the context is relevant to the question, addressing the evidence for both drugs and noting the lack of direct comparative or hospitalization data for Trelegy. The AI's answer is appropriately grounded in the context, accurately summarizing the available evidence and limitations without introducing external information or unsupported claims.",567,4,4,227.75,911,"Dupilumab (Dupixent) - NCBI Bookshelf; Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis - PMC; Differences in asthma-related outcomes by anti-IL-5 biologics, omalizumab, and dupilumab based on blood eosinophil counts - PubMed; The efficacy and safety of Fluticasone Furoate/Umeclidinium/vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma (COCOA study) - PubMed",https://www.ncbi.nlm.nih.gov/books/NBK601813/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9574251/; https://pubmed.ncbi.nlm.nih.gov/38183647/; https://pubmed.ncbi.nlm.nih.gov/39874464/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 128, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population:\n Define severe asthma using a computable phenotype: e.g., patients aged 18+ with ≥2 asthma-related exacerbations requiring systemic corticosteroids in the past 12 months OR ≥1 asthma-related hospitalization, AND on maintenance ICS-LABA therapy.\n Intervention (Subgroups):\n Compare outcomes across patients initiating [Advair HFA | Symbicort | Dulera | etc.] as maintenance therapy for asthma.\n Outcome:\n Asthma-related hospitalizations, defined as inpatient admissions with a primary ICD-10 code of J45.x (asthma) within 12 months of index therapy start.\n Timeframe:\n Restrict analysis to Jan 1, 2019 – Dec 31, 2023.\n Setting:\n Include patients treated in outpatient settings across integrated delivery networks.\n Question:\n Among adults with severe asthma initiating different ICS-LABA or ICS-LABA-LAMA therapies, what are the rates of asthma-related hospitalization within 12 months?', 'role': 'user'}]}",True,200.0,83.1943371295929,,d3be1223-a6fb-4d4f-aee2-071bd6b25f08,1847.0,"Limitations: No published study was identified that applied the exact computable phenotype (age ≥18,...",2.0,F/T/T,2.0,False,True,True,"The context summarizes multiple real-world and clinical studies comparing hospitalization and acute-care outcomes for adults initiating various ICS-LABA therapies (including Symbicort and Advair). However, none of the studies strictly match the computable phenotype (specific definition of severe asthma, timeframe 2019–2023, integrated delivery network, and outpatient setting) posed in the question, nor do they provide direct rates for asthma-related hospitalizations for that subgroup within 12 months. Thus, the context does not directly answer the question but does address it by providing related comparative evidence from similar, though not identical, populations and timeframes. The AI-generated answer accurately reflects these limitations and bases its statements on the provided evidence, without introducing information not grounded in the context.",862,4,4,293.25,1173,Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol - PubMed; Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis - PubMed; Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials - PubMed; Real-world Comparative Effectiveness in Patients with Asthma Newly Initiating Fluticasone Furoate/Vilanterol or Budesonide/Formoterol: A United Kingdom General Practice Cohort Study - PubMed,https://pubmed.ncbi.nlm.nih.gov/18930647/; https://pubmed.ncbi.nlm.nih.gov/25439363/; https://pubmed.ncbi.nlm.nih.gov/20456215/; https://pubmed.ncbi.nlm.nih.gov/40956480/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 126, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD patient with >=1 hospitalization or >=2 OCS claims with less than 15 day supply or >= 2 Antibiotic with less than 15 day supply, Intervention: Breztri or Trelegy', 'role': 'user'}]}",True,200.0,107.63926768302917,,d44f841f-2b92-4e35-8743-0b696b667d17,1326.0,"Limitations: No randomized, head-to-head trial directly comparing Breztri (budesonide/glycopyrrolate...",3.0,T/T/T,3.0,True,True,True,"The context directly provides evidence about the efficacy of Breztri (BGF) and Trelegy (FF/UMEC/VI) for COPD patients with a history of exacerbations, specifically in terms of reduction in moderate/severe exacerbation rates. The AI's answer appropriately summarizes the main findings from the pivotal RCTs (ETHOS and IMPACT) and clearly notes the lack of direct head-to-head trials, which is referenced in the context. The response also discusses mixed findings from network meta-analyses, which is well supported by the provided references and highlights the limitations and need for individualized clinical judgment. No information or claims are introduced beyond what is grounded in the context. Thus, the answer fulfills all three criteria.",744,5,5,227.0,1135,Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis - PMC; Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis - PubMed; Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD - NEJM (ETHOS); [IMPACT study in COPD] - PubMed; Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC9402726/; https://pubmed.ncbi.nlm.nih.gov/33929661/; https://pubmed.ncbi.nlm.nih.gov/32579807/; https://pubmed.ncbi.nlm.nih.gov/30680975/; https://pubmed.ncbi.nlm.nih.gov/38318884/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 131, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Incidence and prevalence of patients with acute lymphoblastic leukemia, proportion of patients with acute lymphoblastic leukemia receiving care at academic centers, geographic distribution of patients with acute lymphoblastic leukemia', 'role': 'user'}]}",True,200.0,77.26708102226257,,862f3724-edf3-4f51-947e-5b8225cf74da,2205.0,"Limitations: National estimates differ by age group and data source; a single, up-to-date national p...",3.0,T/T/T,3.0,True,True,True,"The AI's answer clearly synthesizes relevant information from the provided context for all components of the question. It gives incidence figures for both all-age and pediatric populations, explicitly addresses the lack of a definitive national prevalence figure as documented in the sources, and provides the proportion receiving care at academic centers (using an age-restricted, published cohort, as per the context). It also describes the geographic distribution by citing state- and region-level variation in both incidence and mortality rates, matching details from the references. All factual claims are attributed to the context. Limitations in the available data are acknowledged and drawn directly from the provided context. The answer does not introduce unsupported claims and is strictly grounded in the supplied references. Therefore, all evaluation criteria are met.",880,5,5,199.4,997,"Acute lymphoblastic leukemia: a comprehensive review and 2017 update; Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - United States, 2001-2014; Survival Outcomes in Older Adult Acute Lymphoblastic Leukemia Patients Analyzed by Facility Volume and Type: A National Cancer Database Analysis; Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights From the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research Database; A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL)",https://pmc.ncbi.nlm.nih.gov/articles/PMC5520400/; https://pubmed.ncbi.nlm.nih.gov/28910269/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11310087/; https://pubmed.ncbi.nlm.nih.gov/39886753/; https://pubmed.ncbi.nlm.nih.gov/15698386/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 132, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How much percent of adult asthma patients have at least one OCS fill in 2023?', 'role': 'user'}]}",True,200.0,74.79837131500244,,47c6a0f4-1130-449d-9368-e4506cc74815,1294.0,No PubMed/NCBI-indexed publication located in this search reported a national one‑year (calendar yea...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly answer the question, as none of the sources report the national percentage of adult asthma patients with at least one OCS fill in 2023. However, the context does address related aspects of OCS use in asthma patients for earlier years and in various subpopulations and countries, making it relevant to the question even if it doesn't provide the specific figure requested. The AI's answer is appropriately cautious, summarizing only what is present in the context and explicitly stating the absence of a 2023-specific, national prevalence figure. All summarized data points are traceable to the provided context and are not hallucinated.",675,4,4,210.0,840,"Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden; Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK; Prevalence of oral corticosteroid use in the German severe asthma population; Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009–2018",https://pmc.ncbi.nlm.nih.gov/articles/PMC6899917/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7270349/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6819991/; https://pubmed.ncbi.nlm.nih.gov/37718472/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 127, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD patient with >=1 hospitalization or >=2 OCS claims with less than 15 day supply or >= 2 Antibiotic with less than 15 day supply, Outcomes: Breztri or Trelegy', 'role': 'user'}]}",True,200.0,103.21642017364502,,a8789265-d804-4a8c-904a-3a5e3728fb19,1823.0,Limitations: no randomized head‑to‑head trial comparing Breztri (budesonide/glycopyrronium/formotero...,3.0,T/T/T,3.0,True,True,True,"The provided context contains direct evidence relevant to the question, discussing outcomes of both Breztri (BGF) and Trelegy (FF/UMEC/VI) in COPD patients similar to the population described. The AI's answer correctly summarizes that both therapies reduce exacerbation rates compared to dual therapies, and also highlights that there is no direct, randomized head-to-head comparison between Breztri and Trelegy, which is supported by the context. The mention of systematic reviews/network meta-analyses reporting no consistent differences is also accurate and grounded in the context provided. The AI's caution regarding pneumonia risk with ICS-containing regimens is similarly based on the provided material. No unsupported claims are present and the answer stays within the boundaries of the context. Therefore, all three evaluation criteria are met.",853,4,4,222.75,891,"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD; Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study; Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease; Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis",https://pubmed.ncbi.nlm.nih.gov/29668352/; https://pubmed.ncbi.nlm.nih.gov/35512458/; https://pubmed.ncbi.nlm.nih.gov/34382422/; https://pubmed.ncbi.nlm.nih.gov/32335859/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 124, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: asthma patients with blood eosinophil levels ≥300 cells/µL, Intervention: Dupixent, Control: Trelegy, Outcomes: Asthma related hospitalizations', 'role': 'user'}]}",True,200.0,165.58331489562988,,727e98e6-8089-440f-9a0d-5d2c3cfde1fe,1844.0,Limitations: No published head‑to‑head trial comparing dupilumab versus single‑inhaler FF/UMEC/VI (T...,2.0,F/T/T,2.0,False,True,True,"The provided context discusses the efficacy of dupilumab in reducing asthma exacerbations—including in patients with blood eosinophil levels ≥300 cells/µL—and separately discusses data supporting FF/UMEC/VI, but not asthma-related hospitalizations specifically, nor direct comparisons between dupilumab and Trelegy in this population. The AI answer accurately summarizes this situation, including noting the lack of head-to-head and hospitalization-specific data matching the PICO question. Therefore, while the context is relevant to the question, it does not directly answer it with the required outcome (asthma-related hospitalizations in this population for both interventions), but the AI answer remains appropriately grounded in the context.",747,4,4,212.25,849,"Dupilumab in persistent asthma with elevated eosinophil levels - PubMed; Liberty Asthma QUEST: Phase 3 Randomized, Double‑Blind, Placebo‑Controlled, Parallel‑Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate‑to‑Severe Asthma - PubMed; Dupilumab improves lung function in patients with uncontrolled, moderate‑to‑severe asthma - PubMed; Real‑World Study of Single‑Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US - PubMed",https://pubmed.ncbi.nlm.nih.gov/23688323/; https://pubmed.ncbi.nlm.nih.gov/29725983/; https://pubmed.ncbi.nlm.nih.gov/32010719/; https://pubmed.ncbi.nlm.nih.gov/38058516/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 133, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype, as identified via ICD codes., Cohort_1: Use of Dupixent (dupilumab) as an add-on maintenance therapy, Cohort_2: Patients managed with breztri or trelegy, Outcomes: Decrease in the rate of moderate to severe COPD exacerbations (e.g., hospitalizations or ED visits) over a 12-month period', 'role': 'user'}]}",True,200.0,84.88822555541992,,d8f21697-eea8-447e-a64e-095b40603db5,1785.0,Limitations: No randomized head‑to‑head trials were identified that directly compare add‑on dupiluma...,2.0,F/T/T,2.0,False,True,True,"The provided context does not include any randomized, head-to-head trials directly comparing dupilumab (Dupixent) as add-on therapy to Breztri or Trelegy in patients with eosinophilic COPD. Instead, the context offers separate evidence: Dupilumab added to background inhaled triple therapy reduces exacerbation rates versus placebo, and single-inhaler triple therapies (Breztri, Trelegy) reduce exacerbation rates versus dual therapies—not versus dupilumab. The AI's answer correctly states these limitations, summarizes the evidence for each intervention versus its own comparator from the context, and does not introduce ungrounded claims. Therefore: the context does NOT directly answer the comparative question, but it is clearly relevant, and the AI's answer is grounded in the context.",791,4,4,216.25,865,"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts; Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double‑blind, placebo‑controlled trials; Budesonide/Glycopyrronium/Formoterol: A Review in COPD; Once‑Daily Single‑Inhaler Triple versus Dual Therapy in Patients with COPD (IMPACT trial)",https://pubmed.ncbi.nlm.nih.gov/37272521/; https://pubmed.ncbi.nlm.nih.gov/39900091/; https://pubmed.ncbi.nlm.nih.gov/34342835/; https://pubmed.ncbi.nlm.nih.gov/29668352/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 130, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: U.S. patients with acute lymphoblastic leukemia, Cohort_1: Patients with acute lymphoblastic leukemia, Cohort_2: not applicable, Outcomes: Incidence and prevalence of patients with acute lymphoblastic leukemia, proportion of patients receiving care at academic centers, geographic distribution of patients with acute lymphoblastic leukemia', 'role': 'user'}]}",True,200.0,104.39229393005371,,fd275d70-60cf-4be9-8b2a-5f6c9c60b36a,2360.0,Limitations: The identified national surveillance and registry publications report incidence and geo...,3.0,T/T/T,3.0,True,True,True,"The AI's answer cites specific figures for incidence and incidence trends, references population subgroups (including pediatric and Hispanic populations), and discusses geographic distribution and disparities in outcomes, all in alignment with what is provided in the context. It transparently notes limitations where the context does not supply a prevalence value or an exact national proportion of patients treated at academic centers, instead accurately summarizing what the relevant studies report. The answer relies solely on the data in the context, making no unsupported claims or introducing external knowledge.",619,5,5,168.6,843,"Epidemiology and Etiology of Leukemia and Lymphoma; Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - United States, 2001-2014; Trends in Acute Lymphoblastic Leukemia Incidence in the United States by Race/Ethnicity From 2000 to 2016; Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility; Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights From the CDC WONDER Database",https://pmc.ncbi.nlm.nih.gov/articles/PMC7263093/; https://pubmed.ncbi.nlm.nih.gov/28910269/; https://pubmed.ncbi.nlm.nih.gov/33034340/; https://pubmed.ncbi.nlm.nih.gov/34493143/; https://pubmed.ncbi.nlm.nih.gov/39886753/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 134, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with confirmed severe asthma, defined by repeated asthma diagnoses, Intervention: Any of the following biologics - (Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire), Outcomes: Counts of systemic corticosteroid prescriptions, asthma-related hospitalizations and emergency department visits', 'role': 'user'}]}",True,200.0,76.50104022026062,,bc8194e2-ebfa-42ae-89ed-d798c461fd0c,1869.0,Limitations: Few studies report raw event counts for all listed biologics together; most evidence re...,3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately reflects the evidence in the provided context. The answer points out the limitation that pooled raw counts for all named biologics are uncommon in the literature, which is appropriately documented in the context. It then summarizes the available findings: reductions in hospitalizations, exacerbations, and systemic corticosteroid exposure, all of which are explicitly supported by the cited meta-analyses and real-world studies. The AI references specific findings, such as rate ratios and OCS dose reduction from the relevant studies, and provides detailed counts from the PONENTE study for benralizumab, mirroring the context. The synthesis of the answer is grounded in the context evidence without introducing unsupported claims, and all key outcome domains (steroid use, hospitalizations, ED visits) are addressed. Therefore, all three criteria are satisfied.",891,4,4,267.0,1068,"Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials; Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis; Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use; Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study",https://pmc.ncbi.nlm.nih.gov/articles/PMC11040390/; https://pubmed.ncbi.nlm.nih.gov/37972921/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8585664/; https://pubmed.ncbi.nlm.nih.gov/34619104/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 129, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the incidence and prevalence of acute lymphoblastic leukemia (ALL) patients in the United States broken down by region (Midwest, Northeast, South, West) and state? Where available, please also report on the proportion of patients who are receiving care at academic centers.', 'role': 'user'}]}",True,200.0,125.00860238075256,,89ec4e6f-ef10-485c-9d87-35cdb2326ae6,2790.0,"Limitations: No single NCBI/PubMed source located provides a complete, all-ages, state-by-state tabl...",2.0,F/T/T,2.0,False,True,True,"The context provided offers substantial information relevant to the question, specifically about national incidence rates, pediatric incidence patterns by region and state (with highest rates in certain states), and the lack of available data on state-by-state prevalence and academic center care proportion. The AI answer correctly states the limitations and accurately summarizes what the context reports, making clear where precise data is not available. However, the question asks for incidence and prevalence of ALL broken down by region and state and care at academic centers, and the context does not provide all-ages, state-by-state breakdowns or prevalence (only partial pediatric data and general trends), nor specific proportions for academic centers. Thus, the context does not directly answer the full question but addresses it comprehensively and the answer remains grounded entirely in the supplied materials.",924,5,5,253.8,1269,"Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - United States, 2001-2014; Epidemiology and Etiology of Leukemia and Lymphoma (review, PMC); Acute lymphoblastic leukemia: a comprehensive review and 2017 update (PMC); Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 (PMC); Disparities in Acute Lymphocytic Leukemia Outcomes Among Young Adults (multi-site study, PMC)",https://pubmed.ncbi.nlm.nih.gov/28910269/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263093/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520400/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517941/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379050/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 139, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma patients on Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Fluticasone-Salmeterol, Budesonide-Formoterol, Mometasone-Formoterol, Cohort_1: Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire, Cohort_2: Not on (Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire), Outcomes: ER visits, urgent care visits, asthma-related inpatient hospitalizations, systemic corticosteroid prescription initiation', 'role': 'user'}]}",True,200.0,52.14826703071594,,157224b7-0c18-4f99-9e29-65308bcf13b1,1791.0,Limitations: Most RCTs and real‑world cohorts enrolled patients receiving background inhaled control...,3.0,T/T/T,3.0,True,True,True,"The context consists of several systematic reviews and real-world studies directly assessing the outcomes for asthma patients on biologics (the requested Cohort_1) versus those not on these medications (Cohort_2), specifically mentioning reductions in severe exacerbations, hospitalizations, ER/ED visits, and systemic corticosteroid use. The AI answer accurately synthesizes and grounds its claims in these data, matching the outcomes listed in the question. The answer also correctly notes the limited reporting about urgent-care visits, which is supported by a statement directly from the context. Thus, the answer is fully grounded in and directly answers the question using the provided context.",700,4,4,156.0,624,"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma - PubMed; Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis - PubMed; Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis - PubMed; Real-world effectiveness of dupilumab versus benralizumab and mepolizumab - PubMed",https://pubmed.ncbi.nlm.nih.gov/32034960/; https://pubmed.ncbi.nlm.nih.gov/30533206/; https://pubmed.ncbi.nlm.nih.gov/35174566/; https://pubmed.ncbi.nlm.nih.gov/38760161/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 135, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients (≥18 years) with severe asthma who initiated biologic therapy, Intervention: Continuous use of biologic therapy for ≥12 months, Control: Discontinuation of biologic therapy within 12 months of initiation, Outcomes: Differences in healthcare utilization, including asthma-related hospitalizations and emergency department visits, during the 12-month period', 'role': 'user'}]}",True,200.0,81.67787194252014,,26908ecf-a3fb-426f-9683-146fc51cd571,2022.0,Limitations: No randomized trials were identified that directly compare continuous biologic use ≥12 ...,3.0,T/T/T,3.0,True,True,True,"The AI's answer is well-grounded in the provided context and correctly synthesizes the findings from the source documents. It accurately summarizes evidence for continuous biologic therapy (especially omalizumab) versus early discontinuation, referencing specific reductions in hospitalizations and ED visits. It also correctly reports that one study found similar short-term exacerbation rates after stopping versus continuing therapy, while another review noted gradual loss of control and increased exacerbations after discontinuation of some biologics (e.g., mepolizumab). The answer provides a clear, direct response to the question about healthcare utilization outcomes during the 12 months, appropriately notes limitations around study design, and makes no unsupported claims. All cited findings can be traced back to the context provided.",846,4,4,224.75,899,"Association between consistent omalizumab treatment and asthma control; Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab; Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics; Discontinuation of biologic therapy in severe asthma: Evidence and strategies for safe withdrawal: A scoping review",https://pubmed.ncbi.nlm.nih.gov/24229822/; https://pubmed.ncbi.nlm.nih.gov/30049502/; https://pubmed.ncbi.nlm.nih.gov/33652135/; https://pubmed.ncbi.nlm.nih.gov/40893465/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 136, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with confirmed severe asthma, defined by repeated asthma diagnoses and high-dose of any of the following - Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Intervention: Any of the following biologics - (Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire), Control: Not on any of the following biologic therapy (Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire), Outcomes: Counts of systemic corticosteroid prescriptions, asthma-related hospitalizations and emergency department visits', 'role': 'user'}]}",True,200.0,76.63861179351807,,c3c52d24-424f-46cd-bc71-a773bb86f6fa,2090.0,Limitations: The available randomized trials and meta-analyses evaluated biologics in patients defin...,3.0,T/T/T,3.0,True,True,True,"The context provides specific evidence regarding the effects of biologic therapies (the listed agents) in patients with severe or moderate-to-severe uncontrolled asthma, including data on reductions in asthma exacerbations leading to hospitalization/ED visits and systemic corticosteroid (OCS) use. The AI’s answer relays these findings accurately and grounds all claims in the cited context, discussing the direct effects on the outcomes of interest (OCS prescription reduction, hospitalizations, and ED visits). The answer explicitly addresses the slight misalignment between the context’s population definitions and the question’s strict inhaler-based cohort, reflecting nuance and caution. No unsupported claims or hallucinations are present; all statements are supported by the evidence provided in the context. Therefore, all criteria are fulfilled.",855,4,4,276.75,1107,"Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma; Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma; Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma; Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma",https://pubmed.ncbi.nlm.nih.gov/40261563/; https://pubmed.ncbi.nlm.nih.gov/25199060/; https://pubmed.ncbi.nlm.nih.gov/29782224/; https://pubmed.ncbi.nlm.nih.gov/33364788/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 137, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Puerto Rico Asthma age 12 and above, Intervention: Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Fluticasone-Salmeterol, Budesonide-Formoterol, Mometasone-Formoterol, Outcomes: Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire', 'role': 'user'}]}",True,200.0,79.47729325294495,,0089592a-06ad-41a8-b569-64e3fc5d3b64,1729.0,"Limitations: No published studies were identified that directly evaluate, in Puerto Rican patients a...",2.0,F/T/T,2.0,False,True,True,"The context does not provide direct evidence or studies addressing the specific question (i.e., whether use of the specific ICS/LABA combinations in Puerto Rican asthma patients ≥12 years affects the need for or outcomes of biologic therapies Xolair, Nucala, Cinqair, Fasenra, Dupixent, or Tezspire). However, the context is relevant to the question in that it discusses Puerto Rican asthma prevalence, general biologic use and approval in adolescents (including ≥12 years), and comparative-effectiveness studies of biologics—although not specific to Puerto Ricans or the inhaled therapies listed. The AI's answer accurately summarizes this, does not make unsupported claims, and relies solely on the provided context, drawing appropriate limitations and practical implications.",778,4,4,165.0,660,"A meta-analysis of genome-wide association studies of asthma in Puerto Ricans; Asthma in Hispanics; Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab; Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation - PubMed",https://pmc.ncbi.nlm.nih.gov/articles/PMC5527708/; https://pmc.ncbi.nlm.nih.gov/articles/PMC2662985/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10600295/; https://pubmed.ncbi.nlm.nih.gov/36740144/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 138, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Asthma patients on Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Fluticasone-Salmeterol, Budesonide-Formoterol, Mometasone-Formoterol, Cohort_1: Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire, Cohort_2: Not on Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire, Outcomes: ER visits, urgent care visits, asthma-related inpatient hospitalizations, systemic corticosteroid prescription initiation', 'role': 'user'}]}",True,200.0,79.41451525688171,,bfe74716-b882-4df9-92e6-4f91f05320d1,1764.0,Limitations: No identified RCTs or meta-analyses stratified outcomes by specific inhaled‑controller ...,3.0,T/T/T,3.0,True,True,True,"The context provides direct quantitative data from systematic reviews and meta-analyses about the effects of biologics compared to placebo or standard therapy, specifically noting reductions in exacerbations, ER visits, hospitalizations, and systemic corticosteroid use. The AI’s answer summarizes these findings, explicitly referencing the context's numerical outcomes for ED/hospital visits and hospitalizations, as well as describing the limitations regarding stratification by inhaler brand (which the context does not provide). There is no introduction of unsupported claims; the answer is strictly grounded in the supplied context and addresses each of the specified outcomes. Thus, all three evaluation criteria are satisfied.",733,4,4,194.25,777,"Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials - PMC; Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma - PMC; Severe asthma exacerbations in the United States: Incidence, characteristics, predictors, and effects of biologic treatments - PubMed; Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management - PubMed",https://pmc.ncbi.nlm.nih.gov/articles/PMC11040390/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12085395/; https://pubmed.ncbi.nlm.nih.gov/34273485/; https://pubmed.ncbi.nlm.nih.gov/31525297/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 147, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please provide count of the number of HCPs with HCPCS or CPT codes for the following lab tests:\n Blood eosinophil count\n Blood IgE count\n FeNO', 'role': 'user'}]}",True,200.0,10.973166942596436,,6ea89d96-0f3d-4e60-a803-fba3fb39761a,250.0,"Do you mean (A) the number of distinct HCPCS/CPT codes that exist for each test, or (B) the number o...",1.0,F/F/T,1.0,False,False,True,"There is no context provided, so the original question cannot be answered directly or even partially addressed with the available information. The AI assistant recognizes the ambiguity in the question and asks for clarification, rather than providing unsupported information. Therefore, the answer does not introduce external knowledge and remains grounded in the lack of context, but none of the evaluation criteria related to the context are satisfied.",454,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 140, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the demographic profile and population size of patients receiving anifrolumab and belimumab?', 'role': 'user'}]}",True,200.0,79.57935786247253,,fb47658a-8df7-4555-a9dc-bebf47c5394e,984.0,Limitation: available data derive from phase‑3 clinical trials and pooled trial analyses rather than...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question by providing the population size and demographic breakdown for both anifrolumab and belimumab, citing specific clinical trial data as provided in the context. Details such as the number of patients, age, sex, and ethnicity for each drug's trial population are included and matched to information from the references. The discussion of limitations (clinical trial data vs. real-world data) is consistent with the context. The answer does not introduce any unsupported claims or external knowledge and stays grounded within the details presented in the context.",607,4,4,107.75,431,"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials; Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials - PMC; Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials - PMC; Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by BICLA - PubMed",https://pubmed.ncbi.nlm.nih.gov/38288923/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12056589/; https://pmc.ncbi.nlm.nih.gov/articles/PMC3465857/; https://pubmed.ncbi.nlm.nih.gov/40274305/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 148, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please list all the medical procedure codes for these lab tests: Blood eosinophil count, Blood IgE, FeNO', 'role': 'user'}]}",True,200.0,18.296082496643066,,a78366ab-5b1e-41a1-a487-98c6f5a18f22,136.0,"Which coding system do you mean (CPT/HCPCS for billing, LOINC for lab identifiers, or something else...",1.0,F/F/T,1.0,False,False,True,"No context was provided, so the AI's answer cannot be assessed for direct relevance or whether the context addresses the question. The answer itself does not invent information and simply requests clarification from the user. Therefore, while the answer is not grounded in any context (since none is provided), it does not hallucinate or introduce unsupported claims.",367,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 151, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many tagrisso patients with at least 3 years follow up and in which tumor areas?', 'role': 'user'}]}",True,200.0,15.323332786560059,,d8794ef9-c01d-4c26-84c2-3a8c3845baa0,472.0,I need one clarification before searching: do you mean a specific trial or dataset (for example FLAU...,1.0,F/F/T,1.0,False,False,True,"The context provided is empty, so there is no information relevant to the question about the number of Tagrisso patients with at least 3 years follow up or the tumor areas. The AI's answer does not make any claims and instead asks for clarifications from the user, which means it does not introduce unsupported information. However, due to the absence of relevant context, none of the first two criteria are met.",412,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 149, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please count HCPs by all the medical procedure codes for these lab tests: Blood eosinophil count, Blood IgE, FeNO', 'role': 'user'}]}",True,200.0,37.36780786514282,,873f6ce3-5df7-4463-9170-5960b9d6fac7,69.0,The published literature does not contain an answer to this question.,1.0,F/F/T,1.0,False,False,True,"There is no context provided, so the answer does not contain specific evidence or relevant information to directly answer or address the question regarding HCPs or procedure codes. However, the AI's answer accurately reflects the absence of information from the provided context and does not introduce any unsupported or hallucinatory facts, remaining grounded in what was given (i.e., nothing).",395,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 142, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients initiating anifrolumab or belimumab in the United States, Cohort_1: anifrolumab, Cohort_2: belimumab, Outcomes: demographic distribution', 'role': 'user'}]}",True,200.0,97.98808288574219,,5af19ff3-4f38-4414-8498-89ce1b34b33b,927.0,Limitations: No large published US real‑world cohort directly comparing baseline demographics of pat...,3.0,T/T/T,3.0,True,True,True,"The AI accurately summarizes and distinguishes the sources of demographic data for anifrolumab (from pooled phase 3 TULIP-1/2 trials) and belimumab (from US real-world cohorts), referencing the specific mean ages, female proportions, and racial/ethnic distribution as reported in the context. The limitations regarding differences in data sources are also supported by the context. All details presented are directly from the provided references, without unsupported extrapolation.",481,3,3,167.33333333333334,502,"Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study; A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings; Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials",https://pmc.ncbi.nlm.nih.gov/articles/PMC10011356/; https://pubmed.ncbi.nlm.nih.gov/26547483/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10070065/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 141, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many patients have initiated anifrolumab?', 'role': 'user'}]}",True,200.0,111.26305747032166,,148c3837-9566-4360-9d50-ed08a3421e48,742.0,"The question is ambiguous; the published literature does not report a single global ""initiated anifr...",3.0,T/T/T,3.0,True,True,True,"The context provides specific numbers from the TULIP-1 and TULIP-2 trials regarding how many patients initiated anifrolumab, directly addressing the question. The AI's answer closely cites these numbers, accurately summing up that 273 patients in TULIP-1 and 180 in TULIP-2 received anifrolumab, for a total of 453. The answer is solely grounded in the provided context and does not introduce information from outside sources. All three criteria are met.",454,3,3,145.33333333333334,436,"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials; Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial; Trial of Anifrolumab in Active Systemic Lupus Erythematosus",https://pubmed.ncbi.nlm.nih.gov/38288923/; https://pubmed.ncbi.nlm.nih.gov/38229377/; https://pubmed.ncbi.nlm.nih.gov/31851795/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 144, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the estimated population of patients diagnosed with SLE in the United States, and how is this population distributed across different demographics such as age, gender, and ethnicity?', 'role': 'user'}]}",True,200.0,104.88092160224915,,8decdd7c-a5aa-4807-ac3b-d5e693d5c45b,1480.0,Limitations: The CDC registry meta-analysis used for national prevalence estimates did not provide d...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question by providing the estimated prevalence (204,295 persons in 2018), demographic breakdowns by gender (noting a 9-fold higher prevalence in females), and specific prevalence rates among ethnic groups (highest among Black and American Indian/Alaska Native females). It also uses data from a large Medicaid cohort to give additional, albeit less representative, information about age distribution, clearly noting the limitation that it may not be nationally representative. All figures and statements in the answer are traceable to the context provided, with no unsupported claims or usage of external knowledge. The AI also includes relevant caveats about the limitations in the available data, demonstrating accurate grounding in the source material.",794,3,3,290.3333333333333,871,Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries - PMC; Racial/Ethnic Variation in Stroke Rates and Risks among Patients with Systemic Lupus Erythematosus - PMC; Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries - PMC,https://pmc.ncbi.nlm.nih.gov/articles/PMC8169527/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6377855/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8685969/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 150, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with early lung cancer, Intervention: Tagrisso, Outcomes: death', 'role': 'user'}]}",True,200.0,57.36838698387146,,d34f898d-c5b4-4e99-8c57-9e59b62598ec,670.0,"In patients with completely resected, EGFR‑mutated stage IB–IIIA non–small‑cell lung cancer, adjuvan...",3.0,T/T/T,3.0,True,True,True,"The AI's answer is directly supported by the provided context. It specifically states that adjuvant osimertinib (Tagrisso) reduced the risk of death (HR 0.49) and improved 5-year overall survival (88% vs. 78%), in full alignment with the final ADAURA analysis cited in the context. It also accurately reflects earlier reports about disease-free survival and the timing and basis for FDA approval, as indicated in the references. The answer does not introduce any unsupported or external information. Therefore, all evaluation criteria are met.",543,3,3,151.33333333333334,454,"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC; Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer; FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review",https://pubmed.ncbi.nlm.nih.gov/37272535/; https://pubmed.ncbi.nlm.nih.gov/32955177/; https://pubmed.ncbi.nlm.nih.gov/34301748/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 146, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please provide count of the number of HCPs with procedures for the following lab tests:\n Blood eosinophil count\n Blood IgE count\n FeNO', 'role': 'user'}]}",True,200.0,77.16193699836731,,02d354ab-6dcf-436e-99eb-680de75c4053,1284.0,No published study was identified that reports a population-level count of healthcare providers (HCP...,2.0,F/T/T,2.0,False,True,True,"The AI's answer correctly states that there is no published population-level count of HCPs with procedures for the specified lab tests, which is supported by the context—all referenced context documents discuss test availability, usage, or sample practice usage, but none enumerate provider or procedure counts. The answer is relevant to the question and grounded in the context, as it accurately reflects the limits of available data described in the provided sources. However, it does not provide a direct answer (the actual count) as the context itself does not contain this information.",590,4,4,208.0,832,"Fractional Exhaled Nitric Oxide Testing for the Diagnosis and Management of Asthma: a Health Technology Assessment; Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions; Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis; A Pragmatic Primary Practice Approach to Using Specific IgE in Allergy Testing in Asthma Diagnosis, Management, and Referral",https://pubmed.ncbi.nlm.nih.gov/39329005/; https://pubmed.ncbi.nlm.nih.gov/29408317/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8756293/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9392458/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 143, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please provide longitudinal exacerbation rate for severe asthma patients on Tezspire.', 'role': 'user'}]}",True,200.0,114.41230201721191,,7aac08c3-dda6-4310-972d-4d4cac9fccf3,902.0,Limitations: the long-term extension (DESTINATION) reports exacerbation-rate ratios over 104 weeks b...,3.0,T/T/T,3.0,True,True,True,"The AI's answer provides the annualized asthma exacerbation rate (AAER) for severe asthma patients on Tezspire (tezepelumab), directly referencing the specific trial result (AAER of 0.93 with tezepelumab over 52 weeks) from the NAVIGATOR study. It also discusses long-term (104-week) exacerbation rate ratios from the DESTINATION extension study, noting the limitation that absolute 104-week AAER values are not reported in the provided context, which aligns with the supplied DESTINATION abstract. The AI accurately summarizes the evidence, includes proper trial references, addresses the question of longitudinal rates, and does not introduce unsupported claims or external knowledge. Thus, all three criteria are satisfied.",726,3,3,186.66666666666666,560,"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma; Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials; Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study",https://pubmed.ncbi.nlm.nih.gov/33979488/; https://pubmed.ncbi.nlm.nih.gov/37015033/; https://pubmed.ncbi.nlm.nih.gov/36702146/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 156, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with 12 month of continuous outpatient use of Lokelma during a 12-month follow-up period, with a clearly defined baseline period of the 12 months immediately prior to Lokelma initiation to capture patient comorbidities and relevant characteristics, Intervention: Lokelma, Outcomes: Assessment of patient characteristics including baseline comorbidities (e.g., heart failure, hypertension, diabetes, chronic kidney disease identified via diagnosis codes); risk of acute myocardial infarction and stroke determined using specific diagnosis codes from EHR data (operationalizing MACE); risk of hyperkalemia recurrence defined as one or more serum potassium measurements above 5.0 mmol/L using laboratory result data, supplemented by hyperkalemia-related diagnostic codes from claims or EHRs to capture events potentially missed by lab draw timing; risk of edema defined based on specific diagnostic codes for peripheral or fluid retention edema; risk of all-cause inpatient admission.', 'role': 'user'}]}",True,200.0,62.04353857040405,,d4e609ef-805e-4a30-b4e8-d344ed50f0e1,2253.0,Limitation: No published study was identified that exactly matches the requested EHR/claims-based co...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain direct evidence or data matching the highly specific cohort (12 months of continuous outpatient Lokelma use with a 12‑month pre-index baseline) and the precise outcomes and operational definitions (EHR/claims-based MACE, hyperkalemia recurrence combining lab and diagnosis codes, etc.) asked in the question. The trials described focused on serum potassium outcomes and adverse events (including edema) but did not report outcome measures using the exact code-based or EHR/claims-based definitions. One real-world claims study assessed hospitalizations and edema using encounter and diagnostic codes, but did not fully match all requested outcomes or the cohort inclusion criteria. Thus, the context does not directly answer the question but is broadly relevant, addressing aspects of the requested endpoints and study design. The AI's answer accurately reflects these limitations and relies strictly on the information provided in the context, without introducing unsupported claims or additional data.",1041,4,4,271.75,1087,Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study; Clinical Evidence - Clinical Review Report: Sodium Zirconium Cyclosilicate (Lokelma); Efficacy and Safety of Sodium Zirconium Cyclosilicate for the Management of Acute and Chronic Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE; The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer,https://pubmed.ncbi.nlm.nih.gov/31110051/; https://www.ncbi.nlm.nih.gov/books/NBK563716/; https://pubmed.ncbi.nlm.nih.gov/31658466/; https://pubmed.ncbi.nlm.nih.gov/39303023/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 160, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with at least one SABA (albuterol) rescue inhaler fill in 2023, a documented asthma diagnosis during the study period, and no documented COPD diagnosis, Cohort_1: commercially insured, Cohort_2: Medicare, Cohort_3: Medicaid, Outcomes: count of asthma-related exasperation events by hospitalization, ER and outpatient visits and count of corticosteroids fills', 'role': 'user'}]}",True,200.0,55.815202713012695,,ac600414-193f-4150-9341-74acf6cea9be,1708.0,The published literature does not contain the specific 2023 US counts for the cohorts defined (patie...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain the precise 2023 US counts of asthma exacerbations or corticosteroid fills separated by insurance cohorts (commercial, Medicare, Medicaid) as specified in the question. However, it does present data from prior years and summarizes relevant findings regarding the distribution of insurance payers and the association between SABA use and exacerbation risk. Therefore, while the context does not answer the specific question directly, it is clearly relevant to the topic. The AI's answer accurately reflects the limitations of the context and does not introduce information not supported by the references; its statements are well grounded in the provided context.",700,3,3,208.66666666666666,626,Patterns of Rescue and Maintenance Medication Claims Surrounding an Asthma Exacerbation in Patients Treated as Intermittent or Mild Persistent Asthma; Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme - PubMed; Adverse Outcomes Associated With Short-Acting Beta-Agonist Overuse in Asthma: A Systematic Review and Meta-Analysis,https://pmc.ncbi.nlm.nih.gov/articles/PMC11409924/; https://pubmed.ncbi.nlm.nih.gov/31949111/; https://pubmed.ncbi.nlm.nih.gov/40491263/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 153, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients on continuous 8 month of Lokelma use, Intervention: Lokelma, Outcomes: description of long term use characteristics', 'role': 'user'}]}",True,200.0,102.63514566421509,,04e62ebc-4389-4854-9902-7ee14b2a55ba,1627.0,Limitations: No published trial reports outcomes specifically for a prespecified cohort treated cont...,2.0,F/T/T,2.0,False,True,True,"The provided context does not specifically report outcomes for patients on exactly 8 months of continuous Lokelma use, so the context does not directly answer the question as stated. However, the context discusses long-term use characteristics of Lokelma from open-label extension studies up to 11-12 months and outlines relevant efficacy, dosing, completion rates, tolerability, and adverse events, thus addressing the general topic of long-term use. The AI’s answer appropriately synthesizes the context, clarifies limitations of available evidence for a strict 8-month window, and stays grounded in the evidence provided, without introducing unsupported claims.",664,3,3,224.33333333333334,673,Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE; Clinical Review Report: Sodium Zirconium Cyclosilicate (Lokelma): (AstraZeneca Canada Inc.): Indication: For the treatment of hyperkalemia in adults; Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting system,https://pubmed.ncbi.nlm.nih.gov/31658466/; https://www.ncbi.nlm.nih.gov/books/NBK563716/; https://pubmed.ncbi.nlm.nih.gov/40151141/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 158, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients who were diagnosed with hyperkalemia during the index hospitalization and discharged from hospital, no history of lokelma, patrimer, or SPS use prior to hyperkalemia hospitalization; report baseline mean serum potassium level , Intervention: Lokelma outpatient initiation and continued use as documented in structured EHR or claims data, Control: no lokelma, patrimer, SPS treatment during the follow-up period, Outcomes: serum potassium control defined by specific metrics such as the mean serum potassium level and the proportion of patients achieving a target potassium range (e.g., 3.5-5.0 mEq/L) during follow-up', 'role': 'user'}]}",True,200.0,83.78927206993103,,fad95d05-026c-49cc-b29f-60b437035159,3297.0,Limitations: No published study was found that exactly matches all specified criteria (patients with...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The context does not include specific, relevant evidence that directly and fully answers the question (i.e., a study with the exact requested population, intervention, control, and outcome metrics). The context confirms that no published study reports on post-discharge Lokelma versus no-binder using structured EHR/claims data with mean serum K and proportion in target range as outcomes.

2. context_addresses_question: True. The context is highly relevant to the question, as it discusses studies of Lokelma (SZC) use in outpatient settings, randomized controlled trials, pooled analyses of efficacy, and real-world claims studies—while each falls short of the full requested design, they address similar populations and endpoints, and the CONTINUITY study is described as being designed to answer this question.

3. answer_grounded_in_context: True. The answer faithfully relies only on the context provided, refraining from introducing unsupported claims or external data, and clearly contextualizes the limitations and relevance of each context source to the question.",1119,4,4,402.5,1610,Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease - PMC; Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial - PubMed; Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level 65.5 mmol/L: pooled analysis from two phase 3 trials - PMC; Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC10310508/; https://pubmed.ncbi.nlm.nih.gov/25402495/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6889520/; https://pubmed.ncbi.nlm.nih.gov/36576213/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 159, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'long term trajectory of hyperkalemia recurrence in non-ESRD or dialysis adult patients newly diagnosed with hyperkalemia with confirmed lab measurement of serum potassium level greater than 5.0 mmol/L with greater than 5 years of continuous enrollment. primary oucome is chronic hyperkalemia defined as greater than 3 episodes of serium potassium greater than 5.0 mmol/L with greater than 30 days apart of each episode. also report on time to recurrence, frequency, and proportion of time with elevated potassium level.', 'role': 'user'}]}",True,200.0,81.37961292266846,,30637a34-8667-4477-9982-35476541684f,1745.0,No published study meeting the exact inclusion/outcome criteria (non‑ESRD adults with a laboratory‑c...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the primary question regarding the long-term (≥5 years) trajectory of hyperkalemia recurrence, nor does it report data using the requested chronic hyperkalemia definition, time to recurrence, frequency, or proportion of elevated potassium time. The studies cited provide information on 1-year recurrence and associated risk factors, but none address the ≥5-year outcomes or the specific primary outcome definition. The AI's answer accurately reflects this gap, summarizes the available evidence, and does not introduce unsupported claims.",575,4,4,257.75,1031,Liver Disease Is a Risk Factor for Recurrent Hyperkalemia: A Retrospective Cohort Study; Hyperkalemia Recurrence and Its Association With Race and Ethnicity in United States Veterans: A Retrospective Cohort Study; Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence; Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan,https://pmc.ncbi.nlm.nih.gov/articles/PMC10380673/; https://pubmed.ncbi.nlm.nih.gov/38800332/; https://pubmed.ncbi.nlm.nih.gov/33608262/; https://pubmed.ncbi.nlm.nih.gov/33319198/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 152, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with transthyretin amyloid neuropathy (ATTR-PN), Cohort_1: patients with V122I genetic mutation subtype, Cohort_2: patients with V30M mutation subtype, Outcomes: ATTR treatment choices', 'role': 'user'}]}",True,200.0,130.72748517990112,,31fb52fa-8375-4771-8610-4ccb4a20641f,1872.0,Limitations: evidence is mutation‑specific rather than from randomized head‑to‑head genotype compari...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The AI answer provides specific details regarding the ATTR treatment choices for both the V30M and V122I subtypes, citing liver transplantation, tafamidis, and patisiran, each supported by referenced studies in the provided context.
2. context_addresses_question: True. The context focuses directly on treatment outcomes associated with specific mutations (V30M, V122I) in ATTR-PN patients, as well as relevant studies regarding disease progression and therapy effects.
3. answer_grounded_in_context: True. The AI answer is tightly grounded in the context, referencing each supporting study by number and not introducing claims or treatments not mentioned in the context. No unsupported or external information is added.",764,5,5,219.8,1099,"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial; Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients; Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study; Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis; Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry",https://pubmed.ncbi.nlm.nih.gov/22843282/; https://pubmed.ncbi.nlm.nih.gov/29924456/; https://pubmed.ncbi.nlm.nih.gov/40974604/; https://pubmed.ncbi.nlm.nih.gov/29972753/; https://pubmed.ncbi.nlm.nih.gov/34079032/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 155, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with at least 8 month of continous outpatient use of Lokelma in a 12 month follow-up period, Intervention: Lokelma, Outcomes: description patient characteristics, risk of MACE; risk of hyperkalemia recurrence as measured as having serium potesasium level above 5.0 mmol/l during the follow-up period; risk of edema; risk of all-cause inpatient admission;', 'role': 'user'}]}",True,200.0,105.74883937835693,,a66e9aa9-6dc7-4792-a283-00d67f5ce4f0,2397.0,Limitations: No published study explicitly defines a cohort as “≥8 months continuous outpatient Loke...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: FALSE. While the AI summarizes the provided literature well, there is no direct evidence or dataset for a cohort defined as '≥8 months continuous outpatient Lokelma use'—the trial data and real-world analyses offered only approximate or indirect evidence. The answer explicitly notes this limitation, and while it provides details on patient characteristics, risks, and outcomes from closely matched studies, there is not direct, specific evidence for the target cohort and outcomes.

2. context_addresses_question: TRUE. The context provided is relevant to the question, as it includes information about populations with long-term Lokelma/SZC use (albeit not exactly matching ≥8 months continuous use), patient characteristics, risks of hyperkalemia recurrence, risk of edema, and all-cause inpatient admissions.

3. answer_grounded_in_context: TRUE. The answer does not introduce unsupported claims or hallucinate data. It relies solely on evidence from the cited context, repeatedly acknowledging limitations in the direct applicability of study populations and outcomes to the exact target cohort.",1139,4,4,157.25,629,Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study - PubMed; Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study - PubMed; Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial - PubMed; Clinical Evidence - Clinical Review Report: Sodium Zirconium Cyclosilicate (Lokelma) - NCBI Bookshelf,https://pubmed.ncbi.nlm.nih.gov/31110051/; https://pubmed.ncbi.nlm.nih.gov/36576213/; https://pubmed.ncbi.nlm.nih.gov/25402495/; https://www.ncbi.nlm.nih.gov/books/NBK563716/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 145, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Please provide a list of procedure codes to identify the following lab test procedures in medical claims data:\n Blood eosinophil count\n Blood IgE count\n FeNO', 'role': 'user'}]}",False,,,"HTTPSConnectionPool(host='dbc-7a32c3d1-0aa9.cloud.databricks.com', port=443): Read timed out. (read timeout=180)",,,,0.0,,,,,,,0,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 162, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the average treatment duration of mepolizumab?', 'role': 'user'}]}",True,200.0,47.31294274330139,,df8c23d0-64b9-431f-aa30-48349541c61a,796.0,Reported treatment durations for mepolizumab vary by study type and follow‑up interval. In a prospec...,3.0,T/T/T,3.0,True,True,True,"The provided context gives specific information on the average, median, and range of treatment durations for mepolizumab, referencing several clinical studies and reviews (mean duration about 340 days, median 2.2 years, up to 4.5 years in extensions, and typical trial period of 4-6 months). The AI's answer accurately summarizes and cites this evidence, including correct data points and noting the variability across studies and contexts. The answer is highly relevant, directly answers the question, and is strictly based on the provided context with no unsupported claims.",576,4,4,204.25,817,Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study - PubMed; Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis - PMC; Efficacy and Safety of Mepolizumab in the Management of Severe Eosinophilic Asthma: A Systematic Review - PMC; Persistence of Asthma Biologic Use in a US Claims Database - PMC,https://pubmed.ncbi.nlm.nih.gov/31447130/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7559868/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10757760/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8572312/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 161, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with severe eosinophilic asthma, Intervention: mepolizumab, Control: none, Outcomes: asthma exacerbations', 'role': 'user'}]}",True,200.0,71.73035383224487,,fb1a843b-f26b-4078-b1f3-57d266aac10a,841.0,Randomized controlled trials demonstrate substantial reductions in clinically significant exacerbati...,3.0,T/T/T,3.0,True,True,True,"The provided context contains direct evidence regarding the effect of mepolizumab on asthma exacerbations in patients with severe eosinophilic asthma, including RCT (DREAM trial), meta-analyses, and real-world studies, all quantifying reductions in exacerbations. The AI's answer accurately summarizes these findings, providing specific statistics as shown in the context and referencing specific studies accordingly. There are no unsupported claims; the answer is firmly grounded in the context. Therefore, all three criteria are met.",535,3,3,205.66666666666666,617,"Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis; Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial; Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis",https://pubmed.ncbi.nlm.nih.gov/30533206/; https://pubmed.ncbi.nlm.nih.gov/22901886/; https://pubmed.ncbi.nlm.nih.gov/33962763/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 157, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: New users of Lokelma, defined as patients who initiate Lokelma therapy during the study period with no evidence of Lokelma prescriptions during the 12-month baseline period, and who have continuous outpatient lokelma prescriptions post-initiation with less than 30 day gaps and a minimal of 12 month follow-up data for outcome assessment. The baseline period (the 12 months immediately prior to Lokelma initiation) is used to capture patient comorbidities and relevant clinical characteristics., Intervention: Lokelma, Outcomes: Assessment of patient characteristics including baseline comorbidities (e.g., heart failure, hypertension, diabetes, chronic kidney disease identified via diagnosis codes); risk of MACE+; risk of hyperkalemia associated events defined as inpatient or ED visits with hyperkalemia associated diagnosis code on the principle position; risk of edema defined inpatient or ED visits with specific diagnostic codes for peripheral or fluid retention edema at the principle position; risk of all-cause inpatient admission.', 'role': 'user'}]}",True,200.0,127.62819123268127,,10f2448b-bcbf-4c27-bacc-207eb16b5d44,3186.0,"Limitations: Available studies differ in design (randomized short-term trials, ED cohorts, outpatien...",2.0,F/T/T,2.0,False,True,True,"The context provides relevant and detailed study results about the population initiating Lokelma (SZC), including baseline characteristics, risks of hospitalization, edema, and other outcomes. However, none of the referenced studies strictly follow the exact definition required by the original question: new Lokelma users with a 12-month baseline and continuous prescription for at least 12 months, with outcome assessment per the specified criteria (e.g., MACE+, coded definitions in ED/inpatient principle position). The AI answer correctly notes this limitation, synthesizes the closest-available evidence, and grounds its statements in the studies provided, without introducing unsupported facts. The context addresses the question broadly and is highly relevant but does not directly, fully answer the narrowly focused question as posed.",843,4,4,250.25,1001,The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer; Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study; Outcomes and Resource Utilization in Hyperkalemic Emergency Department Patients Treated With Patiromer or Sodium Zirconium Cyclosilicate; Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial,https://pubmed.ncbi.nlm.nih.gov/39303023/; https://pubmed.ncbi.nlm.nih.gov/36576213/; https://pubmed.ncbi.nlm.nih.gov/40485883/; https://pubmed.ncbi.nlm.nih.gov/25402495/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 163, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the average annual number of doses of mepolizumab?', 'role': 'user'}]}",True,200.0,52.76649808883667,,66e066ca-8ff8-423c-989e-b0baea6c715d,167.0,Mepolizumab is administered as a subcutaneous injection once every 4 weeks [1]. That dosing interval...,1.0,F/T/F,1.0,False,True,False,"The context clearly states that mepolizumab is administered once every 4 weeks, but it does not explicitly calculate or mention the annual number of doses. The AI's answer correctly derives the average annual number by dividing 52 weeks by 4, resulting in approximately 13 doses per year. However, this calculation is not directly present in the context, so the answer includes an inference that is logical but not explicitly supported by the provided materials. Therefore, the context is relevant but does not directly answer the question, and the AI's answer is not completely grounded in the context.",603,2,2,154.0,308,Mepolizumab (Nucala) For Severe Eosinophilic Asthma - PMC; DRUG INTERACTIONS and DOSING (Mepolizumab) - PMC article,https://pmc.ncbi.nlm.nih.gov/articles/PMC5046999/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4896350/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 154, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients on continuous 8 month of Lokelma use, Intervention: Lokelma, Outcomes: Serum Potassium Change measured by the difference in serum potassium levels from baseline to 8 months using laboratory EHR data; Hypokalemia Incidence determined by identifying diagnosis codes for hypokalemia occurrences over the 8-month period; all-cause hospital admission rate during 12 month follow-up; hyperkalemia-related hospital admission rate during 12 month follow-up; mortlaity during 12 month follow-up, MACE during 12 month follow-up; number of encounters where serum potassium level is measured greater than 5.0 mmol/l; number of encounters where serum potassium level is measured greater or equal to 5.5 mmol/l; time to first serum potassium greater than 5.0 mmol/l after index day; time to first serum potassium greater or equal to 5.5 mmol/l after index day; rate of edema', 'role': 'user'}]}",True,200.0,155.33795428276062,,d746ef0a-9c7d-4044-bd75-d84ee7ce7af7,3896.0,Limitations: No published study was identified that reports all requested EHR-derived outcomes for a...,2.0,F/T/T,2.0,False,True,True,"The provided context contains studies addressing outcomes related to Lokelma (sodium zirconium cyclosilicate), but none address all the specific outcomes for patients continuously on Lokelma for 8 months as defined in the question. The most relevant studies present related outcomes (e.g., maintenance of potassium, hypokalemia incidence, hospitalization rates, edema), but with different inclusion criteria (such as durations of >90 days, hemodialysis patients, or comparisons to other treatments). The AI's answer correctly represents these limitations and accurately summarizes and grounds its claims in the provided studies, making clear when evidence is indirect or missing for the exact patient/outcome definitions. However, it does not provide a direct answer because the requested cohort and specific outcomes are not available in the context.",851,4,4,280.25,1121,Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study; The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis; The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer; Sodium Zirconium Cyclosilicate for Renin-Angiotensin-Aldosterone System Inhibitor Optimization in Patients with Heart Failure with Reduced Ejection Fraction: A Retrospective Analysis,https://pubmed.ncbi.nlm.nih.gov/36576213/; https://pubmed.ncbi.nlm.nih.gov/40618849/; https://pubmed.ncbi.nlm.nih.gov/39303023/; https://pubmed.ncbi.nlm.nih.gov/39485602/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 169, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Severe asthma patients in Puerto Rico, Outcomes: asthma‐related hospitalization (hospital admissions with a primary diagnosis of asthma)', 'role': 'user'}]}",True,200.0,46.3550078868866,,0a968d52-0389-40c3-b541-617ed0578b46,1319.0,Limitations: No identified Puerto Rico study reports asthma-related hospitalization rates specifical...,2.0,F/T/T,2.0,False,True,True,"The context provides hospitalization rates for all asthma patients in Puerto Rico, as well as findings stratified by age and asthma control, but does not offer data specifically for patients classified as 'severe asthma.' The AI's answer accurately conveys this limitation and summarizes the relevant findings from the context without introducing outside information. Therefore, the context does not answer the question directly but is clearly relevant and the answer is grounded in the context.",495,3,3,264.0,792,Characterizing environmental asthma triggers and healthcare use patterns in Puerto Rico; Association between Health Care Utilization with Asthma Control Levels among a Sample of Adult Patients in Puerto Rico; Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma,https://pmc.ncbi.nlm.nih.gov/articles/PMC8225466/; https://pubmed.ncbi.nlm.nih.gov/27232869/; https://pubmed.ncbi.nlm.nih.gov/14617512/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 165, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the overlap of HCPs who are treating Hypertension and Dyslipidemia among Cardiologists?', 'role': 'user'}]}",True,200.0,72.76943731307983,,cbd3d912-045f-4322-8618-dc7538547489,1673.0,No published study located provides a direct numeric estimate of the proportion of cardiologists who...,2.0,F/T/T,2.0,False,True,True,"The provided context does not supply a direct, quantified estimate of the overlap or percentage of cardiologists treating both hypertension and dyslipidemia, and the AI answer correctly notes this absence. However, the evidence in the context (survey responses, prescription data, and studies on cardiologist engagement in managing both conditions) is relevant and strongly suggests that there is substantial overlap, even though no single number or explicit overlap percentage is reported. The AI answer accurately grounds its statements in the context, only referencing findings available in the supplied sources and clearly qualifying the lack of a specific overlap statistic. Therefore, the answer: (1) does not directly answer the question with a statistic, (2) is relevant to the question, and (3) is grounded in and consistent with the context.",851,5,5,247.6,1238,Survey on arterial hypertension management: a report from the ESC Council for Cardiology Practice and the ESC Council on Hypertension; Patterns and Predictors of Physician Adoption of New Cardiovascular Drugs; Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry); Impact of cardiologist intervention on guideline-directed use of statin therapy; Management of hypertension and dyslipidemia,https://pmc.ncbi.nlm.nih.gov/articles/PMC9241483/; https://pmc.ncbi.nlm.nih.gov/articles/PMC5910251/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6526057/; https://pubmed.ncbi.nlm.nih.gov/32879704/; https://pubmed.ncbi.nlm.nih.gov/17087859/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 164, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic obstructive pulmonary disease, Intervention: proportion of patients on spiriva, Outcomes: spiriva', 'role': 'user'}]}",True,200.0,75.22640228271484,,1701623a-8dc3-4ef3-b55c-598e9d3ab255,1154.0,"Published studies do not provide a single, current population-wide proportion of COPD patients takin...",3.0,T/T/T,3.0,True,True,True,"The AI's answer accurately synthesizes and cites the information from the provided context. It addresses the question of the proportion of COPD patients on Spiriva (tiotropium) but notes—correctly, per the context—that no single, universal proportion is available across all populations. It directly references the specific findings from each study: the 17.4% rate from US ambulatory visits (NAMCS), initiator counts from US claims data, and the 10.4% LAMA (which includes Spiriva) usage among Canadian patients. The answer consistently stays within the facts of the provided context and refrains from introducing unsupported or external information. The context is both directly relevant and adequately answers the nature of the question given available data.",760,3,3,197.0,591,Prescription Practices for Chronic Obstructive Pulmonary Disease: Findings from the National Ambulatory Medical Care Survey 1999–2010; The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study; Are COPD Prescription Patterns Aligned with Guidelines? Evidence from a Canadian Population-Based Study,https://pmc.ncbi.nlm.nih.gov/articles/PMC4559259/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10398184/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8006812/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 167, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients with hypertension defined by either two or more separate SBP readings >130 mmHg or the presence of documented hypertension diagnosis codes in the EHR/claims data to minimize misclassification., Cohort_1: Patients receiving exactly three hypertensive medications with detailed identification of medication classes based on available EHR/claims data. For example, specify if the medications are from classes such as ACE inhibitors, ARBs, beta blockers, or thiazide diuretics (with individual agent names noted when possible)., Cohort_2: Patients receiving exactly four hypertensive medications with explicit identification of each medication class or agent. For instance, document use of combinations potentially including ACE inhibitors, ARBs, beta blockers, thiazide diuretics, and/or calcium channel blockers, with specific agents noted if available., Outcomes: Outcomes operationalized using validated EHR/claims definitions. Stroke is defined by differentiating ischemic (e.g., ICD codes I63) and hemorrhagic subtypes (e.g., ICD codes I61), MI is identified using acute myocardial infarction hospitalization codes (e.g., ICD-10 I21/I22), and heart failure is defined based on robust diagnostic criteria and hospital admission records (e.g., ICD codes I50 with confirmatory hospitalization).', 'role': 'user'}]}",True,200.0,73.3158769607544,,6f1227e3-e538-485f-9b43-8fa5558b7bd6,2091.0,Limitations: No published study was identified that directly compares cohorts defined as “exactly th...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the question, as there is no evidence provided on outcomes by cohort defined as 'exactly three' versus 'exactly four' antihypertensive agents. However, the context is relevant, as it discusses outcomes in patients with resistant hypertension (defined by use of ≥3 agents) and provides validation data for outcome definitions in EHR/claims. The AI's answer is grounded in the context, accurately citing the studies and their findings without introducing unsupported claims. The limitations noted in the answer appropriately reflect the available evidence from the context.",608,5,5,191.6,958,Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES); Validation of ICD-10 Diagnosis Codes for Identification of Acute Myocardial Infarction From a US Integrated Healthcare System; Validation of ICD-10 hospital discharge diagnosis codes to identify incident and recurrent ischemic stroke from a US integrated healthcare system; Validation of ICD-10-CM Diagnosis Codes for Identification of Patients with Acute Hemorrhagic Stroke in a National Health Insurance Claims Database; Validation of Acute Myocardial Infarction and Heart Failure Diagnoses in Hospitalized Patients With the Nationwide Claim-Based JROAD-DPC Database,https://pmc.ncbi.nlm.nih.gov/articles/PMC6485047/; https://pubmed.ncbi.nlm.nih.gov/40552766/; https://pubmed.ncbi.nlm.nih.gov/37528669/; https://pubmed.ncbi.nlm.nih.gov/33469381/; https://pubmed.ncbi.nlm.nih.gov/33738345/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 171, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the prevalence of nighttime symptoms in patients with asthma', 'role': 'user'}]}",True,200.0,45.07022023200989,,656ea6e0-ba02-4455-bb4d-9f57d631f981,688.0,"Estimates vary by study and definition, but nocturnal (nighttime) asthma symptoms are common and oft...",3.0,T/T/T,3.0,True,True,True,"The answer gives direct, specific prevalence estimates for nighttime symptoms in asthma, referencing multiple sources from the provided context: 44–61% (review), 0–63% in children and 50–73% in adults (systematic review), and 61% (survey). This information comes directly from the context, matches the details presented, and clearly addresses the original question. The answer also appropriately attributes variability to factors mentioned in the context. There is no material introduced that is not grounded in the provided references.",536,3,3,147.0,441,Nocturnal Asthma - PubMed; Effects of physical exercise training on nocturnal symptoms in asthma: Systematic review - PubMed; Prevalence and impact of nighttime symptoms in adults and children with asthma: a survey - PubMed,https://pubmed.ncbi.nlm.nih.gov/34174807/; https://pubmed.ncbi.nlm.nih.gov/30346958/; https://pubmed.ncbi.nlm.nih.gov/19020366/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 170, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Severe asthma patients in Puerto Rico on intervention, Intervention: Advair HFA, Symbicort, Dulera, Breo Ellipta, AirDuo RespiClick, Wixela Inhub, Trelegy Ellipta, Enerzair Breezhaler, Trimbow pMDI, Outcomes: asthma‐related hospitalization (hospital admissions with a primary diagnosis of asthma)', 'role': 'user'}]}",True,200.0,57.7210636138916,,631e7049-e713-41b6-a294-9f2ee9363e00,68.0,The published literature does not contain an answer to this question,1.0,F/F/T,1.0,False,False,True,"There is no context provided, so the context neither answers the question directly nor addresses it at all. However, the AI's answer is appropriately grounded in the absence of context by indicating that no published answer was found.",234,0,0,0.0,0,,,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 173, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'I want to know how many metastasis breast patients have BRCAm', 'role': 'user'}]}",True,200.0,48.98488783836365,,e81c15d6-6cee-4e68-94c9-b930a43d3abb,932.0,Estimates of germline BRCA (BRCA1/2) mutation prevalence in metastatic breast cancer vary by study d...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question by providing prevalence rates of BRCA mutations among metastatic breast cancer patients from three referenced studies in the context. The prevalence rates from the systematic review (2.7%–4.3%), the BREAKOUT study (9.7% in HER2-negative patients), and the ESME database (~1.6% but noted as likely underestimated due to low testing) are accurately summarized. The answer is grounded solely in the provided context and does not introduce unsupported claims. The context is both directly relevant and sufficiently answers the question about the frequency of BRCA mutations in metastatic breast cancer patients.",655,3,3,248.66666666666666,746,"A systematic review of the international prevalence of BRCA mutation in breast cancer; Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study; Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database",https://pmc.ncbi.nlm.nih.gov/articles/PMC6628947/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7590609/; https://pubmed.ncbi.nlm.nih.gov/36161271/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 166, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Among Asthma patients in 2023 what is the healthcare resource utilization among 3 cohorts of systemic steroid usage:\n - No Systemic steroid usage\n - <500mg in a year\n - 500mg - 1000mg a year\n - >1000mg a year', 'role': 'user'}]}",True,200.0,101.58734250068665,,a03ef857-911e-4f0e-8846-2b36838e81d3,2075.0,Limitations: No single publicly available study was found that reports healthcare-resource–use (HCRU...,2.0,F/T/T,2.0,False,True,True,"The provided context does not directly report healthcare resource utilization (HCRU) in 2023 stratified across the exact steroid dose cohorts (<500mg, 500-1000mg, >1000mg) requested in the question. Instead, it describes HCRU for no OCS versus any OCS, provides some quantitative data for these two groups, and presents general findings about dose-response trends (e.g., increasing HCRU with higher steroid doses), but without specific data matching each dose cohort. Therefore, the context addresses the topic and partially informs the question, but does not directly answer with the requested cohort-specific data. The AI's answer accurately grounds itself in this limitation, does not introduce information not in the context, and gives a correct synthesis of findings within the boundaries of the available evidence.",820,3,3,231.33333333333334,694,Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma - PubMed; Low‑dose oral corticosteroids in asthma associates with increased morbidity and mortality; Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management,https://pubmed.ncbi.nlm.nih.gov/38919734/; https://pubmed.ncbi.nlm.nih.gov/35144997/; https://pubmed.ncbi.nlm.nih.gov/31525297/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 172, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Severe asthma patients in Puerto Rico, Intervention: Advair HFA, Symbicort, Dulera, Breo Ellipta, AirDuo RespiClick, Wixela Inhub, Trelegy Ellipta, Enerzair Breezhaler, Trimbow pMDI, Outcomes: asthma‐related hospitalization (hospital admissions with a primary diagnosis of asthma)', 'role': 'user'}]}",True,200.0,69.52864933013916,,3a3c730a-dd7d-4c49-9587-be1309969776,2015.0,"No published study was identified that directly compares Advair HFA, Symbicort, Dulera, Breo Ellipta...",2.0,F/T/T,2.0,False,True,True,"The context does not provide direct, comparative evidence for the listed inhalers in severe asthma patients in Puerto Rico regarding asthma-related hospitalizations. The AI's answer accurately states that there are no published studies directly addressing this specific question, which is substantiated by the first context reference. The remainder of the context discusses general asthma hospitalization rates in Puerto Rico and comparative data from other geographical settings or for other outcomes (such as exacerbations), but not the exact population, intervention, or outcome requested. Thus, the context addresses the question broadly (with related data and negative evidence), and the AI's answer remains grounded solely in this context.",745,4,4,216.25,865,Characterizing environmental asthma triggers and healthcare use patterns in Puerto Rico; Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta‑analysis; Comparative effectiveness of fixed‑dose inhaled corticosteroid/long‑acting beta‑agonist therapy in adult patients with asthma; Comparative analysis of real‑world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management,https://pmc.ncbi.nlm.nih.gov/articles/PMC8225466/; https://pubmed.ncbi.nlm.nih.gov/36472162/; https://pubmed.ncbi.nlm.nih.gov/41033437/; https://pubmed.ncbi.nlm.nih.gov/39806413/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 177, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Proportion of COPD patients with comorbid Asthma', 'role': 'user'}]}",True,200.0,44.93421959877014,,7073f123-12f6-4d4e-98dd-7faf7150357d,503.0,A systematic review and meta-analysis estimated that 29.6% (95% CI 19.3–39.9%) of patients with COPD...,3.0,T/T/T,3.0,True,True,True,"The context provides specific data points on the proportion of COPD patients with comorbid asthma (as asthma-COPD overlap, or ACO), citing prevalence from 20% to 29.6% based on different sources, which directly answers the original question. The assistant's answer accurately summarizes these context data, including numerical prevalence figures and noting variability based on diagnostic criteria. There is no unsupported information or hallucination—each claim in the answer is grounded in the provided context. Thus, all three evaluation criteria are met.",558,3,3,133.0,399,Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis; Update on Asthma-COPD Overlap (ACO): A Narrative Review; Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices,https://pubmed.ncbi.nlm.nih.gov/31647021/; https://pubmed.ncbi.nlm.nih.gov/34168440/; https://pubmed.ncbi.nlm.nih.gov/31162945/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 168, 'customer': 'Astrazeneca BBU', 'messages': [{'content': ""Population: patients with hypertension in the United States, Intervention: Prescriptions filled will be analyzed to compute an objective medication adherence metric, such as the proportion of days covered (PDC) or medication possession ratio (MPR), to better assess patients' actual use of prescribed therapies using claims or electronic health records data., Outcomes: Aggregated SBP computed as the average of multiple SBP readings from routine clinical visits, stratified by age to minimize measurement error and better reflect patients’ typical blood pressure levels"", 'role': 'user'}]}",True,200.0,110.43574476242065,,813cc85f-d798-474b-b75e-52564daa2e86,1950.0,Limitations: No published study was identified that exactly matches the PICO (using prescription-fil...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False – The provided context does not contain direct evidence specifically tying fill-derived analytic metrics like PDC/MPR to age-stratified, aggregated clinic systolic blood pressure based on multiple readings. The AI answer accurately reflects that no study exactly matching the PICO is identified in the context.

2. context_addresses_question: True – The context discusses the use of PDC/MPR from claims/EHR and their association with hypertension outcomes (e.g., hospitalizations, clinical interventions), as well as the feasibility and limitations in using these data for research. These topics are highly relevant to the question, even though none provide a direct answer.

3. answer_grounded_in_context: True – The AI answer adheres closely to the evidence and limitations described in the context. It avoids extrapolation beyond what is supplied in the source material and clearly delineates what is and is not directly supported by the studies cited.",999,5,5,272.8,1364,Medication Adherence in Hypertension: A Cluster Randomized Clinical Trial - PubMed; Approach to Estimating Adherence to Heart Failure Medications Using Linked Electronic Health Record and Pharmacy Data - PubMed; Medication Adherence and Incident Preventable Hospitalizations for Hypertension - PubMed; Effect of Electronic Health Record-Based Medication Support and Nurse-Led Medication Therapy Management on Hypertension and Medication Self-management: A Randomized Clinical Trial - PubMed; Hypertension Severity as Quantified by Hypertension Daily Dose and Blood Pressure With Risk of Stroke in REGARDS - PubMed,https://pubmed.ncbi.nlm.nih.gov/40632527/; https://pubmed.ncbi.nlm.nih.gov/39585579/; https://pubmed.ncbi.nlm.nih.gov/26526163/; https://pubmed.ncbi.nlm.nih.gov/29987324/; https://pubmed.ncbi.nlm.nih.gov/39158538/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 175, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients diagnosed with advanced biliary tract cancers between March 2022 - February 2024, Outcomes: first-line treatment regimens', 'role': 'user'}]}",True,200.0,78.7567629814148,,c768a70d-4929-4a60-a4e6-45996a0215f8,1812.0,Limitations: Available evidence for first-line regimens in the requested period comes from the TOPAZ...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The context provides specific evidence regarding first-line regimens used for patients with advanced biliary tract cancers during the specified period (March 2022–February 2024), referencing both trial and real-world data explicitly matching the time and population described in the question.
2. context_addresses_question: True. All context documents are directly relevant, discussing treatment regimens, approval timelines, the transition from chemotherapy alone to combination with immunotherapy, and real-world adoption, which align with the question's requirements.
3. answer_grounded_in_context: True. The AI's answer is well-anchored in the context, citing sources for every major claim. It does not introduce unsupported or external information and rigorously references both the trials and regulatory approvals in the specified timeframe.",891,5,5,203.4,1017,"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer; FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer; UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme; Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population; Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer - NCBI Bookshelf",https://pubmed.ncbi.nlm.nih.gov/38319896/; https://pubmed.ncbi.nlm.nih.gov/38856639/; https://pubmed.ncbi.nlm.nih.gov/40940830/; https://pubmed.ncbi.nlm.nih.gov/39002348/; https://www.ncbi.nlm.nih.gov/books/NBK613265/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 179, 'customer': 'Astrazeneca BBU', 'messages': [{'content': '% of Asthma patients who also have COPD', 'role': 'user'}]}",True,200.0,59.9496636390686,,6c2cc35b-604b-443f-b6b8-554b688f6453,408.0,Pooled evidence from a systematic review/meta-analysis estimates that 26.5% (95% CI 19.5–33.6%) of p...,3.0,T/T/T,3.0,True,True,True,"The context directly addresses the percentage of asthma patients who also have COPD, specifically providing a pooled prevalence of 26.5% (95% CI: 19.5–33.6%). Additional context discusses variation depending on definition (ranges from 3.8% to 18.4%, or 11.1% to 61.0%). The AI's answer accurately cites all these numbers and correctly attributes the variability to different definitions and populations, strictly adhering to the provided context. No extraneous information or unsupported claims are introduced. Thus, all three evaluation criteria are satisfied.",561,3,3,109.66666666666667,329,Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis; Asthma-COPD Overlap-A Discordance Between Patient Populations Defined by Different Diagnostic Criteria; Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO),https://pmc.ncbi.nlm.nih.gov/articles/PMC6813073/; https://pubmed.ncbi.nlm.nih.gov/31034998/; https://pubmed.ncbi.nlm.nih.gov/29551279/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 182, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with RSV and hMPV, Outcomes: count', 'role': 'user'}]}",True,200.0,49.9399471282959,,b450397e-7398-4ab7-acc8-d9e1694a1404,789.0,Selected published studies report counts of laboratory-confirmed respiratory syncytial virus (RSV) a...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly reports patient counts with RSV and hMPV in each study, matching data provided in the context. Each count is correctly attributed to the study source and population, without introducing information beyond that in the context. The answer also provides relevant notes regarding the scope, years, and population differences across studies, which is accurate. Therefore, the answer is directly based on and well-grounded in the supplied context.",466,4,4,98.25,393,Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016–2023; The prevalence and role of human metapneumovirus in respiratory tract infections: a systematic review and meta-analysis of global data; Human metapneumovirus and respiratory syncytial virus in hospitalized danish children with acute respiratory tract infection - PubMed; A comparison of characteristics and outcomes in severe human metapneumovirus and respiratory syncytial virus infections in children treated in an intensive care unit - PubMed,https://pmc.ncbi.nlm.nih.gov/articles/PMC12265064/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12418874/; https://pubmed.ncbi.nlm.nih.gov/15370669/; https://pubmed.ncbi.nlm.nih.gov/23811741/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 176, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients under the care of a nephrologist, Outcomes: disease distribution lupus nephritis vs other CKD conditions', 'role': 'user'}]}",True,200.0,102.30051326751709,,8582dd25-9b84-4071-a239-d2b02cf5eae5,1267.0,Limitations: Few studies report disease distribution specifically among patients under active nephro...,3.0,T/T/T,3.0,True,True,True,"The AI's answer provides a direct and detailed comparison of the distribution of lupus nephritis (LN) versus other CKD etiologies among patients under nephrology care, supported by evidence from the provided context. Specific data points are cited, such as the 3.4% LN representation in a CKD cohort, 8.8% in a biopsy series, and the higher incidence rates of other CKD etiologies. The answer also references the low general incidence of LN (1.0/100,000/year) and notes it is a minority cause in most nephrology practices, which is consistent with the source material. It further distinguishes higher prevalence of LN within SLE cohorts, directly supported by context. All claims made in the answer are carefully grounded in the context provided, with relevant references noted. Therefore, the answer meets all three evaluation criteria.",837,5,5,122.8,614,"Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population-Based Study Over Four Decades—The Lupus Midwest Network (LUMEN); Causes of Chronic Kidney Disease and Their Associations with Cardiovascular Risk and Disease in a Sub-Saharan Low-Income Population; Aetiology of chronic kidney disease and risk factors for disease progression in Chinese subjects: A single‐centre retrospective study in Beijing; The frequency and outcome of lupus nephritis: results from an international inception cohort study; Implementation of Kidney Biopsy in One of the Poorest Countries in the World: Experience from Zinder Hospital (Niger)",https://pmc.ncbi.nlm.nih.gov/articles/PMC10065880/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11180468/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7496201/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4939728/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10856258/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 181, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic obstructive pulmonary disease, Cohort_1: patients identified as White, Cohort_2: patients identified as African American, Cohort_3: patients identified as other races, Outcomes: age at incident diagnosis', 'role': 'user'}]}",True,200.0,81.26254677772522,,ce17a462-165b-4d25-a306-f03bb68514cd,1826.0,"Limitations: No single published cohort was identified that reports direct, head‑to‑head estimates (...",2.0,F/T/T,2.0,False,True,True,"The context provided does not include direct, head-to-head mean or median estimates of age at incident COPD diagnosis stratified by White, African American, and other races, as specified in the question. Therefore, it does not directly answer the question. However, the context is relevant to the topic, discussing cohort racial composition, patterns of diagnosis, and genetic risk in relation to age of COPD onset, which addresses the question indirectly. The AI's answer accurately reflects these limitations and does not introduce unsupported claims, grounding its response entirely in the provided context.",610,3,3,178.0,534,"A polygenic risk score and age of diagnosis of COPD; Race and Gender Disparities are Evident in COPD Underdiagnoses Across all Severities of Measured Airflow Obstruction; 10‑Year Follow‑Up of Lung Function, Respiratory Symptoms, and Functional Capacity in the COPDGene Study",https://pubmed.ncbi.nlm.nih.gov/35115341/; https://pubmed.ncbi.nlm.nih.gov/30584581/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8937219/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 174, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with stage I breast cancer, Cohort_1: hormone receptor positive, Cohort_2: human epidermal growth factor receptor 2 positive, Cohort_3: BRCA positive, Cohort_4: germline BRCA positive , Cohort_5: human epidermal growth factor receptor 2 negative, Outcomes: prevalence rate', 'role': 'user'}]}",True,200.0,116.63842439651489,,e7e19497-3c97-4134-8d6f-6b959720091a,1968.0,Limitations: Few studies report BRCA prevalence specifically by stage I; a recent systematic review ...,3.0,T/T/T,3.0,True,True,True,"The AI answer provides direct prevalence estimates for most of the requested cohorts using specific data from the context. It gives clear stage I percentages for hormone receptor positive, HER2 positive, and HER2 negative subgroups, referencing specific values and their sources. For BRCA/germline BRCA positive cohorts, the answer accurately notes the lack of detailed stage I-specific data, directly reflecting the context's statement about poor reporting by stage, and cites appropriate prevalence ranges from the studies. The answer is grounded in and consistent with the context, without introducing unsupported statements, and addresses both the data that is available and the limitations where information is lacking. All elements are fully addressed.",758,4,4,251.0,1004,"Interplay of Receptor Status, Age, and Stage in Breast Cancer: A Prospective Analysis - PMC; Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US - PMC; A systematic review of the international prevalence of BRCA mutation in breast cancer - PMC; Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants - PMC",https://pmc.ncbi.nlm.nih.gov/articles/PMC12256065/; https://pmc.ncbi.nlm.nih.gov/articles/PMC5094051/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6628947/; https://pmc.ncbi.nlm.nih.gov/articles/PMC7567851/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 184, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with de novo Stage III unresectable, and Stage IV, EGFR-mutated non-small cell lung cancer diagnosed between April 2022 and Dec 2024, Intervention: first line osimertinib monotherapy, Outcomes: death, duration of therapy', 'role': 'user'}]}",True,200.0,66.24720883369446,,9985e3b0-8f4b-4f2e-b3bf-aa3155e46b0a,1286.0,Limitations: No published cohort was identified that restricts inclusion to patients diagnosed speci...,2.0,F/T/T,2.0,False,True,True,"The context provides data on outcomes (death, duration of therapy) for real-world cohorts of patients with advanced EGFR-mutant NSCLC treated with first-line osimertinib, including specific data on overall survival, progression-free survival, and time on treatment. However, none of the cited studies limit inclusion to the precise diagnostic window (April 2022 to December 2024) required by the question; the AI answer acknowledges this limitation and accurately summarizes the available evidence within the broader timeframe reported in the context. Thus, the answer is grounded in the context and relevant to the question, but the context does not directly answer the question for the specified population/time window.",721,4,4,157.75,631,"Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS) - PubMed; Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World - PubMed; The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) - PubMed; Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data - PubMed",https://pubmed.ncbi.nlm.nih.gov/40582919/; https://pubmed.ncbi.nlm.nih.gov/38520745/; https://pubmed.ncbi.nlm.nih.gov/39416709/; https://pubmed.ncbi.nlm.nih.gov/38159972/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 178, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Can you give me a comparison of demographic summary of breast cancer HER2+ patients with enhertu in the second line vs third line?', 'role': 'user'}]}",True,200.0,106.2962875366211,,f0acba63-f351-4b2d-a75e-f48e70d29776,1952.0,Limitations: No randomized head‑to‑head demographic comparison of second‑line versus third‑line Enhe...,3.0,T/T/T,3.0,True,True,True,"The AI-generated answer closely compares the demographic summaries of HER2+ breast cancer patients treated with Enhertu (trastuzumab deruxtecan) in the second-line setting (DESTINY-Breast03) versus the third-line or later setting (DESTINY-Breast01), directly pulling from the context. All demographic data mentioned—median age, sex, regional distribution, baseline brain metastases, prior therapy exposure, and regimen counts—are present in the provided context, mapped to the appropriate studies. The AI also transparently states limitations regarding the lack of a head-to-head trial and clearly delineates the settings for each study. There are no hallucinated facts or claims not supported by the context. Therefore, all criteria are satisfied.",748,3,3,295.0,885,Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial; Trastuzumab Deruxtecan in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer: Updated Survival Results From a Phase 2 Trial (DESTINY‑Breast01); FDA Approval Summary: Fam‑trastuzumab deruxtecan‑nxki for the treatment of unresectable or metastatic HER2‑positive breast cancer,https://pmc.ncbi.nlm.nih.gov/articles/PMC11333275/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11322859/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8570919/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 183, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with de novo, unresectable Stage III or Stage IV non-small cell lung cancer, Intervention: osimertinib monotherapy in Stage III non-small cell lung cancer, Control: osimertinib monotherapy in Stage IV non-small cell lung cancer, Outcomes: duration of therapy', 'role': 'user'}]}",True,200.0,89.06790971755981,,976df813-d82e-444f-a34d-2eb8f0eff87b,1239.0,Limitation: the LAURA (unresectable Stage III) publication reports progression-free survival (PFS) a...,3.0,T/T/T,3.0,True,True,True,"The AI answer correctly identifies the available outcomes (progression-free survival and treatment exposure) for osimertinib monotherapy in both unresectable Stage III and Stage IV non-small cell lung cancer populations, referencing the LAURA and FLAURA trials. The AI clarifies the limitation regarding the absence of reported time-on-drug in LAURA and sensibly uses PFS as a surrogate based on trial protocol. Relevant numerical data is extracted verbatim from the context for both settings. The synthesis step accurately compares the durations as asked by the question using only evidence present in the context. There are no unsupported extrapolations or external data introduced. Therefore, the answer is directly supported by the context, addresses the specific PICO question, and is fully grounded in the provided documentation.",835,3,3,217.33333333333334,652,"Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC; Oncogenic alterations in advanced NSCLC: a molecular super-highway; Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC",https://pubmed.ncbi.nlm.nih.gov/38828946/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10863183/; https://pmc.ncbi.nlm.nih.gov/articles/PMC8536603/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 180, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: metastatic non-small cell lung cancer patients, Intervention: first-line use of pembrolizumab, Control: first-line use of nivolumab, Outcomes: duration of thearpy', 'role': 'user'}]}",True,200.0,116.740731716156,,bc129b67-03ef-4545-8ee7-138f185f402d,1020.0,Limitations: no randomized head‑to‑head trial comparing first‑line pembrolizumab versus nivolumab wa...,2.0,F/T/T,2.0,False,True,True,"The provided context summarizes clinical trials with first-line pembrolizumab and nivolumab in metastatic NSCLC. For pembrolizumab, it gives a median real-world time on treatment (7.4 months) and references the KEYNOTE-024 trial duration (7.9 months). For nivolumab, the main comparator is median progression-free survival (PFS) from the CheckMate-026 trial (4.2 months), and a review of phase I data notes that some cohorts had a durable response, but with median duration not reached. However, there is no direct reporting of a head-to-head comparison or explicit median duration of therapy for nivolumab comparable to that for pembrolizumab. Thus, while the context addresses the question's topic and provides partially relevant data, it does not directly answer the specific question of the relative duration of therapy for both agents. The AI answer is appropriately grounded in context, mentioning the lack of head-to-head trials and providing only the values given.",972,4,4,254.75,1019,Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression 250%: 3-Year Follow-Up Data; Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score 2 50; First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer (CheckMate-026); New targeted treatments for non-small-cell lung cancer 1 role of nivolumab,https://pmc.ncbi.nlm.nih.gov/articles/PMC8870405/; https://pubmed.ncbi.nlm.nih.gov/33872070/; https://pubmed.ncbi.nlm.nih.gov/28636851/; https://pmc.ncbi.nlm.nih.gov/articles/PMC4975160/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 185, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with de novo Stage III unresectable and Stage IV, EGFR-mutated non-small cell lung cancer , Intervention: osimertinib monotherapy, Outcomes: death, duration of therapy', 'role': 'user'}]}",True,200.0,78.25465726852417,,8fe083ff-651c-466b-a883-bd447829f781,1259.0,Limitations: Trial publications report outcomes for patients with previously untreated advanced (loc...,3.0,T/T/T,3.0,True,True,True,"The AI’s answer uses all of the key statistics from the provided context, including median overall survival, duration of response, median exposure, percentage of patients remaining on treatment at 3 years (from FLAURA trial), and additional real-world data. The answer is upfront about the limitation that data is not reported separately for de novo unresectable Stage III versus IV, which matches the context. All claims are grounded entirely in the provided documents and no outside information is introduced. Therefore, it directly answers the question based on the relevant and available evidence.",601,3,3,248.0,744,"Overall Survival with Osimertinib in Untreated, EGFR‑Mutated Advanced NSCLC; Osimertinib in Untreated EGFR‑Mutated Advanced Non‑Small‑Cell Lung Cancer; A Real‑World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First‑Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice",https://pubmed.ncbi.nlm.nih.gov/31751012/; https://pubmed.ncbi.nlm.nih.gov/29151359/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10968877/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 186, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the duration of therapy and overall survival among patients diagnosed with de novo Stage III unresectable, and Stage IV, EGFR-mutated non-small cell lung cancer, who were diagnosed between April 2018 and Dec 2022, and initiated first line osimertinib monotherapy after diagnosis?', 'role': 'user'}]}",True,200.0,78.50345015525818,,7a06ec98-7630-4f5c-8f65-58b0db5e11be,1547.0,Published randomized-trial and real-world reports provide median treatment-duration (reported as PFS...,2.0,F/T/T,2.0,False,True,True,"The provided context contains real-world and clinical trial data relevant to first-line osimertinib treatment for EGFR-mutated advanced NSCLC, reporting median PFS, TTD, and OS in cohorts that include both Stage III unresectable and Stage IV patients. However, none of the context sources give outcomes specifically and separately for de novo Stage III unresectable versus Stage IV patients within the exact diagnosis window asked (Apr 2018–Dec 2022). The AI answer correctly summarizes these findings, gives the reported ranges, and accurately states that stage-specific and time-window-restricted outcomes are not available in the cited sources. The answer is grounded exclusively in the context and does not introduce unsupported claims. Therefore, it does not directly answer the precise question, but it does address the question's general topic with relevant context.",873,4,4,158.25,633,"The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) - PubMed; Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS) - PubMed; Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World - PubMed; Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC - PubMed",https://pubmed.ncbi.nlm.nih.gov/39416709/; https://pubmed.ncbi.nlm.nih.gov/40582919/; https://pubmed.ncbi.nlm.nih.gov/38520745/; https://pubmed.ncbi.nlm.nih.gov/31751012/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 192, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What % patients with V122 (Val122I or Val142I) variant of ATTR develop PN (Polyneuropathy) symptoms?', 'role': 'user'}]}",True,200.0,53.07679319381714,,a81f8ec8-558b-49a1-91e9-34c19de5a78e,1163.0,Estimates vary by study design and case ascertainment. In population-based biobank analyses of V122I...,3.0,T/T/T,3.0,True,True,True,"The context provides specific percentages of V122I/Val142I carriers who develop polyneuropathy (PN) symptoms from population-based studies (2.1%, 4.8%, 9%) and from clinic-based cohorts (40%, and majority with various PN signs, e.g., 74%). The AI's answer accurately summarizes these percentages, notes the difference between population and clinic cohorts, and discusses reasons for variation, all grounded in the context. The context is highly relevant and directly responsive to the question, and the answer does not introduce unsupported claims.",548,3,3,203.66666666666666,611,Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry; Peripheral Neuropathy in p.Val142Ile (Val122Ile) Variant Hereditary Transthyretin‑Mediated Amyloidosis: United Kingdom Experience; Peripheral Nervous System Involvement of Hereditary Transthyretin Amyloidosis in the United States: A Multi‑Center Perspective,https://pmc.ncbi.nlm.nih.gov/articles/PMC8172853/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12462426/; https://pubmed.ncbi.nlm.nih.gov/40395027/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 190, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What are the first-line treatment regimens of patients with biliary tract cancers diagnosed between March 2022 - February 2024.', 'role': 'user'}]}",True,200.0,85.70520877838135,,b14eac3f-1a6b-4537-9716-8955df740b58,1050.0,Sources report that the standard first-line systemic backbone for unresectable/metastatic biliary tr...,3.0,T/T/T,3.0,True,True,True,"The AI assistant's answer is fully supported by the provided context. The answer states that cisplatin plus gemcitabine is the standard first-line regimen, which is established in source [1]. It adds that as of September 2, 2022, durvalumab with gemcitabine/cisplatin became an approved first-line regimen following the TOPAZ-1 results ([2] and [4]), and further notes that pembrolizumab with gemcitabine/cisplatin was approved as of October 31, 2023, following KEYNOTE-966 results ([2] and [3]). These are all explicitly mentioned in the provided citations, with dosing/schedules derived directly from study details in the context. The answer contains no extraneous information and does not rely on external knowledge. Therefore, all three evaluation criteria are satisfied.",775,4,4,234.75,939,"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer - PubMed; FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer - PubMed; Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed; Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer - PubMed",https://pubmed.ncbi.nlm.nih.gov/20678012/; https://pubmed.ncbi.nlm.nih.gov/38856639/; https://pubmed.ncbi.nlm.nih.gov/37075781/; https://pubmed.ncbi.nlm.nih.gov/40622010/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 193, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'does terzepitide or semaglutide lead to greater changes in bmi', 'role': 'user'}]}",True,200.0,78.14654636383057,,7c06fde5-8d0b-41e8-983f-dfd7f2f3cc94,1048.0,"Limitations: Most direct-comparison studies report weight change (kg or %), not BMI change; therefor...",2.0,F/T/T,2.0,False,True,True,"The provided context contains data comparing weight loss (in kg or percentage) between tirzepatide and semaglutide, consistently showing greater weight loss with tirzepatide. However, there is no direct comparison of changes in BMI, as noted by the AI. The AI's answer accurately represents the context, clarifying the limitation in BMI data and grounding its statements in the provided evidence about weight loss (which is closely correlated with BMI in most adults). The context is highly relevant and directly addresses weight-related effects of both drugs but does not answer the question about BMI specifically, only by inference.",635,3,3,198.66666666666666,596,Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity; Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data; Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials,https://pubmed.ncbi.nlm.nih.gov/38976257/; https://pubmed.ncbi.nlm.nih.gov/40503067/; https://pubmed.ncbi.nlm.nih.gov/40978842/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 188, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the duration of therapy among patients diagnosed with de novo Stage III unresectable, and separately, de novo Stage IV, EGFR-mutated non-small cell lung cancer who initiated first line osimertinib monotherapy between April 2018 and Dec 2022?', 'role': 'user'}]}",True,200.0,110.85926151275635,,7629978f-2b67-479f-8c18-8b18a5b88d05,1585.0,No published article was identified that reports duration of therapy (DOT) separately for patients d...,2.0,F/T/T,2.0,False,True,True,"The provided context contains multiple studies on first-line osimertinib for EGFR-mutated NSCLC, but none report the duration of therapy (DOT) separately for de novo Stage III unresectable versus de novo Stage IV within the requested time window. The AI assistant accurately states that the exact breakdown by stage and incident window is not available, citing the relevant studies and their limitations. Thus, the context does not answer the question directly, but it addresses the question by providing related evidence and clarifying the absence of specific data. The AI's answer is grounded in and limited to this context, making no unsupported claims.",656,4,4,270.0,1080,"De Novo Versus Secondary Metastatic EGFR‑Mutated Non‑Small‑Cell Lung Cancer; Osimertinib in Patients With Treatment‑Naive EGFR‑Mutant Non‑small Cell Lung Cancer: Overall Survival, Post‑progression Management and Budget Impact Analysis in Real‑World; Real‑world comparative outcomes of EGFR‑TKIs for first‑line treatment of EGFR+ metastatic non‑small‑cell lung cancer; First‑line Osimertinib in Patients With EGFR‑Mutated Non‑Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments",https://pmc.ncbi.nlm.nih.gov/articles/PMC8063726/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11224988/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12302967/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9661557/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 195, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with hereditary transthyretin amyloidosis (E85.0, E85.1, E85.2), Outcomes: polyneuropathy symptoms', 'role': 'user'}]}",True,200.0,61.36077904701233,,8b4966c4-9826-4ad7-98cc-4f49024b2d52,1178.0,Key features of the polyneuropathy in hereditary transthyretin (ATTRv) amyloidosis: 1) Pattern: a le...,3.0,T/T/T,3.0,True,True,True,"The provided context includes details about polyneuropathy symptoms in hereditary transthyretin amyloidosis (such as length-dependent involvement, loss of temperature and pain sensation, autonomic dysfunction, progression to sensory-motor polyneuropathy, and the multisystem progressive nature of the disease). The AI's answer synthesizes these points, referencing small-fiber involvement, early sensory symptoms, autonomic dysfunction, and disease progression, all of which are directly supported by the context (especially references 1, 2, and 4). While some clinical descriptors (like referencing 'red flags') stem from clinical interpretation, the substantial content is grounded in the context. The context is both relevant and sufficiently detailed to directly answer the question about polyneuropathy symptoms in this patient population.",844,4,4,247.5,990,"Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts - PubMed; Familial amyloid polyneuropathy - PubMed; Familial amyloid polyneuropathy - PubMed; TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients - PubMed",https://pubmed.ncbi.nlm.nih.gov/38174864/; https://pubmed.ncbi.nlm.nih.gov/22094129/; https://pubmed.ncbi.nlm.nih.gov/23797140/; https://pubmed.ncbi.nlm.nih.gov/22592564/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 194, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What % patients with V122I (Val122Ile or Val142Ile) variant of ATTR develop PN (Polyneuropathy) symptoms?', 'role': 'user'}]}",True,200.0,80.16957497596741,,ccc0176f-ee9c-4d7b-be9d-f61d4cff58b8,1093.0,Estimates differ by study population and ascertainment. In population-based cohorts of V122I (Val122...,3.0,T/T/T,3.0,True,True,True,"The context provides specific data regarding the percentage of V122I (Val122Ile or Val142Ile) variant ATTR patients who develop polyneuropathy symptoms across several studies, including general population cohorts and specialty clinic populations. The AI answer summarizes these numbers accurately (2.1%, 9.0%, and 4.8% for population cohorts; 38-40% in an unselected clinical cohort; 90% in a neurology-referral cohort) and explains why estimates differ depending on the cohort. All data points and conclusions are directly supported by the provided context, and no additional, unsupported claims are introduced. Therefore, all three criteria are met.",651,3,3,204.66666666666666,614,"Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry - PubMed; Peripheral Neuropathy in p.Val142Ile (Val122Ile) Variant Hereditary Transthyretin-Mediated Amyloidosis: United Kingdom Experience - PubMed; Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis - PubMed",https://pubmed.ncbi.nlm.nih.gov/34079032/; https://pubmed.ncbi.nlm.nih.gov/41018688/; https://pubmed.ncbi.nlm.nih.gov/36941075/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 189, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the time to discontinuation among patients diagnosed with de novo Stage III unresectable, and separately, de novo Stage IV, EGFR-mutated non-small cell lung cancer who initiated first line osimertinib monotherapy between April 2018 and Dec 2022?', 'role': 'user'}]}",True,200.0,116.19942998886108,,7f73036d-4692-4803-9484-64b8380f9906,2192.0,No published report was identified that provides median time-to-discontinuation (TTD) separately for...,2.0,F/T/T,2.0,False,True,True,"The provided context does not contain the specific information requested in the question, i.e., the median time to discontinuation (TTD) separately for de novo unresectable Stage III versus de novo Stage IV EGFR-mutated NSCLC patients treated with first-line osimertinib between April 2018 and December 2022. Multiple context documents confirm that no studies report TTD stratified by these specific groups; only aggregate TTD values are reported. The AI's answer correctly reflects these limitations, references relevant real-world data, and does not introduce information beyond what is supported by the context. The answer is therefore grounded in the context and addresses the question by explaining what the literature does and does not contain, but it does not directly answer the question due to a lack of published stratified data.",839,4,4,267.25,1069,"Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World; The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study); Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC; Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs",https://pmc.ncbi.nlm.nih.gov/articles/PMC11224988/; https://pubmed.ncbi.nlm.nih.gov/39416709/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11333428/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11481380/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 187, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What is the duration of therapy among patients diagnosed with de novo Stage III unresectable, and Stage IV, EGFR-mutated non-small cell lung cancer between April 2018 and Dec 2022 who began first line osimertinib monotherapy?', 'role': 'user'}]}",True,200.0,145.97072076797485,,e93fd097-890b-4cd3-94ad-23076d00ca98,1429.0,No single published report exactly matched all requested criteria (patients with de novo unresectabl...,2.0,F/T/T,2.0,False,True,True,"The context does not provide a single study that directly answers the full specificity of the question (duration of osimertinib therapy specifically among de novo Stage III unresectable and Stage IV EGFR-mutated NSCLC patients diagnosed between Apr 2018 and Dec 2022). However, the context does address the question by offering several relevant population-based cohorts using first-line osimertinib during overlapping timeframes, reporting median durations of therapy (ranging from 10.1 to 27.9 months). The AI's answer correctly synthesizes this contextual information, stating that no single study matches the exact criteria and summarizing the available real-world evidence from the context without introducing outside facts. Thus, the answer is appropriately grounded in context but the context itself only addresses, rather than directly answers, the question.",865,4,4,190.5,762,"Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States; Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World (FLOWER study); Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data; First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic",https://pubmed.ncbi.nlm.nih.gov/40320171/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11224988/; https://pubmed.ncbi.nlm.nih.gov/38159972/; https://pubmed.ncbi.nlm.nih.gov/37577326/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 196, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: systolic blood pressure is 130 mmHg or higher, Cohort_1: plasma aldosterone is 10 ng/dL or higher (excess), Cohort_2: plasma aldosterone is less than 10 ng/dL (no excess), Outcomes: prevalence of excess aldosterone', 'role': 'user'}]}",True,200.0,79.41628766059875,,144d5f7d-6f8c-4220-a4b2-ecdd456487a1,1761.0,Limitation: No published study reports the prevalence of plasma aldosterone concentration (PAC) ≥10 ...,2.0,F/T/T,2.0,False,True,True,"The provided context offers population-based and selected-cohort prevalence figures for primary aldosteronism (PA) and discusses the impact of different diagnostic thresholds (such as a plasma aldosterone cutoff of ≥10 ng/dL). However, there is no direct reporting of the prevalence of plasma aldosterone ≥10 ng/dL in a population defined solely by systolic blood pressure ≥130 mmHg. The AI's answer reflects this gap, accurately noting the limitations of available data and summarizing the relevant studies. The context is clearly relevant, and the AI's answer is grounded in the evidence provided; there is no use of external data or unsupported claims. However, since the context does not directly answer the specific prevalence question as posed with the PAC ≥10 ng/dL threshold, the 'context_answers_question_directly' criterion is not met.",845,4,4,262.75,1051,The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study; Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects; Prevalence of primary aldosteronism in primary care: a cross-sectional study; Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore,https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/; https://pubmed.ncbi.nlm.nih.gov/20927116/; https://pubmed.ncbi.nlm.nih.gov/29335324/; https://pubmed.ncbi.nlm.nih.gov/10946893/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 191, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with systemic lupus erythematosus, Outcomes: time from diagnosis to treatment with on label biologics', 'role': 'user'}]}",True,200.0,129.78922772407532,,a9d67c50-1488-40b6-81aa-d1c045e060d4,1108.0,Limitations: Few publications report an explicit “time from diagnosis to on‑label biologic initiatio...,3.0,T/T/T,3.0,True,True,True,"The context provides specific data regarding disease duration at biologic initiation in both adult and pediatric SLE populations (e.g., mean/median disease duration around 6–7 years in adults and 18 months in pediatric patients for belimumab). Although these studies do not always explicitly label this as 'time from diagnosis to on-label biologic initiation,' the reported 'disease duration at biologic start' serves as a practical proxy, directly relevant to the outcome in question. The AI's answer accurately synthesizes these findings, clearly distinguishes between adult and pediatric data, appropriately notes limitations, and cites the data in alignment with the context. No external facts or hallucinations are introduced. Therefore, all three criteria are satisfied.",776,4,4,150.5,602,"Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials; Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study; Proceedings of the 2024 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting; Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials",https://pmc.ncbi.nlm.nih.gov/articles/PMC9538665/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9845912/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11394934/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10070065/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 197, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'what is the difference in efficacy of breztri on exacerbations in patients with copd between pateints with blood eosinophil values greater than 150 and less than 150.', 'role': 'user'}]}",True,200.0,89.92787051200867,,d83b2da3-d5f9-4703-b314-f1c4cfd13be7,2014.0,"Limitations: No pivotal trial reports a single, directly comparable numerical efficacy estimate for ...",2.0,F/T/T,2.0,False,True,True,"The context addresses the relationship between blood eosinophil counts and the efficacy of Breztri (BGF) on exacerbations in COPD patients, stating that higher baseline eosinophil counts (>150 cells/mm^3) are associated with greater benefit. However, the context does not provide a direct, single numeric efficacy comparison between patients with counts greater than and less than 150 cells/mm^3. The AI answer correctly conveys this limitation while accurately summarizing the contextual data without introducing unsupported claims. Therefore, while the context is relevant and well-reflected in the answer, it does not directly or quantitatively answer the precise question posed.",682,3,3,265.0,795,"Budesonide/Glycopyrronium/Formoterol: A Review in COPD; Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS; Benefits of budesonide/glycopyrronium/formoterol fumarate versus dual therapies on lung function and exacerbations: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history",https://pmc.ncbi.nlm.nih.gov/articles/PMC8384783/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9738173/; https://pubmed.ncbi.nlm.nih.gov/39103901/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 199, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: Patients >=18 years of age with asthma defined by enhanced diagnostic validity, requiring at least two separate asthma diagnostic codes over a 12-month period along with concurrent asthma medication fills recorded within the EHR., Intervention: inhaled triple therapy , Outcomes: Frequency of short-acting beta-agonist (SABA) refills or emergency department visits for asthma exacerbations (operationalized as events accompanied by an ICD code for asthma exacerbation), oral corticosteroid (OCS) utilization operationalized by categorizing prescription fills into short-term bursts for acute management versus patterns suggestive of chronic use (using metrics such as number of prescriptions filled, cumulative dose, and timing criteria), and asthma control measured by validated ACT scores obtained at standardized intervals (e.g., every 3 months) with predefined thresholds for clinically significant changes.', 'role': 'user'}]}",True,200.0,59.339064836502075,,f80b27b1-0b80-490f-ab73-b3aee42121a5,1361.0,Limitations: available randomized trials and reviews report exacerbations and questionnaire-based co...,2.0,F/T/T,2.0,False,True,True,"The provided context offers relevant systematic reviews and meta-analyses regarding the effectiveness of inhaled triple therapy (ICS/LABA/LAMA) for reducing asthma exacerbations and improving control. However, none of the cited references directly address the specific outcomes laid out in the question—namely, EHR-derived SABA refill rates, ED visits for exacerbations with ICD codes, or detailed oral corticosteroid prescription metrics (burst vs chronic use), nor do they describe ACT scores at standardized 3-month intervals. The AI's answer accurately reflects these limitations and remains grounded in the given context, explaining what is reported and highlighting the need for real-world studies with the sought-after outcomes. Therefore, the context does not directly answer the question, but it is relevant, and the answer is grounded in the context.",860,4,4,136.5,546,"Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement; Single inhaler with beclometasone, formoterol, and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis; Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications; Expert Consensus on Single-Inhaler Triple Therapy for the Treatment of Asthma in Adult Patients",https://pubmed.ncbi.nlm.nih.gov/38864834/; https://pubmed.ncbi.nlm.nih.gov/39905183/; https://pubmed.ncbi.nlm.nih.gov/34478578/; https://pubmed.ncbi.nlm.nih.gov/40502858/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 201, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with systemic lupus erythematosus, Cohort_1: Saphnelo or Benlysta, Cohort_2: Not on Saphnelo or benlysta', 'role': 'user'}]}",True,200.0,64.36823725700378,,aa02c0a1-bc11-4267-9ea6-50cdc5a63d17,2065.0,Limitations: no randomized head‑to‑head trials between anifrolumab (Saphnelo) and belimumab (Benlyst...,3.0,T/T/T,3.0,True,True,True,"The context provides direct comparative evidence relevant to the cohorts of interest: patients with SLE treated with Saphnelo (anifrolumab), Benlysta (belimumab), and those not on either drug, via indirect treatment comparisons and real-world studies. The AI's answer accurately synthesizes findings from the referenced studies, including efficacy outcomes, safety considerations, and acknowledges the absence of head-to-head trials. The response is clearly grounded in the supplied context, cites data appropriately, and avoids introducing unsupported claims. It addresses both efficacy and relevant safety for the cohorts as described in the question.",653,5,5,244.8,1224,"Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus - PubMed; Real‑world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reduction - PubMed; Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials - PubMed; Belimumab for the treatment of systemic lupus erythematosus - PubMed; Belimumab or anifrolumab for systemic lupus erythematosus? A risk‑benefit assessment - PubMed",https://pubmed.ncbi.nlm.nih.gov/35546484/; https://pubmed.ncbi.nlm.nih.gov/40625101/; https://pubmed.ncbi.nlm.nih.gov/32814461/; https://pubmed.ncbi.nlm.nih.gov/25543845/; https://pubmed.ncbi.nlm.nih.gov/36119023/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 206, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients diagnosed with advanced biliary tract cancer between January 2016 and March 2022, Outcomes: first-line treatment regimens', 'role': 'user'}]}",True,200.0,51.4677460193634,,c300caa0-789e-4127-b325-37f3c1fa56e1,573.0,In a US retrospective cohort of 559 patients who began first-line gemcitabine-based chemotherapy bet...,2.0,T/T/F,1.0,True,True,False,"The context directly answers the question by stating that GemCis was the most common first-line therapy, with percentages for de novo and recurrent cases. This is directly relevant and addresses the question about first-line regimens. However, the AI's answer includes information about the US retrospective cohort size (559 patients), time to discontinuation, number of cycles, overall survival, and the usage of other regimens, none of which are mentioned in the original context provided. Therefore, the answer is not fully grounded in the context and introduces details that may be unsupported or hallucinated.",614,1,1,92.0,92,Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study,https://pubmed.ncbi.nlm.nih.gov/39858087/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 203, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD patients aged 40 and above, Cohort_1: White on Breztri or Trelegy, Cohort_2: White not on Breztri or Trelegy, Cohort_3: Black on Breztri or Trelegy, Cohort_4: Black not on Breztri or Trelegy, Outcomes: Hospitalization', 'role': 'user'}]}",True,200.0,76.63954186439514,,7950751f-96e1-44fc-a331-32e5a7225e53,2043.0,No published study was identified that reports hospitalization outcomes stratified simultaneously by...,2.0,F/T/T,2.0,False,True,True,"The context does not provide studies that directly answer the hospitalization outcomes for the four specified cohorts (stratified by both race and specific medication use). However, it does provide relevant information regarding the effectiveness of triple therapy (including Breztri/Trelegy) compared to dual therapy, as well as racial differences in COPD outcomes and medication access. The AI accurately synthesizes these findings and explicitly states that no published study reports on the combined stratification required by the question, thus the context addresses the question but does not directly answer it. The AI's answer is grounded in the context, making no unsupported claims or introducing external knowledge.",725,5,5,227.0,1135,"Triple inhaled therapy of formoterol/glycopyrrolate/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions - PubMed; Comparative effectiveness of triple therapy versus dual bronchodilation in COPD - PubMed; Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes - PubMed; Effect of ethnicity on the prevalence, severity, and management of COPD in general practice - PubMed; Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: A Real-World Population Study - PubMed",https://pubmed.ncbi.nlm.nih.gov/39827764/; https://pubmed.ncbi.nlm.nih.gov/31497610/; https://pubmed.ncbi.nlm.nih.gov/33007162/; https://pubmed.ncbi.nlm.nih.gov/22520773/; https://pubmed.ncbi.nlm.nih.gov/35946353/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 198, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with COPD defined as having 2 or more COPD ICD diagnosis codes at least 30 days apart, Intervention: Breztri, Control: Trelegy, Outcomes: COPD exacerbations requiring emergency room or inpatient admission', 'role': 'user'}]}",True,200.0,108.677565574646,,8e74ff43-6d62-4cb6-935e-589a0e867753,1595.0,Limitations: None of the identified studies explicitly state a claims-based COPD case definition of ...,3.0,T/T/T,3.0,True,True,True,"The context provides direct comparative data on COPD exacerbations (particularly severe ones, which include events requiring ED visit or inpatient admission) between Breztri and Trelegy. The first study explicitly reports a 29% higher hazard of first severe COPD exacerbation with Breztri compared to Trelegy, using language that matches the outcome of interest. The other studies report on moderate–severe exacerbations and further support the main finding. The AI's answer accurately summarizes these findings and makes clear any limitations about the specific claims-based COPD case definition, reflecting what is present in the context. Therefore, all three criteria are met: the context addresses and directly answers the question, and the answer is grounded in the context provided.",788,3,3,293.0,879,Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease; Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy,https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/39731707/; https://pubmed.ncbi.nlm.nih.gov/40619503/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 202, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic obstructive pulmonary disease aged 40 and above, Cohort_1: White, Cohort_2: African American, Cohort_3: other races, Outcomes: Breztri and Trelegy', 'role': 'user'}]}",True,200.0,113.60238718986511,,afffcb52-9531-42b9-83ed-1e13b71fad0e,2008.0,Limitations: No published head-to-head analyses reporting race‑stratified comparative effectiveness ...,2.0,F/T/T,2.0,False,True,True,"The AI's answer clearly states that the available studies do not provide head-to-head, race-stratified comparative effectiveness or safety data for Breztri versus Trelegy in White, African American, and other race cohorts. Instead, the summary accurately describes the outcomes and limitations of the reported studies, all of which concern overall or clinical subgroups but not direct race-stratified results. The response also notes the representation of different races in the populations and the absence of clinically relevant race-specific findings from pharmacokinetic analyses. The answer is thoroughly grounded in the provided context and reflects the contents of all three sources. It does not, however, directly answer the original question with specific comparative evidence by race, as such evidence is not present in the context; it does explain this limitation clearly and correctly. Therefore, while the context addresses the question and the answer is grounded in it, the response is not a direct answer with specific evidence for the populations requested.",1072,3,3,193.0,579,"Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study; Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI); Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease",https://pubmed.ncbi.nlm.nih.gov/37849918/; https://pubmed.ncbi.nlm.nih.gov/38310193/; https://pmc.ncbi.nlm.nih.gov/articles/PMC6995987/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 209, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with unresectable hepatocellular carcinoma, Intervention: received STRIDE regimen after diagnosis of uHCC, Outcomes: characteristics', 'role': 'user'}]}",True,200.0,63.612656116485596,,59c3f9f0-a931-4089-8650-eb3bab162c23,1363.0,Key characteristics of patients with unresectable hepatocellular carcinoma (uHCC) who received the S...,1.0,F/T/F,1.0,False,True,False,"The provided context mentions that 393 patients were assigned to the STRIDE regimen in the HIMALAYA trial, that the study involved adults with advanced or unresectable hepatocellular carcinoma (Barcelona Clinic Liver Cancer stage B or C) who had not had previous systemic treatment, and that a 36-month overall survival rate for STRIDE was 30.7%. However, the AI's answer includes more detailed characteristics (such as specific dosing, grade 3-4 adverse events rate, hazard ratio, median OS, and statements about long-term survivors and subsequent therapies) that are not directly supported or stated in the given context snippets. While the general population and some outcomes are addressed, the context does not provide comprehensive or specific details for all the characteristics highlighted in the answer; some claims (e.g., about dose, adverse events, and detailed survivor subgroup outcomes) are not found in the context provided. The answer also uses information beyond the provided context, so it is not fully grounded in it.",1036,3,3,111.33333333333333,334,Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma; Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma; Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma - NICE appraisal (NCBI Bookshelf),https://pubmed.ncbi.nlm.nih.gov/38319892/; https://pubmed.ncbi.nlm.nih.gov/38382875/; https://www.ncbi.nlm.nih.gov/books/NBK618121/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 208, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with advanced biliary tract cancer diagnosed between January 2018 and March 2022, Outcomes: first-line treatment regimens', 'role': 'user'}]}",True,200.0,73.42466902732849,,eb495302-fddf-4b1d-b91c-35ca7e77d91f,1146.0,Limitations: one of the available series extends beyond the requested window (consecutive GCNP serie...,3.0,T/T/T,3.0,True,True,True,"The context provides direct evidence regarding the first-line treatment regimens for patients with advanced biliary tract cancer diagnosed between January 2018 and March 2022. The AI's answer appropriately summarizes that gemcitabine/cisplatin was the predominant regimen (with exact percentages) during this period per the referenced US cohort, and it notes use of combinations involving nab-paclitaxel in other real-world series. The answer is accurate, well-supported by the provided context, and acknowledges the limitations of data outside the specified diagnostic window. No hallucinated or unsupported information is present.",632,3,3,238.33333333333334,715,"Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study; Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis; Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers",https://pubmed.ncbi.nlm.nih.gov/39858087/; https://pubmed.ncbi.nlm.nih.gov/34394748/; https://pubmed.ncbi.nlm.nih.gov/37368175/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 205, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD aged 40 and above, Intervention: Breztri, Control: Trelegy, Outcomes: Hospitalization', 'role': 'user'}]}",True,200.0,124.08108520507812,,f489e3e1-0fba-47d7-b5ef-0da447b0a2f1,1307.0,No randomized head‑to‑head trials comparing Breztri (budesonide/glycopyrrolate/formoterol; BGF) vers...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. The provided context contains indirect evidence relevant to hospitalization as an outcome (primarily via severe exacerbations), but no study directly reports head-to-head results on hospitalization between Breztri and Trelegy. The AI response accurately notes this limitation and relies on proxy outcomes (severe exacerbation rates), which are associated with, but not identical to, hospitalizations.

2. context_addresses_question: True. The context is clearly relevant, discussing comparative outcomes (severe exacerbations, all-cause mortality, and meta-analyses) for the appropriate populations, interventions, and comparators—even if direct hospitalization outcome data aren't reported.

3. answer_grounded_in_context: True. The AI's answer is concordant with the provided context, accurately reporting the lack of direct evidence, summarizing indirect findings, and appropriately qualifying the strength of the evidence. No unsupported claims or external information are introduced.",1033,4,4,256.25,1025,Mortality risk reduction with budesonide/glycopyrrolate/formoterol versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT; Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study; Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease; Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis,https://pubmed.ncbi.nlm.nih.gov/37583267/; https://pubmed.ncbi.nlm.nih.gov/39797646/; https://pubmed.ncbi.nlm.nih.gov/39731707/; https://pubmed.ncbi.nlm.nih.gov/32335859/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 207, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'What are the first-line treatment regimens administered to patients with advanced biliary tract cancer, diagnosed between January 2018 through March 2022.', 'role': 'user'}]}",True,200.0,109.5658791065216,,21757108-7fa3-4de8-8928-4b40c319a7bf,1511.0,Limitation: No single population-level registry explicitly restricted to patients diagnosed only fro...,3.0,T/T/T,3.0,True,True,True,"The context provides direct, relevant evidence regarding the first-line treatment regimens for advanced biliary tract cancer for patients diagnosed between January 2018 and March 2022. Specifically, it states that gemcitabine + cisplatin (GemCis) was the most common first-line regimen, and gemcitabine-based regimens predominated in US practice, which matches the AI's summary. The mention of the gemcitabine/cisplatin/nab-paclitaxel regimen in certain centers during the relevant time interval is also supported by the context. The AI's note about lack of a single population-level registry is a measured interpretation, not an unsupported claim. The AI does not introduce information about other regimens or claim standards that are not present in the context, and summarizes the evidence objectively, with appropriate limitations. Thus, all three criteria are satisfied.",874,4,4,203.75,815,"Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study; Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA; A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer; Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis",https://pubmed.ncbi.nlm.nih.gov/39858087/; https://pubmed.ncbi.nlm.nih.gov/39155836/; https://pubmed.ncbi.nlm.nih.gov/37751011/; https://pubmed.ncbi.nlm.nih.gov/34394748/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 212, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many SLE patients are on Saphnelo or Benlysta', 'role': 'user'}]}",True,200.0,66.41293120384216,,7f861a73-7b14-495d-81de-507a7844570e,1173.0,"The published NLM-indexed literature does not report a current, aggregated count of how many SLE pat...",2.0,F/T/T,2.0,False,True,True,"The context does not directly answer how many SLE patients are currently on Saphnelo or Benlysta in clinical practice, as there is no aggregated data presented for real-world use. However, the context is relevant to the question, as it provides numbers from clinical trials, a real-world cohort protocol, and cumulative clinical study data for both drugs. The AI's answer remains grounded in what is stated in the context, citing available numbers from clinical trials, cohort plans, and cumulative study participation, and explicitly notes the absence of real-world aggregate patient numbers in the literature. No unsupported information is introduced.",653,4,4,211.5,846,"Characteristics and clinical outcomes of patients with systemic lupus erythematosus initiating anifrolumab in a real-world setting in Spain (AZAHAR study): an observational study protocol - PubMed; Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials - PubMed; 10 Years of belimumab experience: What have we learnt? - PubMed; Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial - PubMed",https://pubmed.ncbi.nlm.nih.gov/39939126/; https://pubmed.ncbi.nlm.nih.gov/33216191/; https://pubmed.ncbi.nlm.nih.gov/34238087/; https://pubmed.ncbi.nlm.nih.gov/21296403/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 210, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: uHCC, Cohort_1: IO treatment , Cohort_2: STRIDE regiment , Outcomes: overall survival', 'role': 'user'}]}",True,200.0,86.62031984329224,,4fbc5c8c-5db5-4cf3-b204-07fa117cf5f8,1607.0,Limitations: there are no randomized head-to-head trials comparing STRIDE (tremelimumab + durvalumab...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The provided context gives specific data on overall survival (OS) outcomes for both Cohort 1 (IO: atezolizumab + bevacizumab) and Cohort 2 (STRIDE: tremelimumab + durvalumab) from published clinical trials and an updated network meta-analysis. The AI's answer accurately recounts these results, including OS hazard ratios and 60-month OS rates, which directly address the OS outcome.

2. context_addresses_question: True. The context is focused exclusively on OS outcomes in unresectable HCC (uHCC) populations treated with these regimens and is highly relevant to the question.

3. answer_grounded_in_context: True. The AI answer uses only information available in the provided context, referencing specific hazard ratios, OS rates, and the limitations regarding head-to-head trial evidence. There are no unsupported or external claims.",881,3,3,221.0,663,Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC; Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma; Updated Network Meta-Analysis of First-Line Systemic Treatments for Advanced HCC: Consistent Role of TACE,https://pubmed.ncbi.nlm.nih.gov/40222621/; https://pubmed.ncbi.nlm.nih.gov/34902530/; https://pubmed.ncbi.nlm.nih.gov/40641821/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 200, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Amongst asthma patients (>=18 years) on high dose or medium dose ICS/LABA, what are annual rates of OCS use and symptoms reported, ACQ scores, AIRQ scores?', 'role': 'user'}]}",True,200.0,168.8396759033203,,38b437f1-1890-4390-825d-4c1fcbcb6139,2373.0,Limitations: No single published study was identified that reports all four requested measures (annu...,2.0,F/T/T,2.0,False,True,True,"The provided context contains relevant information relating to OCS use rates (~13% in trial populations), symptom burden (percentage of patients inadequately controlled by ACQ, ACT, and number of symptom-free days), and characteristics of the AIRQ score, but it does not provide direct reports of all three scores (ACQ, AIRQ) or an integrated description of annual rates for all requested outcomes in the specifically defined population (adults ≥18 on high or medium dose ICS/LABA). Some data are from mixed dose groups or do not specify annual rates, especially for ACQ and AIRQ. The assistant accurately reflects these limitations and grounds its synthesis in the provided context without overstepping or introducing unsupported claims. While highly relevant, the context does not answer the question directly with all data points requested.",843,5,5,196.0,980,"Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review; Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial; Suboptimally controlled asthma in patients treated with inhaled ICS/LABA: prevalence, risk factors, and outcomes; Relationship Between Asthma Control as Measured by the Asthma Impairment and Risk Questionnaire (AIRQ) and Patient Perception of Disease Status, Health-Related Quality of Life, and Treatment Adherence; Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting β2-agonists",https://pmc.ncbi.nlm.nih.gov/articles/PMC6277255/; https://pubmed.ncbi.nlm.nih.gov/27609408/; https://pubmed.ncbi.nlm.nih.gov/37156824/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9829987/; https://pubmed.ncbi.nlm.nih.gov/40011538/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 204, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: COPD aged 40 and above, Intervention: Breztri or Trelegy, Outcomes: Hospitalization', 'role': 'user'}]}",True,200.0,157.75338530540466,,ead84c2c-830c-4677-91e3-53d7889a7f81,1324.0,Limitations: COPD trials typically report annualized rates of moderate or severe exacerbations rathe...,2.0,F/T/T,2.0,False,True,True,"1. context_answers_question_directly: False. While the context discusses moderate and severe exacerbation rates—and clarifies that severe exacerbations are those requiring hospitalization—it does not provide data on actual hospitalization rates or direct hospital admission counts. Thus, the context does not directly answer the question about hospitalization outcomes for Breztri or Trelegy.

2. context_addresses_question: True. The context is highly relevant: it presents evidence from large COPD trials involving Breztri and Trelegy, describes outcomes related to moderate/severe exacerbations, and defines severe exacerbations as events requiring hospitalization.

3. answer_grounded_in_context: True. The AI's answer strictly relies on the provided context. It carefully interprets the available evidence (about exacerbation rates and the definition of severe exacerbations) without adding unsupported information or external claims, and clearly notes the limitation that hospitalization is inferred, not directly reported.",1029,4,4,218.75,875,"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD; Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study; Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS); Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study",https://pubmed.ncbi.nlm.nih.gov/29668352/; https://pubmed.ncbi.nlm.nih.gov/33252985/; https://pubmed.ncbi.nlm.nih.gov/39213002/; https://pubmed.ncbi.nlm.nih.gov/22033040/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 215, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with advanced non-small cell lung cancer, Cohort_1: Black patients, Cohort_2: Hispanic patients, Cohort_3: White patients, Outcomes: receipt of Erlotinib, Gefitinib, Afatinib, Osimertinib, Pembrolizumab, Nivolumab, Durvalumab, or Atezolizumab', 'role': 'user'}]}",True,200.0,65.60269784927368,,9118d11a-2dc0-4cd1-bed2-a7d2c72def31,1640.0,Limitations: available US registry analyses report immunotherapy receipt at the class level or repor...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True – The provided context includes direct, relevant evidence about racial/ethnic disparities in receipt of immunotherapy and in genomic testing relevant to targeted therapy among patients with advanced NSCLC. The AI's answer accurately cites studies that address lower odds of Black (and, to a lesser extent, Hispanic) patients receiving immunotherapies and differences in genomic testing (affecting targeted therapy access), with substantial detail and supporting statistics.

2. context_addresses_question: True – All the contextual references specifically discuss racial/ethnic disparities in receipt of immunotherapy and genomic testing for patients with advanced NSCLC, aligning precisely with the populations, cohorts, and outcomes described in the question.

3. answer_grounded_in_context: True – The AI answer closely adheres to the context, referencing specific studies, statistics (odds ratios, confidence intervals), and limitations (lack of agent-specific data) as noted in the sources. There are no unsupported claims or hallucinated facts; interpretations and limitations are consistent with the context provided.",1167,4,4,209.25,837,Unequal racial distribution of immunotherapy for late-stage non-small cell lung cancer - PubMed; Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database - PMC; Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis - PubMed; Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review - PubMed,https://pubmed.ncbi.nlm.nih.gov/37421405/; https://pmc.ncbi.nlm.nih.gov/articles/PMC10199935/; https://pubmed.ncbi.nlm.nih.gov/39758136/; https://pubmed.ncbi.nlm.nih.gov/38321254/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 214, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: SLE, Intervention: Saphnelo or Benlysta', 'role': 'user'}]}",True,200.0,71.2327573299408,,77f8e38b-d780-461b-bea3-66eacfd91706,1487.0,No randomized head‑to‑head trials comparing anifrolumab (Saphnelo) versus belimumab (Benlysta) are a...,3.0,T/T/T,3.0,True,True,True,"The provided context contains specific, directly relevant evidence comparing Saphnelo (anifrolumab) and Benlysta (belimumab) in SLE, primarily via indirect and population-adjusted analyses, fulfilling the criteria for directness. It notes both drugs have been compared in indirect analyses (ML-NMR, simulated treatment comparison) with somewhat conflicting results: one analysis finds them broadly comparable, while another favors anifrolumab for certain endpoints (SLEDAI-2K reduction and SRI-4). The AI's answer closely and correctly synthesizes this evidence, making clear the lack of direct RCT comparisons and summarizing each reference, including relative benefits (e.g., anifrolumab for steroid tapering and flare reduction, belimumab for longer trial experience). The answer is wholly grounded in the evidence provided and introduces no unsupported claims.",864,4,4,227.0,908,Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks - PubMed; Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus - PubMed; Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus - PubMed; Efficacy and safety of belimumab therapy in systemic lupus erythematosus: A systematic review and meta-analysis - PubMed,https://pubmed.ncbi.nlm.nih.gov/37147022/; https://pubmed.ncbi.nlm.nih.gov/35546484/; https://pubmed.ncbi.nlm.nih.gov/33977796/; https://pubmed.ncbi.nlm.nih.gov/35321609/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 213, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: SLE, Intervention: Saphnelo or Benlysta, Outcomes: Flares', 'role': 'user'}]}",True,200.0,96.63470363616943,,0c7ac164-068c-4f38-825b-01a5e3719dc6,1853.0,Limitations: No randomized head-to-head trial directly comparing anifrolumab (Saphnelo) versus belim...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question of Saphnelo (anifrolumab) vs Benlysta (belimumab) for SLE flare outcomes, summarizing both individual agent evidence (anifrolumab vs placebo for overall flares, belimumab vs placebo for mucocutaneous flares) and comparative indirect evidence. All referenced claims are grounded in the provided context, including study findings and limitations (no direct head-to-head trial). The context provided is clearly relevant and the answer does not introduce external information. Thus, all three criteria are met.",554,4,4,229.25,917,Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus - PubMed; Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials - PubMed; Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks - PubMed; Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus - PubMed,https://pubmed.ncbi.nlm.nih.gov/33977796/; https://pubmed.ncbi.nlm.nih.gov/40085009/; https://pubmed.ncbi.nlm.nih.gov/37147022/; https://pubmed.ncbi.nlm.nih.gov/35546484/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 211, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with intrahepatic hepatocellular carcinoma who receive systematic treatment , Intervention: atezolizumab, bevacizumab, cabozantinib, durvalumab, ipilimumab, lenvatinib, nivolumab, pembrolizumab, ramucirumab, regorafenib, selpercatinib, sorafenib, tremelimumab, Outcomes: overall survival', 'role': 'user'}]}",True,200.0,145.61248302459717,,d73d467e-a888-4573-91bc-fc30d5f239ee,1449.0,Limitations: Most randomized trials and network meta-analyses report outcomes in unresectable/advanc...,3.0,T/T/T,3.0,True,True,True,"1. context_answers_question_directly: True. The provided context directly addresses overall survival outcomes in patients receiving the listed agents (including atezolizumab, bevacizumab, cabozantinib, regorafenib, ramucirumab, tremelimumab, durvalumab) for unresectable/advanced hepatocellular carcinoma, which substantially aligns with the population and interventions specified in the question. Multiple references specifically mention significant overall survival benefits for atezolizumab + bevacizumab and STRIDE (tremelimumab + durvalumab), with regorafenib and cabozantinib also identified for OS benefit in refractory/second-line settings.
2. context_addresses_question: True. All context documents are highly relevant to the question, focusing specifically on the efficacy of systemic therapies (including almost all agents queried) for hepatocellular carcinoma, especially regarding overall survival outcomes.
3. answer_grounded_in_context: True. The AI answer accurately reflects the findings and limitations stated in the provided context, such as OS benefits for certain regimens, the applicability mainly to unresectable or advanced disease, and notes on trial coverage limitations regarding all listed agents.",1225,4,4,237.25,949,Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma; Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma; Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis; Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: A systematic review and network meta-analysis of randomized phase III trials,https://pubmed.ncbi.nlm.nih.gov/34902530/; https://pubmed.ncbi.nlm.nih.gov/38382875/; https://pubmed.ncbi.nlm.nih.gov/33090186/; https://pubmed.ncbi.nlm.nih.gov/40645358/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 217, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with chronic lymphocytic leukemia, Cohort_1: patients of lower socio-economic status, Cohort_2: patients of higher socio-economic status, Outcomes: access to targeted therapies', 'role': 'user'}]}",True,200.0,80.96088099479675,,10614f58-c0a9-47c6-87d6-2c1739d3ed59,1911.0,"Limitations: No published, CLL-specific study comparing receipt of targeted therapies between lower-...",2.0,F/T/T,2.0,False,True,True,"The context does not directly answer whether CLL patients of lower SES have poorer access to targeted therapies compared to higher SES patients. Instead, it provides strong, relevant evidence from hematologic malignancies broadly regarding poorer outcomes and care access for lower SES groups, and it highlights affordability issues specific to CLL with targeted therapies. This aligns with the AI's conclusion that a direct comparison in CLL-specific targeted therapy access was not found. The answer appropriately grounds its statements in the provided context without making unsupported claims, demonstrating accurate synthesis. However, it does not contain direct, specific evidence for differences in targeted therapy access between SES cohorts in CLL.",757,4,4,284.0,1136,"Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review - PubMed; Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States - PubMed; Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States - PubMed; Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents - PubMed",https://pubmed.ncbi.nlm.nih.gov/37639318/; https://pubmed.ncbi.nlm.nih.gov/39808792/; https://pubmed.ncbi.nlm.nih.gov/27870563/; https://pubmed.ncbi.nlm.nih.gov/32634056/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 216, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with non-small cell lung cancer, Intervention: durvalumab, Outcomes: treatment duration', 'role': 'user'}]}",True,200.0,98.52425742149353,,574d5849-b436-4038-9e00-eef4737e574c,728.0,Durvalumab treatment duration depends on the NSCLC setting and trial: prescribing information and pi...,3.0,T/T/T,3.0,True,True,True,"The AI's answer directly addresses the question regarding the treatment duration of durvalumab in patients with non-small cell lung cancer by referencing dosing schedules and maximum durations from three sources in the provided context: the PACIFIC trial (12 months), US prescribing information (up to 12 months or until progression/toxicity), and the PACIFIC-6 trial (24 months). It accurately describes details from each source and does not introduce information unsupported by the context. Therefore, all three criteria are fulfilled.",537,3,3,111.0,333,"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - PubMed; DailyMed - IMFINZI- durvalumab injection, solution; Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial - PubMed",https://pubmed.ncbi.nlm.nih.gov/31601496/; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3; https://pubmed.ncbi.nlm.nih.gov/40435873/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 219, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: systemic lupus erythematosus patients newly initiated on anifrolumab or belimumab, Cohort_1: Not on an immunosuppressant such as “ Methotrexate, Azathioprine, Mycophenolate Mofetil, Tacrolimus, Cyclosporine, Cyclophosphamide, Baricitinib, Sirolimus” in the 12 months prior to initiation, Cohort_2: on an immunosuppressant such as “ Methotrexate, Azathioprine, Mycophenolate Mofetil, Tacrolimus, Cyclosporine, Cyclophosphamide, Baricitinib, Sirolimus” in the 12 months prior to initiation', 'role': 'user'}]}",True,200.0,79.72270059585571,,7d3d51e0-768f-48a9-9980-30fe270ea047,3422.0,Limitation: No published study was found that reports head-to-head effectiveness of anifrolumab vers...,2.0,F/T/T,2.0,False,True,True,"The provided context discusses indirect and real-world comparative effectiveness studies of anifrolumab and belimumab, various relevant outcomes (SRI-4, SLEDAI-2K, flare rates, glucocorticoid reduction), and statistical techniques employed in these studies. However, the context does not directly address or provide specific evidence regarding patients stratified by prior immunosuppressant use, as defined in the question. The AI's answer correctly notes this limitation, bases its recommendations on methodologies seen in the context, and uses no unsupported claims. Thus, the answer is relevant and grounded in the context, but the context does not directly answer the precise question posed (outcomes stratified by prior IS use), only broader methodological and outcome-related aspects.",790,5,5,230.6,1153,"Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks - PubMed; Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus - PubMed; Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus - PubMed; Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials - PubMed; Real-world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reduction - PubMed",https://pubmed.ncbi.nlm.nih.gov/37147022/; https://pubmed.ncbi.nlm.nih.gov/35546484/; https://pubmed.ncbi.nlm.nih.gov/33977796/; https://pubmed.ncbi.nlm.nih.gov/22550315/; https://pubmed.ncbi.nlm.nih.gov/40625101/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 220, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with systemic lupus erythematosus (SLE) who are newly initiated on biologic therapy (P), what proportion had no immunosuppressant use (O) in the 12 months before starting biologics (T), and how does this vary across different racial/ethnic groups (C) and baseline disease activity levels categorized by SLEDAI score (C)?', 'role': 'user'}]}",True,200.0,81.19331502914429,,89d94348-0b16-4294-9adf-2a8b69e57861,1049.0,Limitations: large US claims evidence reporting prior-immunosuppressant status excluded race/ethnici...,2.0,F/T/T,2.0,False,True,True,"The context does not provide the requested proportions stratified by race/ethnicity or SLEDAI scores, and acknowledges that such stratified data were unavailable in the main US claims analysis due to dataset limitations. The AI assistant accurately conveys this limitation and reports the overall proportion of patients without prior immunosuppressant use from the most relevant study. The answer is completely grounded in the provided context and does not introduce any unsupported information. Thus, the context does not directly answer the full question, but is relevant and the answer is faithful to the context.",616,3,3,264.0,792,"Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study; Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study (full text); Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study",https://pubmed.ncbi.nlm.nih.gov/40528076/; https://pmc.ncbi.nlm.nih.gov/articles/PMC12246324/; https://pmc.ncbi.nlm.nih.gov/articles/PMC5434147/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 218, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'How many SLE patients who initiated newly on Saphnelo or Benlysta were not on an immunosuppressant in 12 months prior to the initiation on Saphnelo or Benlysta.', 'role': 'user'}]}",True,200.0,119.17968034744263,,b52821ed-9693-45f2-b9d1-13d4a770760c,873.0,Limitations: No published source was found that reports the count of patients initiating Saphnelo (a...,2.0,F/T/T,2.0,False,True,True,"The context provides a direct count (2,190) for SLE patients initiating Benlysta (belimumab) who were not on an immunosuppressant in the 12 months before initiation, according to a US claims study. However, for Saphnelo (anifrolumab), both the ASTER study and a single-centre cohort do not provide this count, only stating that such data will be collected or is not reported. The AI's answer accurately summarizes this: it gives the available Benlysta count and explains the absence of Saphnelo data. Thus, the context addresses the question (contains data about Benlysta and discusses the current lack of Saphnelo data) and the AI answer is grounded in context, but the context does not provide a combined or complete direct answer for both drugs as asked in the original question.",782,3,3,205.33333333333334,616,"Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study; Anifrolumab Study for Treatment Effectiveness in the Real World (ASTER) among patients with systemic lupus erythematosus: protocol for an international observational effectiveness study; Anifrolumab in systemic lupus erythematosus: real‑world experience from a single academic tertiary care centre",https://pmc.ncbi.nlm.nih.gov/articles/PMC12246324/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11660324/; https://pubmed.ncbi.nlm.nih.gov/41004309/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 221, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with systemic lupus erythematosus initiating biologic therapy (Saphnelo, or Benlysta) between January 2017 and December 2024 and no immunosuppressant use in the 12 months before starting biologics, Cohort_1: Non-Hispanic White, Hispanic, Black or African American, Asian, and Other racial/ethnic groups, Cohort_2: baseline disease activity levels', 'role': 'user'}]}",True,200.0,102.64675092697144,,3e99c41a-562e-4d58-9c5a-e28448f8d19e,2291.0,Limitations: No published analyses were identified that report outcomes specifically for SLE patient...,2.0,F/T/T,2.0,False,True,True,"The provided context includes pooled and post-hoc analyses of trials evaluating anifrolumab and belimumab in SLE, with subgroup analyses by race/ethnicity and baseline disease activity, and notes on background medication use (immunosuppressants/glucocorticoids) at baseline. However, there are no published analyses that exactly match the specified population—SLE patients initiating these biologics from 2017-2024 who were immunosuppressant-free for 12 months prior. The AI answer correctly identifies this evidence gap, summarizes available subgroup findings, and highlights that most trial patients were on background therapy, referencing the provided studies. Thus, the answer is relevant and grounded in context but does not directly answer the question due to the lack of specific evidence for the exact population described.",831,5,5,245.8,1229,"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials; Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials; Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response; Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post‑hoc analysis of pooled data from five randomised clinical trials; Phase III/IV, randomized, fifty‑two‑week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus (EMBRACE)",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213795/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893670/; https://pubmed.ncbi.nlm.nih.gov/22337213/; https://pubmed.ncbi.nlm.nih.gov/39208825/; https://pubmed.ncbi.nlm.nih.gov/34164944/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 222, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with systemic lupus erythematosus (SLE) who newly initiated on biologic therapy between Jan-2017 to Dec-2024, what proportion had no immunosuppressant use in the 12 months before starting biologics, and how does this vary across different racial/ethnic groups?', 'role': 'user'}]}",True,200.0,96.9310052394867,,cb7a8208-f372-415b-a9de-eb28502d87f1,2095.0,Available published studies do not report the exact proportion of all SLE patients initiating any bi...,2.0,F/T/T,2.0,False,True,True,"The provided context does not answer the original question directly: it does not report the proportion of all SLE patients newly starting any biologic therapy (not just belimumab) with no immunosuppressant use in the prior 12 months, nor how this varies by race/ethnicity. It does, however, provide closely related estimates for belimumab initiators—approximately 46.4% with no immunosuppressant use in the previous 12 months, and ~35.8% for a 24-month window—though for a single drug, not all biologics, and without race/ethnicity breakdowns. The context and the AI answer both correctly emphasize the lack of race/ethnicity-stratified data for the relevant cohorts and time period. The AI's answer is appropriately cautious, does not introduce unsupported facts, and is grounded in the provided context.",805,4,4,254.5,1018,"Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study; Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study; Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study; Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA",https://pubmed.ncbi.nlm.nih.gov/40528076/; https://pubmed.ncbi.nlm.nih.gov/38847995/; https://pmc.ncbi.nlm.nih.gov/articles/PMC9716789/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11629018/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 225, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Population: patients with systemic lupus erythematosus newly initiated on anifrolumab or belimumab, Cohort_1: Non-Hispanic White, Cohort_2: African American, Cohort_3: Hispanic, Cohort_4: Asian, Cohort_5: Others, Outcomes: no immunosuppressant use in the 12 months before starting biologics', 'role': 'user'}]}",True,200.0,91.8402509689331,,e3a5a636-0d85-4d3b-b53b-04f1058689f2,1401.0,"No published study was found that reports, stratified by race/ethnicity (Non‑Hispanic White, African...",2.0,F/T/T,2.0,False,True,True,"The AI's answer accurately reflects the information in the provided context. The answer states that there is no published study that reports, stratified by race/ethnicity, the proportion of SLE patients initiating anifrolumab or belimumab who had no immunosuppressant use in the previous 12 months—this matches the context, which specifies that the studies either used a 24-month window, did not stratify by race/ethnicity, or didn't report the relevant outcome. Hence, the context does not directly answer the question, but is relevant to the question and the answer is completely grounded in the context.",606,4,4,292.25,1169,"Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study; Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study; Evaluating the Use of Glucocorticoids Among Belimumab‑Treated Patients With Systemic Lupus Erythematosus in Real‑World Settings Using the Rheumatology Informatics System for Effectiveness Registry; Long‑Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‑Label Extension Study",https://pubmed.ncbi.nlm.nih.gov/38847995/; https://pubmed.ncbi.nlm.nih.gov/36652052/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555183/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252065/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 223, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with systemic lupus erythematosus who are newly initiated on biologic therapy (Saphnelo or Benlysta), what proportion had no immunosuppressant use in the 12 months before starting biologics, and how does this vary across different racial/ethnic groups (Non-Hispanic White, African American, Hispanic, Asian)?', 'role': 'user'}]}",True,200.0,151.41624283790588,,b52521c8-3f23-4d23-b213-67f962589d0e,1792.0,"Limitations: No published study was identified that reports, for patients newly started on Saphnelo ...",2.0,F/T/T,2.0,False,True,True,"The context confirms that there are studies reporting the proportion of SLE patients with no immunosuppressant use before starting belimumab (Benlysta), specifically citing a 12-month period (approx. 46.4%) and a 24-month period (approx. 35.8%), but it also makes clear that these studies do not provide these proportions stratified by race/ethnicity due to lack of data. There is no direct answer for Saphnelo (anifrolumab) regarding the proportions or racial/ethnic breakdowns. The assistant accurately summarizes the data limitations, close available numbers, and absence of racial/ethnic breakdown, remaining within the bounds of the provided context and not introducing unsupported claims. However, since the context does not provide a direct answer to the proportional breakdown by race/ethnicity, it does not answer the question directly but does address it in terms of the closest available evidence and the limitations.",928,3,3,193.33333333333334,580,"Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study; Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study; Anifrolumab in systemic lupus erythematosus: real-world experience from a single academic tertiary care centre",https://pubmed.ncbi.nlm.nih.gov/40528076/; https://pubmed.ncbi.nlm.nih.gov/38847995/; https://pubmed.ncbi.nlm.nih.gov/41004309/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 224, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'In patients with systemic lupus erythematosus who are newly initiated on Saphnelo or Benlysta, what proportion had no immunosuppressant use in the 12 months before starting biologics, and how does this vary across different racial/ethnic groups (Non-Hispanic White, African American, Hispanic, Asian)?', 'role': 'user'}]}",True,200.0,154.85484194755554,,fca9af45-1ece-49e3-aacd-493a543bc71a,1640.0,"Limitations: No published article was found that reports, for Saphnelo (anifrolumab) initiators, the...",2.0,F/T/T,2.0,False,True,True,"The provided context confirms that no published articles report the specific proportion of Saphnelo or Benlysta initiators with no immunosuppressant use stratified by racial/ethnic group. For Benlysta, one US claims analysis gives the proportion of initiators with no immunosuppressant use (46.4%), but explicitly states that race/ethnicity data were lacking. Other articles mention race/ethnicity proportions or discuss Saphnelo use, but do not provide the specific breakdown requested. The AI's answer accurately represents these limitations, does not introduce unsupported claims, and uses only information from the context. However, the answer cannot directly answer the original question due to insufficient published data, but it does closely address the intent and scope of the question based on available evidence.",822,4,4,285.75,1143,"Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study; Safety and efficacy of belimumab in systemic lupus erythematosus academic clinical practices; The role of anifrolumab in reshaping the treatment landscape of extra‑renal systemic lupus erythematosus; Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA",https://pubmed.ncbi.nlm.nih.gov/40528076/; https://pmc.ncbi.nlm.nih.gov/articles/PMC5031077/; https://pubmed.ncbi.nlm.nih.gov/40704391/; https://pmc.ncbi.nlm.nih.gov/articles/PMC11629018/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
2025-10-28 16:07:03,"{'organization_id': 34, 'qidx': 226, 'customer': 'Astrazeneca BBU', 'messages': [{'content': 'Number of patients who were on Osimertinib treatment by year-quarter from Jan 1, 2023:\n 1) FLAURA: Osi mono in 1L among metastatic NSCLC\n 2) FLAURA2: Osi combo in 1L among metastatic NSCLC\n 3) ADAURA: Adjuvant Osi among early stage resectable NSCLC', 'role': 'user'}]}",True,200.0,139.1848270893097,,ccc12475-2090-43f4-82dc-58643aa618fd,1531.0,Limitations: The published trial reports do not provide patient counts on osimertinib by calendar ye...,2.0,F/T/T,2.0,False,True,True,"The context does not directly answer the original question, which asks for the number of patients on osimertinib treatment by year-quarter from Jan 1, 2023. The provided references only give total randomized counts and some follow-up numbers, but not counts broken down by calendar year or quarter. However, the context is relevant because it pertains to the requested trials and treatments and specifies the reporting limitations. The AI's answer accurately reflects what is and is not available from the context, staying grounded in the data without extrapolating or introducing unsupported claims.",600,4,4,180.75,723,"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC; Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC; FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review; Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial",https://pubmed.ncbi.nlm.nih.gov/31751012/; https://pubmed.ncbi.nlm.nih.gov/41104938/; https://pubmed.ncbi.nlm.nih.gov/34301748/; https://pubmed.ncbi.nlm.nih.gov/36720083/,gpt-5-mini-v12,gpt-4.1,Astrazeneca BBU
